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Abstract 
 
This thesis explores the ability of RUNX1 and its fusion oncoprotein derivatives to 
induce senescence-like growth arrest (SLGA) in primary cell cultures. While this 
phenomenon resembles replicative senescence seen in normal diploid human 
fibroblasts after extensive passage, it does not involve telomere attrition. From 
previous studies in the host laboratory it can also be distinguished from Ras 
oncogene-induced senescence (OIS) as it does not appear to depend on a DNA 
damage response secondary to hyper-proliferation.   
Despite these differences, this study supports the hypothesis that RUNX SLGA is 
an anti-cancer fail-safe which protects cells against oncogenic transformation. In 
favour of the fail-safe model, two out of the three RUNX1 fusion oncoproteins 
examined fail to induce SLGA in a well characterised human fibroblast cell 
system (Hs68). In the case of TEL-RUNX1 (TR), a fusion which is associated with 
around 25% of childhood B-cell acute lymphoblastic leukaemias, loss of SLGA 
activity is due to N—terminal fusion to TEL. SLGA activity is regained by deletion 
of the HLH dimerisation domain in TEL or by introduction of a single amino acid 
mutation (K99R). The other major RUNX1 fusion oncoprotein, RUNX1-ETO (RE) 
which is commonly observed in M2 subtype acute myeloid leukaemia (AML), 
induces a potent SLGA. However, the RE phenotype differs from that of RUNX1, 
as RE strongly induces reactive oxygen species (ROS) and a pronounced 
senescence-associated secretory phenotype (SASP). In human AML, RE is co-
expressed with a truncated variant generated by alternative splicing (RE9a), 
which has been shown to be much more potently leukaemogenic in animal 
models. This study demonstrates that RE9a also fails to induce SLGA and induces 
a markedly attenuated SASP. RE is generated by fusion of the N-terminal moiety 
of RUNX1 to the ETO C-terminus that encompasses a series of repressive nervy 
homology regions (NHRs), three of which are missing from RE9a. The effect of 
deleting or mutating NHRs from RE was also examined and show that loss of both 
NHR3 and NHR4 is necessary for complete ablation of RE SLGA. It was also 
demonstrated that aspects of RUNX1-induced SLGA are dissociable as, for 
example, the RUNX1P2 isoform induces profound growth arrest but only a 
minimal SASP.  
12 
 
This study supports the hypothesis that RUNX1-induced SLGA must be overcome 
to allow oncogenic transformation, either by intrinsic inactivation (TR, RE9a) or 
by co-operating mutations (RUNX1, RE). Notably, loss of sensitivity to RUNX1-
induced SLGA appears to correlate with mutational loss of p16INK4A, and it was 
shown that growth of the human leukaemia cell line REH is stimulated rather 
than repressed by the TR K99R mutant. The possibility that the RE-induced SASP 
has pro-oncogenic effects through effects on cell survival or on bystander cells is 
also discussed.   
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1.1. RUNX Transcription Factor Family 
 
The RUNX family of transcription factors are closely related to the Drosophila 
runt gene which regulates segmentation, sex determination and some aspects of 
neurogenesis during Drosophila embryogenesis. While Drosophila have one runt 
gene, duplication events have resulted in the presence of three conserved 
mammalian RUNX genes, RUNX1, RUNX2 and RUNX3 which are located on human 
chromosomes 21, 6 and 1 respectively [1, 2]. The expression of RUNX proteins is 
subject to tight regulation meaning that they are only expressed in certain 
tissues at specific times during development. The three RUNX family members 
display significant homology and are expressed from two distinct promoters, the 
P1 or distal promoter and the P2 or proximal promoter, resulting in isoforms of 
RUNX with distinct N-terminal sequences [3]. 
The RUNX proteins retain a highly conserved Runt homology domain (RHD) which 
is a 128 amino acid motif that is essential for the formation of a functional 
heterodimer with core-binding factor-beta (CBFβ), the non-DNA-binding partner 
of RUNX. The RUNX-CBFβ interaction is required to increase the affinity of RUNX 
for DNA and is essential for the function of RUNX as a transcription factor [1, 2]. 
Additionally, the RHD is required for DNA binding, ATP binding and nuclear 
localisation of RUNX [4]. Other regions of the RUNX proteins that display 
sequence homology are the transactivation/inhibitory domains towards the C-
terminal portion of the protein which enable RUNX proteins to execute context-
dependent transcriptional activation or repression (Figure 1.1). 
 
Figure 1.1 RUNX1 and its functional domains 
Schematic representation of the RUNX1 protein indicating its functional domains. The RUNT 
Homology Domains (RHD) is represented in red and is required for interaction with the RUNX co-
factor, CBFβ and DNA binding. The Transactivation Domain (TAD) is orange and functions to 
recruit co-activator complexes to promote transcriptional activation by RUNX1. The Trans-
Inhibitory Domain (TID) is green and is required for RUNX1-mediated transcriptional repression 
through the recruitment of co-repressor complexes. The C-terminal VWRPY domain is 
represented in brown and is required for CD4 repression during thymocyte development. 
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The RUNX transcription factors play essential roles in development evidenced by 
the severe phenotypes associated with their functional disruption. RUNX1 is 
required for normal definitive haematopoiesis and is often mutated in human 
leukaemia. Additionally, hemizygosity for RUNX1 results in a characteristic 
myeloproliferative disorder with increased risk of acute myeloid leukaemia 
(AML) [5, 6]. RUNX2 is essential for osteogenesis and hemizygosity for RUNX2 
results in cleidocranial dysplasia, a disorder affecting the bones and cartilage 
[7]. The precise function of RUNX3 is less well characterised but evidence 
supports a role in aspects of neurogenesis and development of the 
gastroinstestinal tract and RUNX3 has been found to be epigenetically silenced in 
some gastric cancers [7-9]. 
1.2 RUNX1 Isoforms 
 
RUNX1 expression is controlled by two promoters, the P1 (proximal) promoter 
and the P2 (distal) promoter separated by approximately 160kb [3]. There are 
three major isoforms of RUNX1, denoted in the previous nomenclature system as 
AML1a, AML1b and AML1c [10]. AML1c is transcribed from the P1 or MASDS 
promoter and will be referred to from this point as RUNX1P1. AML1b is 
transcribed from the P2 or MRIPV promoter and will be referred to as RUNX1P2. 
AML1a is also transcribed from the P2 promoter but alternative splicing 
generates a C-terminally truncated protein lacking the RUNX1 transactivation 
domain that has the potential to inhibit the activity of full-length RUNX1P2 [11]. 
RUNX1P1 encodes a 32 amino acid sequence at its N-terminus which is replaced 
by 5 amino acids in RUNX1P2. The different RUNX1 N-termini may result in 
altered transcription factor activity by RUNX1P1 and RUNX1P2. RUNX1 binds to 
the DNA sequence TGTGGNNN (NNN= TTT or TCA) [12-15] where it acts as a 
context-dependent transcriptional regulator through recruitment of co-activator 
or co-repressor complexes to the C-terminal trans-activation domain TAD or 
trans-inhibitory domain (TID) [16, 17]. 
1.3  Transcriptional Regulation 
1.3.1 Transcriptional Activation  
 
RUNX1 is a transactivator of gene expression, including genes required for 
haematopoiesis. It is a relatively inefficient transcriptional activator in its own 
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right and commonly cooperates with other transcription factors such as Ets 
family members that bind adjacent sequence specific recognition sites in RUNX1-
dependent gene promoters [18-23]. In addition, the C-terminal TAD recruits co-
activators. These include the Aly/LEF1 complex which cooperates with RUNX1 
for transcriptional activation of the major histocompatibility complex in T-cells 
[24] and p300/CREB-binding protein (CBP) that is required for RUNX1 mediated 
myeloid specific gene expression [25]. Co-activators do not bind to DNA but 
recruit transcription initiation complexes or modify histones to enable 
transcriptional activation by RUNX1. RUNX1 transcriptional activity is also 
modified by post-translational regulation. Examples include GATA-1-associated 
cyclin-dependent-kinase (CDK) phosphorylation of RUNX1 to directly promote 
RUNX1 transactivation [23] and protein arginine methyltransferase (PMRT) 
methylation of arginines 206 and 210 to abrogate recruitment of the mSin3A co-
repressor and thereby indirectly activate RUNX1 transactivation [26].  
1.3.2 Transcriptional Repression 
 
RUNX1 encodes a TID toward the C-terminus of the protein which directs RUNX1 
transcriptional repression through direct recruitment of corepressors such as the 
histone methyltransferases mSin3A and SUV39H1, and indirect recruitment of 
histone deacetylases (HDACs) via nuclear hormone co-repressor (NCoR) 
complexes [27-29]. Although RUNX1 trans-repression is largely attributed to the 
TID, it can also recruit the transducin-like enhancer of Split (TLE) co-repressor to 
a conserved VWRPY motif at the extreme C-terminus of the protein [30]. While 
the VWRPY motif is not required for definitive haematopoiesis, it is critical for 
efficient repression of CD4 during thymocyte development [31]. TLE recruitment 
of HDACs enhances the trans-repressor activity of RUNX1 [32]. 
1.4  RUNX1 and Haematopoiesis 
 
A critical role for RUNX1 in foetal haematopoiesis was implicated in Runx1-/- 
mouse embryos that die at E11.5-12.5 due to a complete lack of definitive 
haematopoietic progenitors in the foetal liver and yolk sac and severe 
haemorrhage [33, 34]. The RUNX1-/- phenotype significantly overlaps with that of 
CBFβ-/-, consistent with a cooperative role for RUNX1/CBFβ in normal 
haematopoiesis [35-37]. 
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It has been reported that RUNX1P2 is expressed in early haematopoietic stem 
and progenitor cells (HSPC) and colony-forming units while RUNX1P1 expression 
is delayed and restricted to definitive colonies. Depletion of the RUNX1P2 
isoform, however, was also shown to uniquely oppose definitive haematopoiesis 
suggesting that RUNX1P1 and RUNX1P2 play critical but non-redundant roles. 
Mouse models broadly support this conclusion with embryonic survival 
maintained despite loss of RUNX1P1. However, loss of RUNX1P2 proved to be 
more catastrophic with pups dying shortly after birth. Loss of RUNX1P1 was 
associated with perturbations to the white blood cell and platelet counts and 
increased numbers of multipotent progenitors and Lin–Sca+c-Kit+ haematopoietic 
stem cell (HSC) populations but the pups still survived. Furthermore a single 
allele of RUNX1P2 but not RUNX1P1 was sufficient to rescue the RUNX1-null 
embryonic lethal phenotype; these data suggest that normal haematopoietic 
development during embryogenesis is more dependent on the RUNX1P2 isoform 
than RUNX1P1 [38]. 
The role of RUNX1 in adult haematopoiesis appears to be less critical. 
Conditional knock out mouse models revealed that loss of RUNX1 during adult 
haematopoiesis did not negatively affect haematopoietic progenitors. Indeed, 
RUNX1-null adult haematopoietic progenitor cells exhibited a growth advantage 
[39]. However, RUNX1 has also been reported to play a significant role in adult 
megakaryocyte maturation as well as for T- and B-lymphocyte differentiation in 
mouse models supporting a critical function for RUNX1 in specific maturation 
pathways in adult tissue [40].  
1.5 Acute Myeloid Leaukaemia and Acute Lymphoblastic Leukaemia 
Mutations and translocations affecting RUNX1 are frequently observed in human 
leukaemias [41]. Leukaemia describes a group of cancers that typically form in 
the bone marrow and can be characterised by a marked increase in the number 
of abnormal blood cells. Statistics released by Cancer Research UK (Cancer 
research UK, http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/leukaemia, Accessed 02/11/2016) state that 
in 2013 there were 9,301 new reported cases of leukaemia in the UK causing 
over 4,500 deaths making it the 11th most common type of cancer in the UK. 
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Leukaemias can be largely classified as myeloid or lymphoid, according to the cell 
type affected. Lymphoid leukaemias affect common lymphoid progenitors which go 
on to form mature lymphocytes [42, 43] while myeloid leukaemias affect common 
myeloid progenitors which are precursors to red blood cells, platelets and some 
types of white blood cells [44, 45]. Leukaemias can be further classified as chronic 
or acute, leading to the identification of four major subtypes of leukaemia; Acute 
Myeloid Leukaemia (AML), Acute Lymphoid Leukaemia (ALL), Chronic Myeloid 
Leukaemia (CML) and Chronic Lymphoid Leukaemia (CLL). Chronic leukaemias 
demonstrate a long-term accumulation of a more mature population of abnormal 
blood cells(https://bloodwise.org.uk/chronic-myeloid-leukaemia-cml/understanding-
cml and https://bloodwise.org.uk/chronic-lymphocytic-leukaemia-cll/understanding-
cll Accessed 06/11/2016). while acute leukaemias are identified by a rapid 
expansion of immature blood cells which compromise the ability of the bone 
marrow to continue to produce normal blood cells (https://bloodwise.org.uk/acute-
myeloid-leukaemia-adult-aml/understanding-acute-myeloid-leukaemia-aml and 
https://bloodwise.org.uk/acute-lymphoblastic-leukaemia-adult-all/understanding-
acute-lymphoblastic-leukaemia-all, Accessed 25/11/2016). 
 
This study focuses on the RUNX1-derived fusion oncoproteins, RUNX1ETO and 
TEL-RUNX1 that are associated with Acute Myeloid Leukaemia (AML) and Acute 
Lymphoblastic Leukaemia (ALL) respectively. Acute leukaemias are 
characterised by a rapid replacement of normal bone marrow with leukaemic 
cells resulting in increased susceptibility to infections, fatigue, bruising and flu-
like symptoms. Without the appropriate treatment, they progress aggressively 
with death occurring within weeks or months. 
 
AML accounts for approximately 35% of leukaemia cases in the UK (Cancer 
Research UK, http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/leukaemia-aml, accessed 02/11/2016) and 
affects myeloblastic cells which are precursors to mature myeloid cells. AML is 
preceded by a pre-leukaemic state where myeloblasts accumulate mutations 
which compromises their ability to differentiate into mature myeloid white 
blood cells and freezes affected cells in an immature proliferative state. This 
alone does not constitute AML but renders affected cells vulnerable to additional 
mutations that are required to promote the full leukaemic state. ALL represents 
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approximately 1% of leukaemia cases in the UK (Cancer Research UK, 
http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/leukaemia-all/incidence#ref-0, Accessed 
02/11/2016).  Like AML, it results in a proliferating population of immature cells 
but in this case lymphoblastic rather than myeloblastic cells represent the cell 
of origin  
Risk factors for AML and ALL include chromosomal translocations and 
abnormalities such as chromosomal inversions, deletions and translocations [46]. 
Common chromosomal abnormalities identified in AML include the t(8;21) 
translocation (RUNX1-ETO) [47-49], inv(16) inversion (CBFβ/MYH11) [49, 50] and 
deletions affecting chromosomes 5 and 7 [51]. The chromosomal translocation 
that is most commonly associated with ALL is the t(12;21) translocation (TEL-
RUNX1) [49, 52, 53]. Other risk factors include genetic conditions such as Down’s 
Syndrome which is associated with increased incidence of leukaemia [54] and 
exposure to radiation and chemicals which include drugs used in anti-cancer 
therapies.  
Treatment of acute leukaemia has two phases of chemotherapy known as the 
Remission Induction and Consolidation phases. The Induction phase comprises a 
period of treatment with a cytotoxic agent such as cytarabine, followed by 
treatment with an anthracycline such as daunorubicin. This phase of treatment 
is designed to aggressively clear leukaemic cells and increase the chance of a 
complete remission [55, 56]. The Consolidation phase is designed to eliminate 
any potential remaining leukaemic cells and reduce the risk of relapse. This 
phase may consist of courses of chemotherapy or a haematopoietic stem cell 
transplant. Although the treatment of AML and ALL is designed to minimise the 
risk of relapse, patients who do relapse frequently display leukaemias that are 
refractory to traditional treatments. In the case of relapsed leukaemias, the only 
available treatment is a haematopoietic stem cell transplant or alternatively 
patients may participate in a clinical trial. 
 
1.6  RUNX1 and Leukaemia  
 
RUNX1 exhibits dual oncogenic and tumour suppressor functions in cancer 
development [6, 57-61]. All three RUNX genes were initially identified as 
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insertional targets for murine leukaemia virus (MLV) in a transgenic Myc model of 
murine T-cell lymphoma [57, 58]. More recently, recurrent copy number 
alterations involving the 21q22 amplicon encoding RUNX1 have been observed in 
patients with acute lymphoblastic leukaemia (ALL). Increased expression of 
RUNX1 co-segregated with poorer prognosis and a higher chance of relapse [62, 
63]. Furthermore, individuals with Down’s syndrome (DS) were reported to 
display a significantly increased risk of developing acute myeloid leukaemia 
(AML), ALL and myeloproliferative diseases before the age of 5 compared to the 
general population and also possess an extra copy of chromosome 21 where 
RUNX1 resides. To formally test whether increased expression of non-mutated 
RUNX1 was responsible in these patients, retroviral acceleration of 
leukaemogenesis was compared in mice possessing 2 or 3 copies of Runx1. In 
every case, mice overexpressing Runx1 displayed a faster onset of leukaemia 
compared to littermate controls, supporting the suggestion that increased 
dosage of RUNX1 plays a significant role in onset of DS-related leukaemia [64]. 
In contrast to ALL, the role of RUNX1 in certain myeloid and T-cell tumours 
appears more tumour suppressive with loss of function mutations observed in 
myeloproliferative disorders with increased risk of AML [65, 66]. Furthermore, 
RUNX1 loss of function mutations are frequently observed in T-cell precursor ALL 
and have been associated with poor disease outcome [67-69]. 
1.7  RUNX1 Leukaemogenic Fusion Proteins 
 
RUNX1 is a frequent target of chromosomal translocations associated with human 
leukaemia. Approximately 30 partner chromosomes have been identified in 
fusion with RUNX1. The two translocations most frequently observed in 
leukaemia are t(8;21) resulting in the RUNX1-ETO (RE) fusion and t(12;21) 
encoding the TEL-RUNX1 protein (Figure 1.2). 
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Figure 1.2 RUNX1 isoforms and their fusion derivatives. 
Schematic representation of RUNX1P1, RUNX1P2, RE, RE9a and TEL-RUNX1 proteins. RUNX1P1 is 
approximately 32 amino-acids longer than RUNX1P2 (Turquoise) and is transcribed from the 
distal promoter. RUNX1P2 is transcribed from the proximal promoter. The t(8;21) chromosomal 
translocation results in expression of the RUNX1-ETO (RE) fusion protein. The RHD of RUNX1 is 
fused to four nervy homology regions (NHR) of ETO which are represented in grey. RE9a is a C-
terminally truncated splice variant of RE which lacks NHR3 and NHR4. The t(12;21) translocation 
results in the TEL-RUNX1 fusion protein which retains most of the RUNX1P1 protein sequence and 
gains the HLH domain of TEL which is depicted in blue. 
 
1.7.1 RUNX1-ETO (t(8;21))  
 
The t(8;21) translocation was the first chromosomal translocation identified in 
AML [47, 48] and is associated with approximately 40% of M2 subtype AML [49]. 
The RE fusion protein results from the fusion of exons 1-5 of RUNX1 to exons 2-
11 of the Eight-Twenty-One (ETO) gene and has been described as a 
transcriptional repressor [70].  
RE knock-in mice display an embryonic lethal phenotype identical to that 
observed in RUNX1 knock-out mice [71, 72] suggesting that RE functions as a 
dominant-negative regulator of RUNX1. Transient transfection assays support 
this prediction demonstrating that RE can antagonise transactivation by RUNX1 
[73, 74]. A direct comparison of RE and RUNX1-mediated gene transcription in 
3T3 fibroblasts confirmed that a proportion of RUNX1-upregulated targets were 
opposed by RE but also revealed a population of RUNX1-repressed genes that 
were markedly derepressed suggesting that RE may possess additional functions 
such as disruption of RUNX1-recruited co-repressor complexes [75]. Several RE 
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transgenic mouse models have been developed to avoid embryonic lethality. In 
murine models expressing RE under control of tetracycline induction [76], an 
MRP8 promoter [77] or Cre-mediated recombination [78, 79], the mice remained 
healthy throughout their lifespan showing normal haematopoiesis in the 
presence of RE. These data suggest that although RE is strongly associated with 
AML, it is insufficient to induce leukaemia in isolation. In this respect it is 
notable that RE was capable of inducing leukaemia in a retroviral transduction 
model of leukaemia where an alkylating agent was used to generate secondary 
mutations [80]. Moreover, Sca-1-mediated expression of RE specifically within 
the haematopoietic stem cell compartment generated a spontaneous 
myeloproliferative disorder after a period of normal haematopoiesis suggesting 
that stem cell-specific factors may cooperate with RE to enhance its 
leukaemogenicity [81].  
In human CD34+ cells, ectopic expression of RE induced an early proliferative 
arrest that was gradually replaced over 4-5 weeks with a population of 
pluripotent stem cells with enhanced self-renewal and committed progenitors 
with impaired differentiation [82]. It is notable that this phenotype resembles 
AML M2 leukaemia with sustained CD34+ expression, a lack of cellular 
differentiation and enhanced self-renewal [82]. However, despite this, RE failed 
to transform CD34+ cells, strongly supporting a requirement for secondary 
cooperating mutations. A frequent mutation identified in t(8;21) patient samples 
expressing RE is mutated RAS. Co-expression of RE and N-RASG12D in human 
haematopoietic cells enhanced their replating and colony formation ability 
relative to RE alone but was not sufficient to drive immortalisation, suggesting 
that further mutations were still required [83].  
While RE retains the RHD of RUNX1 and therefore its ability to bind to RUNX1 
targets, the fusion replaces the TAD and TID of RUNX1 with four nervy-homology 
region (NHR1, 2, 3 and 4) domains from ETO that effectively recruit co-
repressors to RUNX1 target genes. NHR1 is referred to as TATA-box-associated 
factor homology domain (TAFH) as it shares sequence homology with Drosophila 
TAF-110. It has been demonstrated to interact with E-proteins and also with 
NCoR which can recruit HDACs to assist with transcriptional repression [84, 85]. 
NHR2 is an α-helical tetramer [86] that is predicted to interact with corepressors 
such as mSin3A, NCoR/SMRT and HDACs [86-91]. NHR2 is also essential for 
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oligomerisation of ETO and RE [86]. Disruption of the NHR2 domain by mutation 
or targeting with cell-penetrating peptides resulted in enhanced apoptotic 
activity, decreased proliferation and attenuation of the enhanced self-renewal 
capacity conferred by RE [92]. NHR3 has a predicted coiled-coil structure and 
has been reported to interact with the N-terminus of the regulatory subunit of 
type II cyclic AMP-dependent protein kinase A (PKA RIIα). PKARIIα binds 
subcellular structures such as the Golgi apparatus and the endoplasmic reticulum 
via A-Kinase Anchoring Proteins (AKAPs) leading to speculation that ETO NHR3 is 
a type of AKAP. Abrogation of the interaction between NHR3 and PKA RIIα failed 
to eliminate the RE-mediated block on differentiation or the enhanced self-
renewal of RE-expressing haematopoietic progenitor cells [93] suggesting that 
NHR3 plays only a minor role in leukaemia development but this has yet to be 
determined in vivo. NHR4 is also known as the Myeloid-Nervy-DEAF (MYND) 
domain and contains conserved zinc-chelating motifs [86, 94]. Deletion of NHR4 
reversed RE-mediated proliferative arrest and opposed RE-mediated repression 
of granulocyte differentiation [95]. Furthermore, NHR4 deletion prevented 
recruitment of the NCoR/SMRT co-repressor complex and thence HDACs to RE, 
thereby attenuating its function as a transcription factor. NHR4 has also been 
reported to interact with SON, a large splicing co-factor protein which exhibits 
both DNA and RNA binding capabilities and is thought to contribute to cell cycle 
progression by enhancing the efficiency of mRNA splicing [95, 96]. Prevention of 
this interaction enhanced leukaemia development in mouse models suggesting a 
critical role for SON in leukaemia restraint [95, 97]. It is notable that, while the 
contribution of NHR3 to RE-induced leukaemogenesis is unclear, studies have 
suggested it may cooperate with NHR4 to recruit both NCoR/SMRT [90] and SON 
to RE [97] which indicates that NHR3 may be required to potentiate the effects 
of NHR4 on gene repression and leukaemic restraint in vivo. Indeed a cloning 
artefact resulting in a 200 amino acid C-terminal deletion of RE devoid of NHR3 
and NHR4 domains induced spontaneous leukaemia development in a retroviral 
transduction transplantation mouse model [98]. From these results it was 
concluded that the RUNX1 RHD in combination with the NHR1 and NHR2 domains 
of ETO were sufficient to promote leukaemogenesis while NHR3 and NHR4 
functioned to oppose these effects. Supporting evidence for this assumption was 
generated by a naturally occurring splice variant of RE, RE9a, that introduces 
the small exon 9a and its encoded stop codon into the RE transcript. The 
26 
 
resulting RE9a protein lacks NHR3 and NHR4 domains and, in contrast to RE, was 
reported to spontaneously induce leukaemogenesis in retroviral transduction 
transplantation mouse models with no additional mutagens within a matter of 
weeks [80]. Moreover, RE9a was detected in approximately 90% of t(8;21)-
positive AML patients at varying levels. Patients with higher levels of RE9a 
expression displayed a more primitive, blast-like population of cells and a poorer 
disease outcome supporting suggestions that loss of NHR3 and NHR4 promoted 
leukaemogenesis in vivo [80]. 
1.7.2 TEL-RUNX1 t(12;21) 
 
The TEL-RUNX1 (TR) fusion results from the t(12;21) chromosomal translocation 
between the P1 isoform of RUNX1 and the Ets family transcription factor, TEL. 
TR is associated with approximately 25% of childhood B-cell ALL but is extremely 
rare in adult onset ALL [99]. Evidence indicates that the t(12;21) translocation 
occurs in utero as an initiating mutation driving the existence of pre-leukaemic 
clones that then undergo secondary mutations during childhood to generate the 
fully transformed ALL phenotype [52, 100].  
Several transgenic mouse models have been developed to investigate the role of 
TR in the evolution of ALL. Transgenic mice expressing TR in lymphoid cells were 
observed for over two years but failed to display leukaemogenesis [101]. Murine 
bone marrow transplantation mouse models displayed impaired differentiation in 
the pro-B-cell compartment with an accumulation of early progenitor cells very 
similar to the t(12;21) phenotype observed in ALL patients but no leukaemia was 
observed for over a year post-transplantation [102]. Models that have attempted 
to enhance the potential for secondary cooperating mutations have been 
marginally more successful. A retroviral mouse model revealed cooperation 
between TR and loss of p16INK4a for leukaemia development [103] and co-
expression of TR with the sleeping beauty transposon as an additional insertional 
mutagen developed a B-cell precursor ALL in approximately 20% of the mice 
[104]. The requirement for secondary events is supported by the aetiology of the 
disease in vivo. Indeed, in the context of human ALL, the occurrence of the TR 
fusion far exceeds the incidence of TR-related leukaemia suggesting that TR 
alone is insufficient to induce spontaneous leukaemia. One mutation that is 
frequently found in human TR positive ALL cells is deletion or inactivation of the 
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unrearranged allele of TEL. This is observed in approximately 65%-80% of 
established ALL although its biological significance has not yet been determined 
[105-108].   
The TR fusion retains all of the functional domains of RUNX1 and the N-terminal 
helix-loop-helix (HLH) domain of TEL [99, 109]. Despite retention of the RUNX1 
TAD, TR is compromised in its ability to activate RUNX1 target gene expression 
and has been shown to recruit co-repressors such as HDACs and mSin3A to 
RUNX1-specific gene promoters [110, 111]. From these results, it has been 
suggested that TR functions as a dominant-negative repressor of RUNX1 activity, 
but results from another study showing upregulation of a subset of RUNX1 
targets in the presence of TR suggests that the reality may be more complicated 
[75]. What has been clearly established is that the HLH domain of TEL is critical 
for TR-mediated pre-leukaemic activity. The HLH domain regulates TEL 
localisation and oligomerisation, suggesting that these functions play an 
essential role [112]. Specifically, the TEL HLH domain has been reported as a 
target for SUMOylation [113-115]. SUMOylation is a form of post-translational 
modification involving covalent attachment of small ubiquitin-like modifiers 
(SUMO) at specific amino acid sequences and regulates several cellular processes 
including cell cycle progression, apoptosis and subcellular localisation of target 
proteins [116]. It seems likely that any of these processes could directly 
contribute to TR-mediated leukaemogenicity or provide a more indirect effect 
through antagonism of RUNX1 functions.  
1.8 Anti-Cancer Fail-Safes 
 
Cellular senescence and apoptosis are cellular fail-safe mechanisms that are 
activated in response to potentially harmful cellular events including viral 
infections, pro-oncogenic mutations and hypoxia that can result in altered tissue 
homeostasis. Senescence and apoptosis regulate genetic programmes that share 
some common signalling components such as p53, p38MAPK and reactive oxygen 
signalling. Most importantly, both senescence and apoptosis are considered to be 
primary anti-cancer cell defences which must be overcome for cellular 
transformation to occur. 
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1.8.1 Apoptosis  
 
Apoptosis represents a mechanism of programmed cell death (PCD) that results 
in the regulated destruction of cell organelles and structures in response to 
intrinsic and extrinsic cellular signals [117]. Apoptotic cell death is induced by 
caspases which are a family of cysteine proteases ubiquitously expressed in the 
form of zymogens. Initiator caspases (caspase 2, 8, 9 and 10) become activated 
upon cleavage at conserved aspartate residues. Activated initiator caspases then 
proceed to cleave effector caspases (Caspase 3, 6 and 7) which cleave other 
target proteins within the cell to trigger apoptosis [118]. 
Apoptosis is initiated through one of two pathways, the intrinsic pathway or the 
extrinsic pathway. The intrinsic pathway is initiated by stress signals such as 
activated oncogenes that promote mitochondrial swelling and membrane 
permeabilisation. Cytochrome C is released from the mitochondria into the 
cytoplasm where it forms an apoptosome with apoptosis protease activating 
factor 1 (Apaf1), ATP and procaspase 9 [119] that subsequently forms the site of 
procaspase cleavage to form activated caspase 9 [120]. The extrinsic pathway is 
triggered by cytokines such as tumour necrosis factor α (TNFα) and Fas which 
bind to receptors and form death domains that activate initiator caspases and 
thence effector caspases to promote apoptosis [121, 122]. 
1.8.2 Cellular Senescence 
 
Cellular senescence is characterised as a stable growth arrest undergone by 
normal cells after a finite number of population doublings. Senescence was 
initially described by Hayflick and Moorhead in 1961 [123] who demonstrated 
that primary human fibroblasts have a finite replicative life-span, displaying 
arrested growth after approximately 50-70 population doublings due to 
progressive telomere attrition. Senescent cells have a complex phenotype 
including a flattened and enlarged cell morphology [124], senescence-associated 
β-galactosidase (SA-β-Gal) activity at pH6.0 [125], activation of tumour 
suppressor pathways [126], accumulation of reactive oxygen species and changes 
in gene expression resulting in increased levels of growth factors and 
inflammatory cytokines associated with the  senescence-associated secretory 
phenotype (SASP) [127]. 
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Normal human cells undergo senescence in response to telomere attrition that 
occurs over the life span of the cell as DNA replication takes place [128]. At a 
critical length the shortened telomere is detected as irreparable DNA damage 
and the cell undergoes a form of growth arrest termed replicative senescence 
[129]. Premature senescence is physiologically and morphologically 
indistinguishable from replicative senescence but occurs more rapidly in early 
passage cells in response to diverse stress stimuli, including oxidative stress, 
DNA damage or oncogene activation, that activate  common tumour suppressor 
pathways such as p53 and p16INK4a to execute a cell cycle arrest [126]. 
Oncogene-Induced Senescence (OIS) is an example of premature senescence that 
represents an important failsafe mechanism protecting cells against cancer 
development. OIS was first observed in response to oncogenic RAS. The 
downstream pathways included activation of RAS-RAF-MEK signalling to induce a 
p53 and p16INK4a-dependent cell cycle arrest [130]. OIS has now been identified 
as a response to multiple oncogenes and invariably engages tumour suppressor 
pathways that must be overcome for cancer progression to occur [131-137]. 
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Figure 1.3. Causes and consequences of cellular senescence.  
Cellular senescence can be triggered by a wide range of stimuli including telomere attrition, 
which is related to aging and replicative senescence, and cellular stresses which result in 
premature senescence. The resulting senescence phenotype comprises a plethora of hallmarks 
which can include growth arrest, activation of tumour suppressor pathways and induction of a 
SASP. 
 
 
1.9  Defining Senescence 
 
Senescence is defined by a plethora of “hallmarks” including growth arrest, SA-
β-Gal activity, engagement of tumour suppressor pathways and DNA damage 
[125, 126, 138] (Figure 1.3). Individually, these characteristics are not 
necessarily indicative of cellular senescence and elements must be observed in 
combination to generate the complex phenotype that is defined as senescence. 
Furthermore, several pro-senescence hallmarks have also been implicated in 
oncogenesis suggesting that senescence induction requires a delicate balance to 
prevent oncogenic progression [139]. 
1.9.1 Growth arrest  
 
Growth arrest is a major hallmark of senescence and is considered indispensable 
for the phenotype. The irreversibility of senescence-like growth-arrest (SLGA), 
however, is somewhat more controversial. Previous reports have identified a 
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permanent growth arrest in primary human fibroblasts in response to RAF1, 
p16INK4A, and HDAC inhibitors [140-142]. However, more recent results suggest 
that escape from senescence is possible under certain circumstances. 
Inactivation of p53 may be a key event [127, 143-145] but studies also implicate 
expression levels of p16INK4a as an important determining factor. Cells with low 
levels of p16INK4a at the point of senescence were permissive for growth when 
p53 was inactivated but those expressing high levels of p16INK4a failed to restore 
proliferation [143]. 
1.9.2 Cell Morphology  
 
Cells that undergo senescence often assume a flattened and enlarged 
morphology compared to their proliferating counterparts. In an attempt to 
identify the signalling components responsible, HPV16 E6 or E7 proteins have 
been exploited since they disable the p53 or p16INK4a tumour suppressor 
pathways respectively. Upregulation of actin stress fibres and sporadic 
redistribution of focal adhesion proteins associated with the flattened and 
enlarged senescent morphology of a population of senescent cells was opposed 
in the presence of E7 but not E6. Since E7 directly degrades the Rb protein, it 
was concluded that the senescent morphology was dependent on an intact 
p16INK4a/pRb signalling pathway [124]. It is unclear whether this represents a 
cell-type dependent effect or a more widespread phenomenon. 
1.9.3 Senescence-Associated β-Galactosidase  
 
One of the most common assays used to distinguish senescent and non-senescent 
cells is the detection of SA-β-Gal activity at pH6.0 [125]. SA-β-Gal is expressed 
from the GLB1 locus and is typically detected as a lysosomal enzyme activated 
at pH4.0-4.5. The activity at pH6.0 is novel and restricted to senescent cells. 
Although SA-β-Gal activity represents a useful marker of senescence, it is not 
considered to be an inducer and indeed, in some cases its appearance can be 
somewhat inconsistent. An shRNA targeted to GLB1 failed to abrogate replicative 
senescence in late passage human fibroblasts [146] and SA-β-Gal activity has 
been observed in non-senescent cells under stress conditions, all indicating that 
while SA-β-Gal is a common marker of senescence, it is not essential for 
senescence to occur and is not necessarily indicative of the phenotype [146]. 
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However, with these caveats in mind and in conjunction with other factors, SA-
β-Gal activity can provide a useful marker of senescence.  
1.9.4 Tumour Suppressor Pathways  
 
The stimuli that induce cellular senescence are multiple and diverse but 
ultimately converge on two important tumour suppressor pathways controlled by 
p53 and p16INK4a that function as key regulators of senescence [126]. Their 
importance in senescence is inferred from the frequency at which they are 
inactivated in human cancers [147]. The p53 tumour suppressor protein has been 
described as the "guardian of the genome" [148]. In the absence of stress, p53 
has a short half-life and is maintained at low levels as an inactive transcription 
factor in normally proliferating cells. In response to cellular stresses such as DNA 
damage and oncogene expression the pattern is reversed [149-153]. The levels of 
p53 dramatically increase and the protein is activated to regulate expression of 
a plethora of genes targeting major functional pathways such as cell cycle 
progression and DNA repair [154, 155]. p21CIP1 represents one of the primary p53-
regulated targets controlling cell cycle progression. It functions as a CDK 
inhibitor (CKI) complexing with CDK4/6 and CDK2 to prevent cyclin A/E-
mediated cell cycle progression [156]. p16INK4a represents another CKI associated 
with SLGA. p16INK4a opposes cell cycle progression by binding to CDK 4/6 and 
preventing their association with D-type cyclins. Cyclin-CDK complexes 
phosphorylate pRb, triggering its release from E2F and the subsequent 
expression of E2F-regulated genes required for cell cycle progression. In the 
presence of CKIs, cyclin-CDK activity is opposed and E2F is retained in an 
inactive state by unphosphorylated pRb [157] (Figure 1.4). 
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Figure 1.4 Tumour suppressor pathways 
Senescence is induced in response to a wide range of stimuli, senescence signalling ultimately 
converges on two major tumour suppressor pathways, the p16INK4A pathway and the p53 pathway. 
 
Inactivation of p53 signalling is sufficient to abrogate RAS-induced senescence in 
primary MEFs [130]. Parallel experiments in p16INK4a-null MEFs resulted in a 
premature senescence response that was indistinguishable from wild type MEFs, 
suggesting that p16INK4a is not absolutely required in this system [158]. However, 
the reality may be more complicated since inactivation of pRb or pRb family 
members was also sufficient to oppose senescence in primary MEFs [159, 160]. 
With such contrasting evidence, it seems likely that p53 provides the dominant 
senescence signal in primary MEFs but that both tumour suppressor pathways 
have a role to play [130, 161]. A requirement for p53 and p16INK4a is also 
described in human senescence but in this case a dominant role is emerging for 
p16INK4a since p16INK4a-null human cells displayed resistance to RAS-induced 
premature senescence [143].  
1.9.5 DNA Damage  
 
Double-stranded DNA breaks are induced by multiple stress signals and are 
targeted by cellular complexes for DNA repair. The Mre11/Rad50/Nbs1 (MRN) 
complex recruits the ataxia telangiectasia mutated (ATM) and ataxia 
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telangiectasia and Rad3-related (ATR) DDR factors to sites of double-stranded 
breaks. There they phosphorylate H2AX which serves both as a marker of the 
damage (ϒH2AX) and as a recruitment factor for further ATM molecules and 
repair factors, establishing a positive feedback loop necessary to ultimately 
remove the break and repair the DNA [162, 163]. Although ATM and ATR are 
sufficient to mediate the cell cycle arrest required for low level DNA repair, in 
the event of irreparable DNA damage ATM phosphorylates and stabilises the p53 
tumour suppressor to induce senescence or apoptosis [164, 165]. 
Replicative senescence is considered to represent a response to persistent DDR 
signalling due to the critical shortening of telomeres sensed as double-stranded 
DNA breaks or irreparable DNA damage [129]. DDR signalling has subsequently 
been implicated in various types of premature senescence including OIS. 
Expression of oncogenic RAS is associated with a hyper-proliferative phase that 
drives replicative stress, oxidative DNA damage and the appearance of stalled 
DNA replication forks. The ensuing DNA damage foci activate a persistent DDR 
which blunts the hyper-replicative phase and induces OIS [166]. Similar 
observations have been made for other oncogenes including BRAF [167]. It is of 
note that, despite representing an important factor for the establishment and 
maintenance of senescence, impairment of the DDR can also act as a driving 
force for oncogenesis, promoting genomic instability and increased DNA damage. 
It is perhaps not surprising then that while the DDR can represent a barrier to in 
vivo transformation, mutations and epigenetic silencing affecting DDR 
components are commonly observed in cancer cells [168-172]. 
1.9.6 Reactive Oxygen Species  
 
ROS are normal bi-products of cellular metabolism with functions in cell 
signalling and growth. Several organelles and enzymes have been identified as 
producers of intracellular ROS [173]. In the mitochondrial the electron-transport 
chain passes electrons via a series of proteins through a progression of 
oxidation/reduction reactions. The terminal electron acceptor on this chain is 
molecular oxygen which is most commonly reduced to form water. However, in a 
very small percentage of cases, the acceptor oxygen molecule undergoes 
incomplete reduction which results in the formation of superoxide [174]. Other 
organelles including the endoplasmic reticulum and peroxisomes have also been 
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identified as sources of intracellular ROS [173]. In addition numerous enzyme 
systems have been established as ROS producers. A notable example of a ROS 
producing family of enzymes is the NADPH oxidase (NOX) family of enzymes 
which transfer electrons from NADPH in the cytoplasm to molecular oxygen to 
produce superoxide. ROS production by NOX family enzymes can be induced by 
soluble factors including TNF, PDGF and EGF [175] and is thought to have a role 
in the immune response to pathogens [176] as evidenced by the finding that 
patients with mutations affecting NOX function displayed granulomatous disease 
associated with recurrent bacterial and fungal infections [177]. 
Several strategies for the detection of intracellular ROS have been developed 
including the use of redox dependent fluorescent dyes and protein probes. The 
most frequently used means of measuring intracellular ROS is DCF-DA, a 
membrane permeable dye which is cleaved by intracellular esterases and 
retained within the cell where it can be oxidised, resulting in fluorescence that 
can be measured by flow cytometry [178]. However, more recently, fluorescent 
protein-based probes have been developed, enabling cells to be transduced to 
express redox-sensitive chimeric proteins [179]. For example, HyPer is a protein 
probe which consists of a YFP protein transcript inserted into the regulatory 
domain of the prokaryotic OxyR gene which is sensitive to hydrogen peroxide. 
The use of these probes may enable detection of ROS generated in specific 
subcellular organelles [179]. 
Although ROS have important functions in cell signalling and the cellular 
response to pathogens, in particular contexts ROS can also activate senescence 
[180, 181]. MEFs undergo rapid premature senescence when grown under 
standard tissue culture conditions (20% oxygen) but this is delayed or even 
prevented when the cells are propagated in physiological oxygen (3% oxygen) 
where ROS levels are reduced [181-183]. The replicative life span of primary 
human fibroblasts can also be extended in physiological oxygen conditions [183]. 
In addition, expression of oncogenes such as RASV12 have been reported to induce 
marked increases in ROS that initially had mitogenic effects on the cells, 
resulting in hyperproliferation but ultimately inducing an accumulation of DNA 
damage and OIS due to replicative stress [166]. ROS was also reported to induce 
senescence through direct damage to cellular DNA and proteins via oxidative 
reactions.  
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Complementing its role as an inducer of premature senescence, accumulated 
levels of ROS have also been implicated in the maintenance of senescence. 
Senescent human fibroblasts expressing conditionally active SV40 large-T-antigen 
were susceptible to large-T-antigen mediated inactivation of p53 and 
recommenced proliferation but only under conditions of low ROS generation. 
When growth conditions were adapted to increase ROS production, senescence 
persisted unless N-Acetyl-cysteine was included in the growth medium as an 
antioxidant, thus providing evidence of ROS as a critical senescence 
maintenance factor [184].  
The signalling pathways downstream of ROS responsible for SLGA include p53 and 
p16INK4a. ROS engages the p53 axis through persistent DNA damage signalling and 
activation of the DDR and downstream targets including p53. Accumulation of 
ROS can also induce p16INK4a expression through the stress-induced p38MAPK 
protein [185]. Furthermore, oncogene-induced ROS has been associated with 
induction of the SASP which plays an important role in the maintenance of 
senescence [186].Together, these data indicate an important role for ROS in 
both the induction of SLGA and establishment of the senescence response. 
1.9.7 p38 Mitogen Activated Protein Kinase 
 
The p38 Mitogen Activated Protein Kinase (p38MAPK) is a member of the MAPK 
family of stress-induced protein kinases that play important roles in 
inflammation and the cellular response to a wide range of stress stimuli 
including UV irradiation, exposure to heat, osmotic shock, oxidative stress, 
inflammation and oncogene expression [187, 188]. p38MAPK has also been 
identified as a key inducer of cellular senescence and may provide a common 
link between pro-senescence stimuli and key tumour suppressor pathways as it 
can activate both the p53 and p16INK4a pathways [189]. 
1.9.7.1 p38MAPK Can Be Activated Downstream of Reactive Oxygen 
Species  
 
Many stimuli that induce ROS subsequently activate p38MAPK suggesting that 
they lie on a linear pathway. Treatment of cells with hydrogen peroxide (H2O2) 
as a source of oxidative stress promotes p38MAPK activation whereas the use of 
ROS scavengers opposes p38MAPK activation [188, 190-192]. The signalling 
37 
 
pathways between ROS and p38MAPK are poorly understood and somewhat 
context-dependent. MAPK proteins themselves are susceptible to oxidative 
stress. ASK1, for example, is a MAPK family member that associates with 
thioredoxin under normal cellular conditions. In the presence of oxidative stress, 
thioredoxin is oxidised and dissociates from ASK1, thereby facilitating ASK1 
oligomerisation and the subsequent activation of p38MAPK [193, 194]. Oxidative 
stress is also reported to promote growth factor-mediated activation of 
p38MAPK. Specifically, oxidative modification of key amino acids such as 
cysteine, in response to H2O2, was sufficient to activate p38MAPK. Finally 
oxidative stress can perturb the activity of MAPK phosphatases (MKPs) which are 
required to maintain the MAPK pathway in an inactive state. Oxidation of 
specific cysteines in the catalytic domain attenuates their activity, permitting 
constitutive MAPK activation [195].  
1.9.7.2 p38MAPK Activation in Response to DNA damage  
 
p38MAPK activation represents a stress response to genotoxic stimuli including X-
irradiation and oxidative DNA damage. Thousand and one amino acid (TAO) 
kinases are MAP3Ks that have been reported to activate p38MAPK in response to 
oxidative stress and DNA damage [196]. TAOs are potently activated by ATM in 
response to DNA damage. The use of dominant-negative mutants or specific TAO 
knockdown assays to reduce kinase activity abrogates p38MAPK activation in 
response to genotoxic stress [196]. Furthermore, cells derived from ataxia 
telangiectasia mutated (ATM) patients display severely compromised TAO and 
p38MAPK activation, strongly suggesting that p38MAPK lies downstream of ATM 
and represents a crucial signalling component of the DDR. 
1.9.7.3 p38MAPK is a Key Regulator of Oncogene-Induced Senescence 
 
ROS and DDR signalling pathways are induced by oncogenes such as H-RASV12 that 
are also associated with senescence [166, 169]. It is perhaps no surprise then, 
that p38MAPK activation, which has been linked to oxidative stress and DNA 
damage, is also induced in response to sustained oncogene expression [197-199]. 
The hyperproliferative phase associated with RAS-induced senescence is partially 
driven by constitutive activation of RAF-MEK-ERK signalling that also directs 
phosphorylation of p38MAPK. The significance of this for cellular senescence is 
illustrated by the opposition of SLGA in the presence of p38MAPK inhibitors 
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[198]. A similar finding was observed when Wip1 was overexpressed with 
oncogenic Ras in murine models. Wip1 is a p38MAPK phosphatase which 
dephosphorylates and inactivates p38MAPK [200]. 
p38MAPK activates SLGA through direct engagement of the p53 and p16INK4a 
tumour suppressors. p38MAPK phosphorylates p53 in response to cellular stress 
on key serine residues (Ser 15, 33 and 46) that are associated with p53 mediated 
senescence and apoptosis [201]. Activation of p16INK4a in response to p38MAPK is 
more indirect and a consequence of p38MAPK-mediated activation of ETS 
transcription factors Ets1, Ets2 and ESE-3 which then transactivate p16INK4a 
expression [202-204]. In addition, p38MAPK has been implicated in the 
maintenance of senescence through downstream signalling pathways such as 
nuclear factor kappa-light-chain-enhancer of activated B cells (NFB) that 
promotes development of the SASP. The SASP sustains OIS through inflammatory 
cytokine signalling and chemotaxis [185]. 
1.9.8 The Senescence-Associated Secretory Phenotype 
 
Although senescent cells are no longer proliferating, they remain metabolically 
active and are frequently found to produce a characteristic secretory profile of 
cytokines, growth factors and proteases termed the SASP [205]. The SASP signals 
in an autocrine and paracrine fashion to consolidate SLGA in cells that have 
already undergone senescence and induce senescence in adjacent non-senescent 
populations [206]. Furthermore, numerous SASP components act as attractants 
for the immune system to clear damaged cells, suggesting that the SASP is not 
simply a downstream consequence of senescence but an integral tumour 
suppressor component. In this respect it is notable that autophagy may facilitate 
development of a SASP. Autophagy represents a survival mechanism that is 
engaged in response to cellular starvation [207] but autophagy-related genes 
also display similar patterns of induction to SASP markers and their expression 
appears to be related. Furthermore, it has been reported that knockdown of 
autophagy related genes resulted in late expression of some SASP components 
which can act to further promote senescence [208]. Opposed to these growth 
suppressive functions, the SASP also supports pro-oncogenic effects including the 
proliferation of malignant and pre-malignant cells and the maintenance of tissue 
microenvironments permissive for oncogenesis [127, 209]. From these studies it 
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has been proposed that senescence-associated secretion is “antagonistically 
pleiotropic” exhibiting tumour suppressor and oncogenic activities to both 
support and resist the senescent phenotype.   
1.9.8.1 SASP Initiation and Regulation  
 
The upstream signalling pathways associated with the appearance of a SASP are 
varied and somewhat context-dependent. Early studies demonstrated a clear 
association between a persistent DNA damage signal and the initiation of a SASP.  
DDR mediators such as ATM, Nibrin (NBS1) and checkpoint kinase 2 (CHK2) were 
identified as essential components and assumed to signal the SASP downstream 
of the damage [210]. These conclusions were challenged by observations that 
neither p53 nor p16INK4A were absolutely required and that a transient DDR failed 
to induce the response suggesting that while the DDR may be important for SASP 
induction, it is not sufficient [210]. More recent reports suggest that the active 
phosphorylated form of p38MAPK can induce a potent SASP independently of the 
DDR and that inhibition of p38MAPK activity results in attenuated cytokine 
secretion [185]. Studies have also demonstrated the importance of ROS as a 
potential initiator of the SASP. ROS was previously reported to activate p38MAPK 
in response to oxidative stress [193, 194] but in the context of RAS-induced 
senescence has also been shown to activate NFB through the activation of 
protein kinase D1 (PKD1) [186]. The PKD1 pathway is independent of DNA 
damage or p38MAPK phosphorylation, suggesting that multiple pathways are 
capable of activating a SASP and that cellular context is an important 
determinant of pathway selection.  
The SASP is controlled by pro-inflammatory “master regulators” NFB and 
CCAAT-enhancer-binding protein beta (C/EBP-β), the binding-sites for which are 
frequently found adjacent to each other in the promoters of SASP-associated 
genes such as IL8 and CXCL1 [211]. More recent studies indicate that NFB may 
be the critical determinant [212-214]. NFB is an important sensor of cellular 
stress. It is maintained in the cytoplasm as large precursor proteins, NFB1 
(p105) and NFB2 (p100) that dimerise with REL family members to form 
inactive complexes. In response to stress, these precursor complexes are rapidly 
processed to form the mature p50 and p52 NFB subunits. Stress signalling is 
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mediated through canonical and non-canonical pathways that exhibit distinct 
and overlapping features and ultimately regulate the nuclear localisation of the 
NFB transcription factor. The canonical pathway promotes dissociation of NFB 
from the inhibitory IB subunit whereas the non-canonical pathway regulates the 
phosphorylation and activation of the NFB p100 precursor protein [215]. 
NFB signalling is activated by multiple stimuli including the DDR, ROS and 
p38MAPK. Signalling through ATM or the ROS-PKD1 pathway activates the 
canonical pathway whereas the non-canonical pathway is activated by p38MAPK 
via MAPK signalling components, Mitogen and stress activated kinase (MSK)1 and 
2 [185, 216, 217]. In addition, p38MAPK can phosphorylate histone H3 located 
within the promoters of specific subsets of cytokine and growth factor genes 
thereby increasing the affinity of NFB for the promoter region [218]. Activation 
of NFB is accompanied by a transcriptional response that regulates multiple 
genes associated with the SASP.  
1.9.8.2 Pleiotropic Consequences of the SASP 
 
The secretory phenotype is pleiotropic, mediating both tumour suppressor and 
oncogenic effects in cells and tissues. The acute response serves to reinforce the 
senescent phenotype. Specific inflammatory factors such as IL-6 and IL-8 directly 
mediate these effects. Knock-down of the IL-8 receptor (CXCR2) was reported to 
attenuate OIS induced by oncogenic RAS signalling [211] while opposition to IL-6 
expression completely abrogated BRAF600-induced senescence [145]. SASP 
mediators have also been reported to extend the senescent phenotype to 
surrounding cells via paracrine signalling. In this respect p16INK4a activation has 
been observed in normal cells surrounding malignant lesions [219] and IL1-β was 
demonstrated to induce premature senescence in normal proliferating cells in 
mouse models [206]. Finally numerous SASP components have been identified as 
chemo-attractants that recruit innate immune cells to clear damaged cells. For 
example, reactivation of p53 in a p53 depleted mouse liver carcinoma model 
resulted in the induction of a SASP that was accompanied by extensive tumour 
regression. The effect was attributed to an infiltration of natural killer (NK) 
cells, neutrophils and macrophages due to the release of inflammatory cytokines 
from the senescent cells [220]. Infiltrates of innate immune cells have also been 
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reported to clear senescent cells. In mouse models this resulted in an increased 
healthy lifespan with reduced incidence of tumours and age-related pathologies 
[221, 222]. This self-regulatory mechanism presumably reduces the negative 
effects of chronic inflammation on aging cells and could be considered tumour 
suppressive.   
 
Figure 1.5 Antagonistic Pleiotropy of the SASP  
The SASP produced by senescent cells has effects that can promote transformation and 
oncogenesis as well as senescence and tumour suppression. Although the SASP can promote 
cellular senescence through autocrine and paracrine routes, it is also considered to have pro-
oncogenic activities including promotion of tumour angiogenesis, enhancing cancer cell 
invasiveness and promoting cellular proliferation in certain contexts. 
 
SASP signalling is required to maintain and extend the senescent phenotype but 
a large number of SASP factors also display pro-oncogenic effects supporting a 
role for the SASP in tumour promotion (Figure 1.5). GROα, is secreted by 
senescent fibroblasts but has also been demonstrated to stimulate proliferation 
of pre-malignant mammary epithelial cells, and IL-6, IL-8, bFGF and VEGF 
support cellular migration and invasion to promote a metastatic phenotype [127, 
205, 223]. Chronic inflammatory stimulation may be required for tumour 
promotion since the effects are generally associated with the persistence of 
senescent cells. This is in contrast to the more acute consequences of a SASP for 
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tumour suppression and may provide one explanation for the antagonistic 
pleiotropy associated with the secretory phenotype. 
1.10  RUNX1 and Oncogene Induced Senescence  
 
In primary murine fibroblasts, all three Runx genes exhibit a profound SLGA that 
is dependent on an intact p19ARF/p53 pathway [224]. Moreover all three genes 
collaborate with c-Myc in retroviral mouse models of murine lymphoma 
supporting an oncogenic role in vivo [57]. Extending these observations to human 
fibroblasts it was shown that RUNX1P2 induced a profound SLGA in Hs68 
fibroblasts that required the RUNX1 RHD and TAD and was dependent on 
expression of the p16INK4a tumour suppressor [59]. Moreover, RUNX1-induced 
senescence in contrast to other oncogenes was independent of a DDR or 
hyperproliferation in this cell background lending weight to the existence of 
alternative senescence inducing pathways. The pathway responsible for RUNX1-
induced senescence remains to be elucidated but DDR-independent premature 
senescence has become more widely reported, invoking signalling modules 
downstream of PI3K, p38MAPK and ATR in for a number of oncogenes including 
AKT, RUNX1-ETO, BCR-ABL and CBFβ-MYH1[59, 225, 226] . 
1.10.1 RUNX1-ETO Induces Oncogene-Induced Senescence in Hs68 Cells  
 
The RUNX1 t(8;21) fusion oncoprotein, RE, is expressed in approximately 40% of 
M2 AML and is the most common abnormality in childhood AML [227]. Despite 
these statistics RE is insufficient to induce leukaemia in mouse models [80]. 
Furthermore, RE expression results in OIS in vitro, supporting a requirement for 
secondary collaborating mutations to overcome RE-mediated growth suppression 
[59, 80, 225]. The p53 and p16INK4A tumour suppressors were previously identified 
as critical mediators of RE-induced senescence, with their relative contributions 
depending on the cell background studied, but the most defining phenotype was 
a virtual absence of replicative stress [59]. Few or no ϒH2AX foci marking sites of 
double-stranded DNA damage were observed in either human primary fibroblasts 
or murine haematopoietic progenitors compared to cultures expressing H-RasV12. 
Higher levels of ϒH2AX foci have been observed in other studies where RE was 
ectopically expressed in primary MEFs or human U937 lymphoma cells [228]. It is 
possible that the exquisite sensitivity of MEFs to oxidative stress or specific 
secondary mutations in U937 cells present more susceptible cell backgrounds for 
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DNA damage but the phenotype in this study was also absolutely dependent on 
p21CIP1 suggesting that an alternative senescence pathway was responsible [228]. 
The absence of DNA damage in RE-induced senescence in Hs68 fibroblasts was 
accompanied by an accumulation of ROS [59]. ROS is reported to activate pro-
senescence stress response pathways [59] but has also been associated with an 
induction of DNA damage [166]. In this study, it seems likely that the complete 
absence of hyperproliferation in Hs68 human fibroblasts had attenuated the 
potential for ROS-induced DNA damage in response to RE. A requirement for ROS 
was not directly investigated but it was notable that p38MAPK was activated in 
response to RE in human fibroblasts and murine haematopoietic progenitors and 
that multiple studies indicate that this stress kinase lies downstream of ROS. 
Moreover SLGA was opposed by p38MAPK inhibition demonstrating a critical 
requirement for p38MAPK signalling for the induction of RE senescence. 
While RE alone is insufficient to induce leukaemia in murine models, RE9a, a C-
terminally truncated splice variant of RE induces rapid leukaemogenesis in a 
retroviral transduction-transplantation model in mice [80]. As the reduced 
leukaemogenic potential of RE appears to correlate with its ability to induce 
SLGA, it might be predicted that the increased leukaemogenic potential of RE9a 
will correlate with escape from OIS. 
1.10.2 TEL-RUNX1 Fails to Induce Cellular Senescence in Hs68 Cells 
 
The t(12;21) translocation drives expression of the TR fusion oncoprotein 
associated with childhood B-ALL. TR was insufficient to induce leukaemia in 
murine models [101] but retroviral expression in primary murine haematopoietic 
progenitors enriched for a population of proliferating early B cells, suggesting 
that TR expression was capable of supporting cell growth in this background 
[103]. Ectopic expression of TR in primary human fibroblasts was also compatible 
with cellular proliferation. Growth promotion was not actually observed but the 
cells expanded with similar kinetics to the parental controls and exhibited no 
visible markers of premature senescence [59]. It has been suggested that 
persistent proliferation may be a pre-requisite for the acquisition of secondary 
mutations necessary for cancer development. In this respect it is notable that 
TR-positive murine pre-B cells displayed reduced sensitivity to growth inhibitory 
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signalling by TGF-β [229] suggesting that TR-mediated leukaemogenesis may be 
attributable to a failure to engage the senescence failsafe. 
The observation that TR fails to induce SLGA in human primary fibroblasts is 
somewhat surprising given that the fusion protein retains a virtually intact 
RUNX1 sequence and RUNX1 readily induces senescence in this cell background 
[59]. The pre-leukaemic activity of TR in pre-B cells was shown to require the 
RUNX1 RHD and the HLH domain of TEL [112]. The HLH domain is the only 
functional domain retained by the TEL portion of the fusion and has been 
associated with oligomerisation and subcellular distribution [112]. It is 
conceivable that either or both functions disrupt the ability of RUNX1 to induce 
senescence thereby permitting a proliferating phenotype vulnerable to the 
acquisition of secondary mutations necessary for leukaemia development. 
1.11 Project Aims 
 
1. Studies have demonstrated that, while RE is insufficient to induce 
leukaemogenesis in murine models, RE9a is a potent inducer of 
leukaemia. The low leukaemogenic potential of RE has been related to its 
ability to induce robust cellular senescence in primary cells in vitro. This 
project aims to determine whether the increased leukaemogenic potential 
of RE9a correlates with impaired induction of cellular senescence in 
primary cells. 
2. RE9a is a C-terminally truncated splice variant of RE which lacks the 
repressive NHR3 and NHR4 domains. If RE9a is indeed demonstrated to 
evade senescence, it would be interesting to identify whether disruption 
of one of these domains is sufficient to promote senescence evasion. 
3. The SASP has been identified as a promoter of cellular senescence. 
However, a chronic or persistent SASP has been found to have pro-
oncogenic effects in certain context. This study aims to compare the 
Secretory profiles observed in cells expressing wild-type RUNX1 to those 
observed in cells expressing RE and RE9a to further elucidate the 
mechanisms of enhanced leukaemogenicity induced by RE9a expression. 
4. Previous studies have demonstrated that the TR fusion protein fails to 
induce cellular senescence in primary cells despite its retention of almost 
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full length RUNX1, a known senescence inducer. This study aims to 
identify the critical domains required for TR to evade  senescence . 
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2 Materials and Methods 
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2.1 Mammalian Cell Culture 
 
Mammalian cell culture was performed in a sterile class II laminar flow hood 
using standard aseptic procedures. 
All media and supplements were purchased from Invitrogen Life Technologies as 
sterile solutions unless stated otherwise. 
2.1.1 Cell lines  
 
293T cells (ATCC) are a highly transfectable cell line derived from 293 human 
embryonic kidney (HEK) cells that have been transformed using adenovirus E1a. 
The “T” refers to the expression of the SV40 T-antigen which allows replication 
of plasmids containing an SV40 origin of replication to a high copy number. 
Phoenix (Eco) cells are an ecotropic retroviral packaging cell line derived from 
the 293T cell line. The Phoenix line was created by transfecting 293T cells with 
constructs expressing a retroviral gag-pol under hygromycin selection and the 
ecotropic envelope protein under diphtheria toxin selection. 
Hs68 primary human foreskin fibroblasts (Sigma-Aldrich) isolated from a 
newborn Caucasian male were purchased from Sigma-Aldrich. Hs68 cells were 
expanded to passage 22 and frozen for use. Hs68 cells expressing a MLV 
ecotropic receptor were provided by Professor Gordon Peters. 
Murine Embryonic Fibroblasts (MEFs) were isolated from E13.5 mouse embryos 
[230]. The head and red organs were removed and the body minced and treated 
with 0.5% trypsin to disperse the cells which were then expanded for culture. 
Leiden cells are p16INK4a null human diploid fibroblasts isolated from a male who 
developed multiple naevi from a young age which had become atypical.  
NIH3T3 cells are a line of MEFs established by 3T3 passage culture protocol 
[231]. 
REH cells are a suspension cell line derived from a patient with ALL. 
HepaRG cells are terminally differentiated hepatic cells. The HepaRG cells used 
in this study have been transduced using lentiviruses (pLKO) to express his-
tagged SUMO1, SUMO-2 or SUMO-3. Expression was maintained using continuous 
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puromycin selection. These cells were kindly gifted by Dr Elizabeth Sloan and 
Professor Roger Everett. 
2.1.2 Maintenance of Mammalian Cells 
 
Mammalian cells were cultured at 37°C in humidified incubators maintained at 
5% CO2 and 20% or 3% oxygen. Cells were maintained in complete medium (10% 
foetal-calf serum (FCS), 2mM L-glutamine and 100 units each of penicillin and 
streptomycin). All cells were maintained in DMEM with the exception of HepaRG 
cells which were cultured in WME and REH cells which were maintained in RPMI 
1640. Cells were passaged at 80%-90% confluence every 3-4 days.  
2.1.3 Making Cell Pellets 
 
Adherent cells were trypsinised using a 0.05% trypsin-EDTA solution. Trypsinised 
or suspension cells were harvested and centrifuged at 172g for 5 minutes. The 
supernatant was discarded and cells washed with cold PBS and centrifuged at 
172g for 5 minutes. Cells were resuspended in PBS and transferred into cold 
Eppendorf tubes which were centrifuged at 3823g for 2 minutes before the 
supernatant was discarded and pellets stored at -80°C. 
2.1.4 Cell Cryopreservation and Recovery  
 
To make liquid nitrogen stocks, cells were trypsinised and pelleted as described 
above and resuspended in freezing medium (10% DMSO in FCS) at 3-5x106 
cells/ml; 1ml aliquots were transferred into cryovials. Vials were frozen 
overnight at -80°C in an isopropanol freezing chamber before being transferred 
to liquid nitrogen for long-term storage. 
Cell stocks were thawed rapidly at 37°C prior to use. The outside of the cryovial 
was decontaminated using 70% ethanol and the contents diluted in 7ml pre-
warmed complete medium. Cells were centrifuged for 5 minutes at 172g or 10 
minutes at 62g for 293T and Phoenix cells. Supernatant was discarded and cells 
resuspended in complete medium and transferred into a tissue culture flask.  
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2.1.5 Cell Viability Counts  
 
Trypsinised cells were suspended in media or PBS. 20µl of the cell suspension 
were diluted 1:1 with 0.4% trypan blue and incubated at room temperature for 1 
minute to stain dead cells. The mixture was introduced into the 
haemocytometer and cell counts made by counting the cells in each of the four 
sets of 16 corner squares. Cells lying on the top and bottom perimeters of the 
large squares were included in the counts while those lying on the left of right 
perimeters were excluded. Cells/ml was calculated using the equation;  
Number of cells x (1x104) x dilution factor 
2.1.6 Growth Curves  
 
Cells were plated at 2.5x104/well in 12 well plates in selection medium 
containing 2µg/ml puromycin (Sigma Aldrich). Each cell type was plated out in 
triplicate. Cell viability counts were performed every 2-3 days and cells were re-
fed with fresh selection medium.  
2.1.7 SA-β-Gal Staining  
 
Cells were plated in triplicate at 2.5x104 per well in a 12 well plate for 6 days. 
SA-β-Gal activity was detected as previously described [130]. Briefly, cells were 
washed with PBS then fixed with 0.5% glutaraldehyde in PBS for 10 minutes at 
room temperature. Cells were washed with PBS supplemented with 1mM MgCl2 
before staining overnight at 37°C in 0.22µm filtered X-Gal solution (1mg/ml X-
Gal, 0.12mM K3Fe[CN]6 and K4[Fe]CN6, 1mM MgCl2 in PBS pH6.0. Cells were 
washed with pH6.0 PBS. 
2.1.8 3T3 Passage Culture  
 
3T3 passage culture was performed on MEFs according to the protocol used by 
Todaro and Green [231]. Three independent cultures per retroviral construct 
were harvested and re-plated at 3x105 cells per T25 flask. This was repeated 
every 3 days over 14 passages. Cumulative gains were calculated and plotted. 
2.1.9 ROS analysis  
 
Trypsinised cells were suspended in PBS with 15µM 2’,7’ –dichlorofluorescein 
diacetate (DCF-DA) (Calbiochem) and incubated at 37°C for 20 minutes. Cells 
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were centrifuged at 172g for 5 minutes and the supernatant discarded. Cell 
pellets were resuspended in PBS and the centrifugation step repeated. Cells 
were resuspended in PBS and DCF fluorescence (maximum excitation 495nm; 
maximum emission 530nm) measured on an Accuri C6 flow cytometer (BD 
Biosciences) using a 488nm blue laser and detecting fluorescence using the FL1 
channel with a 533/30 filter. The cell population was gated on a forward 
scatter/side scatter plot to exclude debris and the mean DCF fluorescence of the 
gated population was measured. 
2.1.10 Drug Treatments  
2.1.10.1 Sodium Pyruvate  
 
Sodium pyruvate was diluted in ddH2O and added to cell culture medium at 
250µM. Treatment of cells commenced on the day of antibiotic selection and 
medium was changed every 2-3 days. 
2.1.10.2 SB203580  
 
SB203580 was diluted in DMSO and added to cell culture medium at a final 
concentration of 8µM. Treatment of cells commenced on the day of antibiotic 
selection and medium with inhibitor was changed every 2-3 days. 
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2.2 DNA and Viruses  
2.2.1 Plasmids  
2.2.1.1 pBabe  
 
The pBabePURO vector was derived from the Moloney Murine Leukaemia Virus 
(MMLV) and encodes a viral packaging signal in addition to the MMLV LTR which 
promotes expression of inserted genes. The vector also contains a puromycin 
resistance gene to enable selection of infected cells post-transduction. To 
enable propagation in bacterial cells, pBabePURO also contains the bacterial 
origin of replication (ORI) and an ampicillin resistance gene [232].  
 
 
Figure 2.1 pBabe PURO Plasmid Map 
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2.2.1.2 pLenti6  
 
The pLenti6 vectors are lentiviral expression vectors (a kind gift from Dr John 
Van Tuyn). pLenti6 vectors promote expression from a CMV promoter and 
contain puromycin or neomycin resistance genes to enable selection of infected 
cells post-transduction. To enable propagation of the vectors in bacterial cells, 
pLenti6 vectors also contain a bacterial origin of replication (ORI) and an 
ampicillin resistance gene. 
 
Figure 2.2 pLenti6PURO Plasmid Map 
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2.2.1.3 psPAX2  
 
psPAX2 is a lentiviral helper plasmid expressing the HIV gag, pol, tat and rev 
genes. Gag, pol and env encode viral structural proteins required to assemble a 
functional virus while rev is involved in the regulation of viral protein 
expression. 
 
Figure 2.3  psPAX2 Plasmid Map 
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2.2.1.4 pCMV-VSVG  
 
pCMV-VSVG is a lentiviral helper plasmid expressing the G-glycoprotein of 
vesicular stomatitis virus (VSV-G) under the control of a CMV promoter. The VSV-
G protein facilitates the fusion of viral and cellular membranes by interacting 
with phospholipids on the surface of the target cell. 
 
Figure 2.4  pCMV-VSVG Plasmid Map 
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2.2.2 Bacterial Work 
2.2.2.1 Bacterial strains  
 
Bacteria were cultured in LB broth or on LB agar plates supplemented with 
ampicillin (100µg/ml) as described in Table 1. 
 
 
Bacteria 
 
Culture Conditions 
 
Plasmid 
 
Top10 Chemically 
Competent E.coli 
(Invitrogen) 
 
37°C for 16 hours 
 
pBabePURO, psPAX2, 
pCMV-VSVG 
 
JM110 Chemically 
Competent E.coli (Agilent) 
 
37°C for 16 hours 
 
pLentiPURO/pLentiNEO 
for XbaI cloning 
 
Stbl2 Chemically 
Competent E.coli 
(Invitrogen) 
 
30°C for 48 hours 
 
Cloned 
pLentiPURO/pLentiNEO 
 
Table 1.1  Chemically Competent E.coli 
  
2.2.2.2 Bacterial Transformation  
 
Chemically competent E.coli were transformed with 1-10ng of plasmid DNA in 
accordance with the manufacturers protocols. 50µl of transformed cultures were 
spread on LB agar plates supplemented with ampicillin (100µg/ml).  
2.2.2.3 Glycerol Stocks  
 
Glycerol stocks were prepared by mixing 200µl glycerol with 800µl of culture 
with ampicillin to make a 20% glycerol mixture for storage at -80°C.  
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2.2.3 DNA  
2.2.3.1 Miniprep  
 
Sterile bijoux tubes with 2ml lysogeny broth (LB) with 100µg/ml ampicillin were 
inoculated with bacteria using a sterile pipette tip. Cultures were incubated 
with shaking as described in Table1. 1.5ml of each culture was harvested by 
centrifugation and DNA was extracted using the Qiaprep Miniprep kit (Qiagen) 
according to the manufacturer’s instructions. 
2.2.3.2 Maxiprep  
 
200ml LB media supplemented with 100µg/ml ampicillin were inoculated with 
500µl of miniprep culture or a sterile loop dipped in glycerol stock. Cultures 
were incubated with shaking as described in Table 1. Bacteria were pelleted by 
centrifugation at 4°C at 4000g for 20 minutes. DNA isolation was performed 
using the EndoFree Plasmid Maxi Kit (Qiagen) in accordance with the 
manufacturer’s protocol. 
2.2.3.3 Determining DNA Concentration  
 
DNA concentration was determined using the Nanodrop 2000 Spectrophotometer 
(Thermo Scientific). TE buffer or ddH2O were used as a blank where appropriate. 
2.2.3.4 Gel Electrophoresis of DNA  
 
Agarose powder was melted in 1xTAE buffer (40mM Tris, 20mM acetic acid and 
1mM EDTA) to give a 1% or 1.5% agarose gel which was set and submerged in 
1xTAE buffer. DNA samples were diluted with distilled water or TE buffer 
(Qiagen) to give 1µg of DNA in a final volume of 20µl to which 5ul of sample 
loading buffer was added. Samples were loaded alongside a DNA ladder (1kb or 
10kb) and gels run at 100 volts for 60-90 minutes. The gel was removed to a 
container, submerged in 1xTAE supplemented with ethidium bromide (0.5µg/ml) 
and incubated at room temperature with shaking for 20 minutes. The gel was de-
stained for 10-20 minutes in ddH2O and visualised on a transilluminator. 
2.2.3.5 DNA Purification from Gel  
 
A long-wave UV light source was used to identify the desired DNA fragment 
which was excised from the gel using a clean scalpel and purified using the 
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QiaQuick Gel Extraction kit (Qiagen) in accordance with the manufacturer’s 
instructions. 
2.2.3.6 DNA Sequencing  
 
DNA sequencing was performed by Source Bioscience. Plasmid solutions were 
diluted with ddH2O to give a concentration of 100ng/µl and primers were diluted 
to a concentration of 3.2pmol/µl. A minimum of 5µl each of sample and primer 
were included per reaction. DNA sequencing was subsequently analysed using 
CLC workbench to confirm that the correct sequence was present. 
2.2.4 Viral Vectors  
2.2.4.1 Cloning  
 
Inserts encoding RUNX1P1, RUNX1P2, RE, RE9a, DNHR3, DNHR4, mNHR3, TR and 
TR K99R were subcloned into lentivirus vectors. The inserts encoding RUNX1P1, 
RUNX1P2, TR and TR K99R were excised from the pBabePURO retroviral vector 
by restriction digest with EcoRI. RE was excised from a pCMV vector (a kind gift 
from Professor Scott Heibert) by restriction digest by XbaI. DNHR3, DNHR4 and 
mNHR3 were inserted into Topo subcloning vectors and excised using a SalI 
restriction enzyme. 
Digested fragments were separated by gel electrophoresis, purified using the 
QiaQuick Gel Extraction Kit (Qiagen) and resuspended in 20µl TE buffer. The 
pLenti vectors were simultaneously digested using appropriate restriction 
enzymes (New England Biolabs) and purified as described. The cut vector was 
treated with Antarctic phosphatase (New England Biolabs) to prevent religation, 
according to the manufacturer’s instructions. The excised inserts were ligated 
into the pLenti backbones using the Quick Ligation Kit (New England Biolabs) in 
accordance with the manufacturer’s protocol. Transformation of competent 
bacteria was performed as described. Up to 12 colonies of the transformed 
bacteria were picked and inoculated into LB broth for miniprep. Minipreps were 
screened for successful clones by diagnostic restriction digest, confirmed by 
sequencing and maxipreps performed. 
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2.2.4.2 Lentiviruses  
2.2.4.2.1 Production of a Concentrated Lentivirus Stock 
 
293T cells were plated at 11x106 cells in T150 flasks and incubated overnight. 
293T cells were transfected with lentiviral plasmids (20 µg pLenti6PURO, 8µg 
psPAX2 and 5µg pCMV-VSVG) using Lipofectamine 2000 (Invitrogen) according to 
the manufacturer’s instructions. Viral supernatants were collected 48 hours and 
72 hours post-transfection and filtered through 0.45µm filters. Supernatants 
were concentrated by ultracentrifugation for 2 hours at 166880g. Supernatant 
was discarded and the pelleted virus resuspended in PBS overnight at 4°C with 
shaking. Virus was frozen rapidly on dry ice and stored at -80°C in 20µl aliquots. 
2.2.4.2.2 Calculating Lentivirus Concentration  
 
NIH 3T3 cells were seeded at 8x103 per well in 12-well plates, incubated 
overnight, then the cells were fed with 1ml complete media supplemented with 
polybrene (4µg/ml). Virus was thawed rapidly at 37°C and agitated to resuspend 
particles. 11µl of virus stock were added to one well and mixed. A series of 1:5 
serial dilutions were performed over 6 wells and plates were incubated for 48 
hours at 37°C. The virus/polybrene mixture was replaced with complete media 
supplemented with 2µg/ml puromycin (Sigma) and incubated for 8 days. Cells 
were fixed with 100% methanol for 10 minutes then washed with PBS (pH6.8) and 
stained with 10% Giemsa in PBS (pH6.8) for 30 minutes. The plates were washed 
with water and discreet colonies counted. Plaque-forming units (pfu)/µl was 
calculated using the following equation; 
Number of Plaques x Dilution Factor 
2.2.4.2.3 Lentiviral Transduction 
 
Target cells were plated at 8x105 per 10cm dish and incubated overnight at 37°C 
in 3% oxygen, 5% CO2 conditions. Cells were infected with enough virus to give a 
mulitiplicity of infection (MOI) of 1 which indicates that there should be roughly 
one virus particle for every cell. Infection medium was supplemented with 
polybrene (4µg/ml) to improve transduction efficiency. The cells were incubated 
with the virus/polybrene mixture for 8-10 hours at 37°C then re-fed with 
complete media overnight. Cells were selected with puromycin (2µg/ml) for 5 
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days. Non-transduced cells died under selection, confirming successful selection. 
Transduced cells were plated for experimental purposes. 
2.2.4.3 Retroviruses  
2.2.4.3.1 Retrovirus Production  
 
Phoenix Eco cells were plated at 5x106 cells in 10cm dishes and incubated at 
37°C overnight. Phoenix cells were transfected with pBabePURO expression 
vectors using Superfect Transfection Reagent (Qiagen) in accordance with the 
manufacturer’s instructions. Viral supernatants were harvested after 48 hours 
and 72 hours and filtered through a 0.45μm filter. 
2.2.4.3.2 Retroviral Transduction 
 
Target cells were plated at 8x105 cells in 10cm dishes and incubated overnight. 
Cells were infected using harvested (48 hour) viral supernatant supplemented 
with polybrene (4µg/ml) for 24 hours and then with the 72 hour supernatant for 
8 hours. Supernatants were replaced with complete medium overnight then re-
fed with selection medium with puromycin (2μg/ml). After 5 days, puromycin 
resistant cells were counted and re-plated for experimental work. 
2.3 Protein Analysis  
2.3.1 Protein Extraction  
2.3.1.1 Whole Cell Lysis 
 
Cell pellets were lysed in 100µl lysis buffer per 106 cells. Buffers used were 
whole cell lysis (WCL) buffer (Section 2.7.1.1), immunoprecipitation lysis buffer 
or radioimmunoprecipitation assay (RIPA) buffer (Section 2.7.1.2). Lysates were 
incubated at 4°C with rotation for 10 minutes and centrifuged for 30 minutes at 
20000g. Supernatants were transferred to a fresh, cold eppendorf. Protein 
concentrations were determined (See Section 2.3.2) and lysates stored at -80°C. 
2.3.1.2 Whole Cell Fractionation  
 
Cell pellets were lysed using lysis buffer 1 (Section 2.7.2.1) and homogenised 
using a 21G needle to ensure cells were lysed but nuclei remained intact. 
Samples were then transferred to clean eppendorf tubes. Nuclei were pelleted 
by centrifugation at 3000g for 10 minutes. The supernatants were retained and 
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transferred to clean tubes. Nuclei were washed again in lysis buffer 1 and 
pelleted by centrifugation at 3000g for 10 minutes. The supernatant was again 
retained and combined with supernatant from the previous step. The pelleted 
nuclei were washed with 500µl nuclear lysis buffer 1 (Section 2.7.2.3) and 
centrifuged for 5 minutes at 370g. This was repeated twice before the nuclear 
pellet was resuspended in Nuclear Lysis Buffer 2 (Section 2.7.2.4) and labelled as 
the “Nuclear Fraction”. The supernatants retained after cell lysis were 
centrifuged at 5000g for 15 minutes and then ultracentrifuged for 1 hour at 
100,000g to pellet membrane-associated proteins. Supernatants were retained 
and labelled as the “cytoplasmic fraction”. Pelleted membrane proteins were 
washed with 0.5mM Tris-HCL then dissolved in 500µl of membrane lysis buffer 
(Section 2.7.2.2) and centrifuged at 20000g for 15 minutes. Supernatants were 
stored in fresh tubes and labelled as the “membrane fraction”. All centrifuge 
spins were performed at 4°C. 
2.3.1.3 His-Affinity Purification  
 
Cell pellets were lysed with 1ml of guanidinium lysis buffer (GLB) (Section 
2.7.3.1) per 1x108 cells. Samples were kept on ice and sonicated on 10% 
amplitude for one minute (Branson Digital). This was repeated four times for 
each sample. Lysed samples were centrifuged for 7 minutes at 3800g and 
filtered through a 0.45µm syringe filter. 20µl Nickel NTA agarose beads were 
washed twice in 500µl GLB and centrifuged for 2 minutes at 955g to pellet the 
beads. Samples were then added to the washed beads and the mixture rotated 
at 4°C for 16 hours, centrifuged for 5 minutes at 955g and the supernatant 
discarded. Beads were washed as follows, once with 500µl GLB, twice with pH8 
Wash Buffer (Section 2.7.3.2, twice with pH6.3 wash buffer (2.7.3.3) and once 
with pH8 wash buffer with centrifugation as before. Residual buffer was 
removed from the beads before they were resuspended in 40µl of elution buffer 
(Section 2.7.4.1). The tubes were agitated for 10 minutes at room temperature 
before the samples were boiled at 100°C for 2 minutes. Boiled samples were 
stored at -20°C. 
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2.3.2 Determining Protein Concentration 
 
Bovine serum albumin (BSA) protein standard was diluted using ddH2O to give a 
standard curve (0.2mg/ml to 1.4 mg/ml). The Bicinchoninic Acid (BCA) Protein 
Assay Dye Concentrate (Bio-Rad) was diluted 1:5 with dH2O and filtered through 
1mm filter paper (Whatman). Samples were diluted 1/500 in the prepared dye 
and incubated in sterile cuvettes for 5 minutes at room temperature. OD595 was 
determined against a blank of ddH2O with diluted Protein Assay Dye 
Concentrate. Concentrations were determined using a standard curve produced 
from the BSA standards. 
2.3.3 Western Blot  
 
Whole cell lysates were diluted with ddH2O to 30µg protein per 20µl. Samples 
were supplemented with 2µl Sample Reducing Agent (Invitrogen) and 5µl Sample 
Buffer (Invitrogen) and denatured at 70°C for 10 minutes. Samples were loaded 
into pre-cast NuPAGE™ Novex™ 4-12% Bis-Tris Gels (Life Technologies) which 
were run at 35mA in MOPs SDS running buffer (NP0001, Life Technologies) 
diluted to 1x concentration with ddH2O until the dye front reached the bottom 
of the gel.  
Protein transfer was performed by wet-blotting of gels onto a nitrocellulose 
membrane (Amersham). The transfer was set up in a cassette as described in 
Figure 2.5, submerged in transfer buffer (Section 2.7.4.1) and performed for 1 
hour at 100 volts. The nitrocellulose membrane was blocked in 1xTBST (Section 
2.7.4.2) with 5% fat-free milk powder (Marvel) for 1 hour at room temperature 
or 4°C overnight. 
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Figure 2.5 Western Blotting Transfer Sandwich 
 
2.3.4 Protein Detection  
 
Blocked membranes were washed 3 x 10 minutes in 1xTBST with shaking. 
Primary antibodies were diluted in 1xTBST with 5% milk powder or 5% BSA as 
specified in Section 2.8. Membranes were incubated in the primary antibody 
with shaking for 1-2 hours at room temperature or overnight at 4°C. The 
membrane was washed as above then incubated with the appropriate HRP-linked 
secondary antibody for 1 hour at room temperature with shaking. The membrane 
was washed as previously specified prior to using ECL chemiluminescent 
substrate (Pierce) to detect HRP-linked secondary. Western blots were 
subsequently developed in a dark room using ECL film. Band densitometry was 
determined using ImageJ software. 
2.3.5 Membrane Stripping  
 
Membranes were submerged in a mild stripping buffer (Section 2.7.4.3) and 
incubated at room temperature with shaking for 1 hour. Membranes were then 
washed 3 x 10 minutes with 1xTBST and blocked with 1xTBST with 5% milk 
powder. 
2.4 Immunofluorescence 
 
Glass coverslips or chamber slides were covered with 13.3µg/ml poly-L-lysine in 
ddH2O and incubated overnight at 37°C before the mixture was decanted and 
the slides dried in a sterile laminar flow hood before being washed with PBS. 
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Cells were plated on the poly-L-lysine coated glass chamber slides or coverslips 
and incubated for 1-6 days. Cells were fixed with 4% paraformaldehyde in PBS 
for 15 minutes at room temperature then washed three times with PBS and 
permeabilised with 3 x 10 minute incubations with 0.1% Triton-X-100 in PBS. 
Cells were blocked for an hour with blocking buffer (10% FCS and 0.1% Triton-X-
100 in PBS) and incubated overnight at 4°C with the appropriate primary 
antibody diluted in blocking buffer (Section 2.8.1). Slides were washed 2 x 5 
minutes with 0.1% Triton-X-100 in PBS and 1 x 5 minutes in blocking buffer. 
Slides were incubated with a secondary antibody (Section 2.8.2) diluted in 
blocking buffer (1:100) at room temperature in the dark for 1 hour. Slides were 
mounted using Vectashield hard-set mounting medium with DAPI (Vector 
Laboratories) and imaged using an LSM Confocal 710 (Zeiss). 
2.5 Cytokine Detection  
2.5.1 ELISA  
 
Cells were plated out at 2.5x104 in 12-well plates and fed with fresh media every 
3 days. On day 6 post-selection, the cell culture medium was harvested and 
stored at -80°C and the cells were counted. Harvested media was thawed 
rapidly at 37°C. A Quantikine IL-6 ELISA (R & D Systems) was performed in 
accordance with the manufacturer’s protocol. Plates were analysed at 450nm 
using an ELISA plate reader. Plates were additionally read at 540nm to remove 
background fluorescence. The values were normalised to cell count and final 
values were normalised to the empty vector control. 
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2.5.2 Cytokine Array  
 
Cells were plated out at 2.5x104 in 12 well plates. At 4 days post-selection, 
complete DMEM was replaced with DMEM supplemented with 0.2% FCS. At 6 days 
post selection, the cell culture medium was harvested and stored at -80°C. 
Harvested supernatant was thawed rapidly at 37°C. Supernatants were diluted 
to control for cell-number using DMEM with 0.2% FCS and applied to a human 
cytokine array chip (RayBiotech) and treated as specified in the manufacturer’s 
guidelines. Slide reading and was performed by RayBiotech using a 532nm laser. 
Fluorescence was normalised to remove background fluorescence. 
The following cytokines were measured using this array; 
 
Acrp30 
AgRP 
Amphiregulin 
Angiogenin  
Angiopoietin-2 
Axl 
BDNF 
bFGF 
BLC 
BMP-4 
BMP-6 
b-NGF 
BTC 
CCL-28 
CK beta 8-1 
CNTF 
CTACK 
Dtk 
EGF 
EGF-R 
ENA-78 
Eotaxin 
Eotaxin-2 
Eotaxin-3 
Fas/TNFRSF6 
FGF-4 
FGF-6 
FGF-7 
FGF-9 
Flt-3 Ligand 
Fractalkine 
GCP-2 
GCSF 
GDNF 
GITR 
GITR-Ligand 
GM-CSF 
GRO 
GRO-alpha 
HCC-4 
HGF 
I-309 
ICAM-1 
ICAM-3 
IFN-gamma 
IGFBP-1 
IGFBP-2 
IGFBP-3 
IGFBP-4 
IGFBP-6 
IGF-I 
IGF-I SR 
IL-1 R4/ST2 
IL-1 RI 
IL-10 
IL-11 
IL-12 p40 
IL-12 p70 
IL-13 
IL-15 
IL-16 
IL-17 
IL-1alpha 
IL-1beta 
IL-1ra 
IL-2 
IL-2 Rapha 
IL-3 
IL-4 
IL-5 
IL-6 
IL-6 R 
IL-7 
IL-8 
I-TAC 
Leptin 
LIGHT 
Lymphotactin 
MCP-1 
MCP-2 
MCP-3 
MCP-4 
M-CSF 
MDC 
MIF 
MIG 
MIP-1alpha 
MIP-1beta 
MIP-1-delta 
MIP-3-alpha 
MIP-3beta 
MSP-alpha 
NAP-2 
NT-3 
NT-4 
Oncostatin M  
Osteoprotegerin  
PARC 
PDGF-BB 
PIGF 
RANTES 
SCF 
SDF-1 
sgp130 
sTNF RII 
sTNF-RI 
TARC 
TECK 
TGF-beta 1 
TGF-beta 3 
Thrombopoietin  
TIMP-1 
TIMP-2 
TNF-alpha  
TNF-beta 
TRAIL R3 
TRAIL R4 
uPAR  
VEGF 
VEGF-D 
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2.6 Statistical Tests 
 
Charts and graphs display the mean of at least 3 independent replicates ± 
Standard Deviation (SD). Statistical significance in histograms was calculated 
using the analysis of variance (ANOVA) statistical test to analyse the difference 
between transduced cells relative to the empty vector control (PURO) cultures. 
P-values are denoted using asterisks (* p<0.05, **p<0.01, ***p<0.001). 
2.7 Buffers and Solutions 
2.7.1 Cell Lysis Buffers  
2.7.1.1 Whole Cell Lysis Buffer (WCL)  
 
20mM Hepes (pH 7.0), 5mM EDTA, 10mM EGTA, 5mM NaF, 1mM DTT, 0.4% Triton-
X-100, 10% Glycerol. WCL was aliquoted and stored at -20°C. It was 
supplemented immediately prior to use with 0.1µg/ml okadaic acid (OA) and 
protease inhibitors as follows; 5µg/ml aprotinin, 5µg/ml leupeptin, 5µg/ml 
pepstatin-A, 1mM benzamidine, 50µg/ml PMSF. 
2.7.1.2 Radioimmunoprecipitation Assay Buffer (RIPA)  
 
150mM NaCl, 1% NP40, 0.5% DOC, 0.1% SDS, 50mM Tris (pH8.0). Aliquoted and 
stored at -20°C. Supplemented immediately prior to use with 0.1µg/ml OA and 
protease inhibitors as follows; 5µg/ml aprotinin, 5µg/ml leupeptin, 5µg/ml 
pepstatin-A, 1mM benzamidine, 50µg/ml PMSF. 
2.7.1.3 Immunoprecipitation Lysis Buffer 
 
150mM NaCl, 50mM Tris (pH8.0), 5mM EDTA, 0.5% NP40. Aliquoted and stored at 
-20°C. Immediately prior to use, ILB was supplemented with 1mM DTT, 0.2mM 
sodium orthovanadate (Na3VO4), 10µg/ml leupeptin, 2.5µg/ml pepstatin-A, 1mM 
PMSF, 10µg/ml aprotinin, 10mM β-glycerophosphate. 
2.7.2 Cell Fractionation Buffers  
2.7.2.1 Lysis Buffer 1  
 
10mM Tris/HCl (pH7.5), 0.5mM EDTA, 0.3M sucrose. Aliquoted and stored at -
20°C. Supplemented prior to use with 1mM Na3VO4, 50µg/ml PMSF 
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2.7.2.2 Membrane Lysis Buffer  
 
20mM HEPES (pH7.0), 150mM NaCl, 0.5% NP40. Aliquoted and stored at -20°C 
Supplemented prior to use with 1mM Na3VO4, 50µg/ml PMSF, 5µg/ml pepstatin-
A, 5µg/ml leupeptin, 1mM benzamidine, 5µg/ml aprotinin, 0.1µg/ml OA. 
2.7.2.3 Nuclear Lysis Buffer 1  
 
10mM HEPES (pH7.0), 60mM KCl, 1mM EDTA. 
2.7.2.4 Nuclear Lysis Buffer 2 
 
10mM Hepes (pH7.0), 60mM KCl, 1mM EDTA, 1% NP40. 
2.7.3 Nickel Affinity Purification Buffers  
2.7.3.1 Guanidinium Lysis Buffer  
 
6M guanidinium hydrochloride, 94.7mM Na2HPO4, 5.3mM NaH2PO4, 10mM 
Tris/HCl (pH8.0), 20mM imidazole, 5mM β-mercaptoethanol, EDTA-free protease 
inhibitor cocktail (Roche). 
2.7.3.2 Wash Buffer (pH 8.0)  
 
8M urea, 94.7mM Na2HPO4, 5.3mM NaH2PO4, 10mM Tris/HCl (pH8.0), 5mM β-
mercaptoethanol, EDTA-free protease inhibitor cocktail (Roche). 
2.7.3.3 Wash Buffer (pH 6.3)  
 
8M urea, 22.5mM Na2HPO4, 77.5mM NaH2PO4, 10mM Tris/HCl (pH8.0), 5mM β-
mercaptoethanol, EDTA-free protease inhibitor cocktail (ensure pH6.3, adjust if 
necessary). 
2.7.3.4 Elution Buffer 
 
200mM Imidazole, 2x LDS (Invitrogen), 1x reducing agent (Invitrogen). 
 
2.7.4 Western Blot Buffers  
2.7.4.1 Transfer Buffer  
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Transfer buffer was made as a 10x solution (1.92M glycine and 250mM Tris) and 
diluted using ddH2O and methanol to give a 1x solution containing 20% methanol. 
2.7.4.2 TBST  
 
TBST was made as a 10 x solution (0.1M Tris-Base, 1.5M NaCl, 0.5% Tween-20). It 
was adjusted to pH8.0 and diluted using ddH2O to make a 1x solution prior to 
use. 
2.7.4.3 Membrane Stripping Buffer  
 
0.2M glycine (pH2.5), 1% SDS. Made fresh prior to use. 
2.8 Antibodies  
 
Antibodies were diluted in TBST with 5% skimmed milk powder unless stated 
otherwise. 
2.8.1 Primary Antibodies  
2.8.1.1 Santa Cruz Biotechnology., Inc  
 
Anti-Actin, sc1616 (1:1000)  
Anti-p53, sc-126 (1:1000)  
Anti-p16, sc-468 (1:1000)  
2.8.1.2 Medical and Biological Laboratories Co., Ltd  
 
Anti-RUNX, D207-3 (1:1000)  
2.8.1.3 Cell Signalling Technology  
 
Anti-p38P, 9211 (1:1000 in 5% BSA)  
Anti-p38 (Total), 9212 (1:1000)  
Anti-HA, C29F4 (1:100 in 10% FCS and 0.1% Triton-X-100 in PBS for confocal). 
2.8.1.4 Abcam  
 
Anti-Calnexin, ab22595 (1:1000)  
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Anti-His, ab18184 (1:1000 for western blot and 1:200 in 10% FCS and 0.1% Triton-
X-100 in PBS for confocal).  
2.8.1.5 MerckMillipore 
 
Anti-ϒH2AX, JBW301 (1:200 in 10% FCS and 0.1% Triton-X-100 in PBS for confocal)  
2.8.2 Secondary Antibodies  
2.8.2.1 DAKO Ltd  
 
Polyclonal Swine anti-rabbit Immunoglobulins/HRP (1:3000) 
Polyclonal rabbit anti-mouse immunoglobulins/HRP (1:1000) 
Polyclonal rabbit anti-goat immunoglobulins/HRP (1:2000) 
2.8.2.2 Stratech Scientific Ltd 
 
FITC-conjugated Sheep anti-mouse IgG (1:200 in 10% FCS and 0.1% Triton-X-100 
in PBS for confocal). 
2.9 General Chemicals 
 
General chemicals were molecular grade quality and were supplied by Sigma, 
Thermo-Fisher, Invitrogen or VWR Prolabo unless stated otherwise. 
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3   RUNX1-ETO9a Fails to Induce Premature 
Senescence in Primary Cells 
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3.1 Introduction  
 
The RE fusion protein generated by the t(8;21) chromosomal translocation is 
associated with 40% of AML (M2 subtype) [233]. Despite this strong association 
with AML in humans, expression of RE is insufficient to induce leukaemia in 
retroviral transduction/transplantation mouse models [76]. Furthermore, It has 
been suggested that the t(8;21) fusion is an early event and that it persists for a 
long period of time before leukaemia develops. Indeed, studies in CD34+ cells 
have demonstrated that retroviral expression of RE results in a growth arrest 
that is eventually overcome by a more primitive population of cells. However, 
this cell population is not transformed, further supporting the suggestion that RE 
itself is insufficient for leukaemogenesis to occur [82]. A study of a RE retroviral 
transduction/transplantation model found that the only mouse in the study to 
develop leukaemia was expressing a spontaneous truncated RE mutant [98]. 
Moreover, an alternatively spliced variant of RE, RE9a has since been identified 
and is commonly co-expressed with RE in t(8;21) leukaemias [80]. In contrast to 
RE, RE9a is a potent inducer of leukaemia in mouse model systems with RE9a-
expressing mice developing leukaemia within weeks [80]. This may indicate that 
expression of RE9a is a key leukaemia promoting factor in RE-associated disease.  
RE has been identified as a potent inducer of premature SLGA in primary human 
fibroblasts. As studies have identified premature senescence as a potent tumour-
suppressor mechanism, the finding that RE induces a robust SLGA may correlate 
with its lack of leukaemogenic potential in murine models [59]. To determine 
whether the increased leukaemogenic potential of RE9a is linked to an evasion 
of this anti-cancer failsafe mechanism, RE9a was introduced into human and 
murine primary fibroblasts and the cells examined for markers of premature 
senescence.  
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Aims and Objectives 
 To examine whether primary cells transduced to express RE9a undergo 
premature senescence. 
 To compare the phenotype of RE9a and RE-expressing cells with respect 
to markers of premature senescence.  These will include cellular 
proliferation, SA-β-Gal staining activity and activation of the p53 and 
p16INK4a tumour suppressor pathways.  
3.2 Results 
3.2.1 RUNX1-ETO9a Fails to Induce Premature Senescence in Primary Cells  
 
Lentiviral vector constructs containing RE or RE9a were used to transduce 
primary human foreskin fibroblasts (Hs68 cells). The empty vector expressing a 
puromycin resistance gene was included as a control and will be referred to as 
PURO. Following selection, puromycin resistant cells were replated for a further 
6-10 days and the cells monitored for growth, morphology and the appearance of 
senescence markers. Day 0 refers to the day of replating after the selection 
period. 
To determine the ectopic expression levels of RE and RE9a, western blots were 
performed on samples collected on day 0. Expression of RE was lower than RE9a 
but exceeded that of endogenous RUNX1 in Hs68 cells (Figure 3.1 a). As 
previously reported, expression of RE was associated with a rapid and profound 
growth arrest. In contrast, RE9a-expressing cells continued to proliferate at a 
comparable rate to the PURO controls (Figure 3.1 b). RE-induced SLGA was 
accompanied by a characteristic flat and enlarged cellular morphology 
frequently associated with cellular senescence, and positive staining for SA-β-
Gal. PURO and RE9a cultures retained a spindle-shaped fibroblastoid morphology 
and displayed very little SA-β-Gal staining (Figure 3.1 c). Together, these data 
suggest that expression of RE9a failed to induce premature senescence in vitro. 
The p53 and p16INK4a tumour suppressor pathways have previously been 
identified as key drivers of premature senescence in primary human fibroblasts 
[126]. To determine whether RE9a-mediated evasion of senescence is 
accompanied by inactivation of either of these pathways, western blots were 
performed on samples collected 6 days after puromycin selection, when visible 
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signs of senescence such as altered morphology and SA-β-Gal staining were 
apparent. In contrast to a previous study using a retroviral expression system 
[59], p16INK4a was highly expressed in the presence of RE (Figure 3.1 d (i) and 
(ii)) while p53 expression was only modestly induced (Figure 3.1 e (i) and (ii)). 
Neither p16INK4a nor p53 were upregulated by RE9a, suggesting that failure to 
activate these key pathways underlies bypass or escape from premature 
senescence in RE9a-expressing Hs68s. 
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Figure 3.1 RUNX1-ETO9a fails to induce premature senescence in primary human fibroblasts 
 
Hs68 human fibroblasts were transduced with lentiviral vectors containing RE or RE9a. The 
empty vector (PURO) was included as a negative control. Transduced cells were selected using 
Puromycin. The results shown are representative of three biological replicates. (a) Western blot 
analysis of ectopic RE (83 kDa) and RE9a (62 kDa) in transduced Hs68 cells using an anti-RUNX 
antibody (D207-3, MBL Ltd). GP86 cells transduced to express RE and RE9a were included as 
positive controls. (b) Representative growth curves showing cell proliferation measured over 6 
days. Plots show the mean of three independent replicates and error bars show standard 
deviation. (c) Images captured after staining cells 6 days post-transduction for SA-β-Gal activity 
at pH6.0. Images were captured with a 20x magnification. Western blot analysis of expression of 
(d(i)) p16INK4a (sc-468, Santa Cruz Biotechnology Inc)  and (e(i)) p53 (sc-126, Santa Cruz 
Biotechnology Inc) in transduced Hs68 cells 6 days post-selection. Quantification of (d(ii)) p16INK4a 
and (e(ii)) p53 as determined by measuring the densitometry of bands on the adjacent western 
blots using ImageJ software and normalising the optical densitometry (OD) values to those 
obtained for the actin loading control. 
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3.2.2 RUNX1-ETO9a fails to induce a sustained growth arrest in primary 
MEFs 
 
Murine embryonic fibroblasts (MEFs) senesce more rapidly than their human 
counterparts due to their relatively high sensitivity to cellular stresses such 
oxidative stress and DNA damage [183]. However, they also have a greater 
capacity to escape cellular senescence due to inactivation of tumour suppressor 
pathways. To determine how RE9a affects senescence, primary MEFs were 
transduced with retroviral vectors containing RE and RE9a. An empty vector 
conferring resistance to puromycin was included as a negative control and will 
be referred to as PURO. 
Equivalent expression of RE and RE9a was confirmed by western blot analysis on 
day 0 samples (Figure 3.2 a). Expression of RE was accompanied by a profound 
growth arrest while RE9a cultures continued to proliferate albeit at a slightly 
reduced rate compared to PURO (Figure 3.2 b). In addition, RE9a-expressing 
cultures displayed distinct areas of flattened, enlarged cells that appeared 
senescent along with clear outgrowths of fibroblastoid non-senescent cells 
(Figure 3.2 c) suggesting that RE9a is a weaker inducer of senescence in primary 
MEFs. To examine effects on growth in more detail, 3T3 passage culture was 
performed to facilitate the outgrowth of cells with secondary mutations that can 
immortalise primary MEFs in vitro[231]. To this end, 3 parallel cultures of MEFs 
expressing PURO, RE and RE9a were passaged every 3 days at a fixed cell density 
and cumulative gains in cell number calculated over 14 passages. The Puro and 
RE9a cultures displayed accelerated growth from passage 4 with the RE9a 
cultures demonstrating a higher growth rate at later time points. The RE 
cultures failed to show accelerated growth until after passage 8, however, after 
this point, cumulative gain in cell number increased at a rate equivalent to RE9a 
(Figure 3.2 d). These data suggest that MEFs expressing RE9a are more prone to 
accumulating secondary mutations that favour immortalisation and that this may 
promote escape from senescence in vitro. 
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Figure 3.2 RUNX1-ETO9a induces a weak senescent phenotype in Murine Embryonic 
Fibroblasts (MEFs) 
Murine embryonic fibroblasts (MEFs) were transduced with lentiviral vectors expressing RE or 
RE9a. The empty vector (PURO) was included as a negative or normal cell control. Transduced 
cells were selected using puromycin. Results shown are representative of three biological 
replicates. (a) Western blot analysis of ectopic RE (83 kDa) and RE9a (62 kDa) expression in 
transduced MEFs using anti-RUNX (D207-3, MBL Ltd). GP86 cells transduced to express RE and 
RE9a were included as positive controls. (b) Representative growth curves of transduced MEFs 
recorded over the 7 days following selection. Plots show the mean of three independent 
replicates and error bars show standard deviation. (c) Images of transduced MEFs captured 6 
days post-selection showing proliferating and senescent cell populations. Images were captured 
using 20x magnification. (d) Plots showing cumulative gain in cell number over 14 passages in 
transduced MEFs subjected to 3T3 passage culture as described by Todaro and Green [231]. Plots 
show the mean of three independent replicates and error bars show standard deviation.  
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3.3  Discussion 
 
In this study, ectopic expression of the RE9a splice variant of RE failed to induce 
premature senescence in primary human Hs68 fibroblasts. The cells did not 
display arrested growth and retained a fibroblastoid morphology with no 
evidence of SA-β-Gal staining, all of which are characteristic of the senescence 
phenotype. Since premature senescence is a fail-safe mechanism engaged in 
response to certain oncogenes, the ability to overcome it may account for the 
greater leukaemogenic potential of RE9a in vivo. 
Arrested growth and SA-β-Gal staining are important hallmarks of senescence, 
but other factors including activation of key tumour suppressor pathways such as 
the p53 and p16INK4a axes have important roles in senescence activation and 
maintenance. While a previous study identified p53 as the primary effector of 
RE-induced SLGA in primary human fibroblasts [59], only modest induction was 
observed in this study. Instead, a strong induction of p16INK4a was observed which 
corroborated findings from another study, demonstrating p16INK4a upregulation in 
response to RE expression [225].  
It has previously been reported that human fibroblasts lacking p16INK4a are 
resistant to RAS-induced senescence suggesting that p16INK4a has a more 
significant role in human cell senescence than p53 [234]. In contrast, it was also 
reported that p16INK4a null human fibroblasts are sensitive to RE-induced SLGA 
when expression is driven from a retroviral vector [59]. The disparity between 
this study and our own might be explained by the use of different vector delivery 
systems. Wolyniec et al, [59] used an ecotropic murine retroviral vector to 
transduce Hs68 fibroblasts while this study relied on a lentiviral transduction 
system. It has previously been reported that p53 induction in response to 
reactive oxygen species comprises part of an anti-retroviral response in murine 
astrocytes [235]. Lentiviral vectors, in contrast, encode factors that significantly 
abrogate antiviral mechanisms and may effectively blunt the p53 response [236, 
237]. In addition, Wolyniec et al used Hs68 cells that have been engineered to 
express an ecotropic receptor [59]. It is possible that this extra level of genetic 
manipulation had altered their response to RE compared to the parental Hs68 
cells. More importantly, however, RE9a failed to induce either p53 or p16INK4a 
suggesting that failure to fully activate one or both of these tumour suppressor 
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pathways is critical for escape from RE-induced SLGA and may contribute to the 
leukaemogenicity of this protein in vivo. 
Early studies led to the assumption that senescence is an irreversible process 
[140-142], but more recent data clearly show that escape from senescence can 
occur as a result of inactivation of key tumour suppressor pathways including 
p53 and p16INK4a and can contribute to cellular transformation in vitro and in 
vivo [127, 143-145]. This interpretation is supported by evidence from studies in 
primary MEFs [183, 238]. Premature senescence is engaged in response to a wide 
range of oncogenes but cells can escape this failsafe mechanism when passaged 
routinely to facilitate the accumulation of secondary mutations commonly 
manifested by loss of p16INK4a or p53. When RE9a was introduced into primary 
MEFs, both fibroblastoid and flat, enlarged senescent cells were observed and 
the overall growth rate was intermediate between RE-expressing and control 
cultures. Moreover, growth was accelerated when the cells were subjected to 
3T3 passage culture [231]. Significantly, although RE-expressing MEFs displayed a 
later onset accelerated proliferation, the rate was equivalent to that observed 
in RE9a suggesting that RE has the potential to support secondary mutations but 
that this effect is delayed relative to RE9a-expressing MEFs. It is not known 
whether the earlier onset of accelerated growth represents the ability of RE9a 
to suppress premature senescence or to stimulate growth leading to secondary 
mutations and a further selective advantage for fibroblastoid cells. Since 
primary MEFs represent a heterogeneous cell population derived from a whole 
mouse embryo, it is possible that RE9a induces senescence in a subpopulation 
that affects the overall growth rate of the culture while other more resistant 
cells grow out when the cells are passaged in vitro. This hypothesis could be 
tested in future studies by following the fates of individual cells expressing 
RE9a. 
I suggest that the increased leukaemogenicity of RE9a is at least in part due to 
its failure to engage tumour suppressors including p16INK4a which might induce 
SLGA in RE9a-expressing cells. This allows RE9a-expressing cells to evade cellular 
senescence which may render the cells vulnerable to additional cancer-causing 
mutations. 
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4   RUNX1-ETO9a Fails to Engage Pro-
Senescence p38MAPK-ROS Signalling in 
Hs68 cells 
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4.1  Introduction  
 
Ectopic expression of oncogenic RAS was previously reported to promote 
mitochondrial reactive oxygen species (ROS) in primary human fibroblasts [239].  
Consequences of ROS accumulation include hyper-replication and oxidative DNA 
damage that together induce a rapid DNA damage response [166] and the 
downstream activation of major tumour suppressor pathways such as p53 and 
p16INK4A  required for senescence [169].    
Previous work identified RE as a potent inducer of ROS in human fibroblasts [59]. 
Interestingly previous studies have shown that RE-induced SLGA occurs in the 
absence of hyper-replication and significant DNA damage [59, 225]. This 
phenotype has subsequently been reported for other oncogenes such as BCR-ABL 
and AKT suggesting that the DDR is not absolutely essential for OIS and that 
alternative pathways exist [225, 226]. Although RE-induced senescence occurs in 
the absence of a significant DDR, previous studies have identified p38MAPK 
activation as a critical factor in RE-induced senescence [59, 225]. Furthermore, 
p38MAPK activation has been identified downstream of ROS. Specifically, ROS 
induces the oxidative dissociation of Thioredoxin and ASK1, thereby releasing 
ASK1 to phosphorylate and activate p38MAPK [194, 240]. AS RE has been 
reported to be a potent inducer of intracellular ROS, the ROS-p38MAPK signalling 
axis presents a possible mechanism for RE-induced cellular senescence which 
may be lacking in cells expressing RE9a. 
To address whether the enhanced leukaemogenic potential of RE9a is associated 
with failure to engage the ROS/p38MAPK tumour suppressor axes, DNA damage, 
ROS production and p38MAPK activation were compared in primary human 
fibroblasts expressing RE and RE9a. 
4.1.1 Aims and Objectives 
 Determine whether RE9a-expressing cells display γH2AX foci which are 
indicative of DNA double-stranded breaks. 
 
 Examine whether elevated ROS and p38MAPK activation are features of 
the RE9a phenotype by measuring DCF fluorescence in transduced cells. 
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 Determine whether elevated ROS production in RE-expressing cells is an 
essential pro-senescence factor by scavenging ROS using sodium 
pyruvate. 
 
 Determine whether p38MAPK activation is essential for RE-induced 
senescence using the p38MAPK inhibitor, SB203580, to inhibit signalling 
through this axis. 
4.2  Results  
4.2.1 RUNX1-ETO9a Fails to Induce DNA Damage in Hs68 Cells 
 
Phosphorylated γH2AX foci at sites of double-stranded DNA breaks were 
visualised by indirect immunofluorescence in Hs68 cells transduced with a 
lentiviral vector expressing PURO, RE or RE9a. RUNX1P2 and HRASV12 were 
included as negative and positive controls respectively for DNA damage. As 
expected, expression of HRASV12 was accompanied by a substantial increase in 
the number of FITC-labelled γH2AX foci indicative of a strong DNA damage 
response whereas RUNX1P2 failed to induce DNA damage relative to the PURO 
control as previously reported [59]. RE9a also failed to induce the appearance of 
ϒH2AX foci consistent with the absence of SLGA in these cultures. RE also failed 
to induce the appearance of γH2AX foci (Figure 4.1 a) despite a robust SLGA in 
these cells. These data contrast with others describing modest levels of DNA 
damage in primary human fibroblasts in response to RE [59, 225]. This disparity 
may simply reflect intrinsic differences between lentiviral and retroviral 
expression of RE and strongly suggests that the DDR is not absolutely critical for 
RE-induced SLGA in primary human fibroblasts.  
AKT has been reported to induce premature senescence in human fibroblasts in 
the absence of a DNA damage signal [226]. To determine whether 
phosphorylated AKT signals downstream of RE to induce senescence, day 6 
protein extracts were analysed by western blot. Phosphorylated AKT was 
detected in extracts from RE-expressing cells but at a lower intensity relative to 
cells expressing ectopic RUNX1P2 where the signal was strong. AKT was 
completely undetectable in RE9a expressing cells (Figure 4.1 b). These data 
suggest that, while AKT signalling may play a role in RUNX1P2-induced SLGA, it is 
less significant for senescence induction by RE. 
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Figure 4.1 RUNX1-ETO9a fails to induce DNA damage in Hs68s 
Analysis of double-stranded DNA breaks in Hs68 cells transduced with lentiviruses containing 
RUNX1P2, RE and RE9a 6 days after puromycin selection. Vectors containing the control (PURO) 
or H-RASV12 were included as negative and positive controls respectively (a) Nuclei were stained 
using DAPI (left hand column). Immunodetection of DNA double-stranded breaks was performed 
using an anti-ϒH2AX antibody (JBW301, MerckMillipore) and a FITC conjugated secondary 
antibody (Stratech Scientific Ltd.) (Middle column). The right hand column shows the ϒH2AX 
(FITC) and nuclei (DAPI) overlaid. Images were captured using 40x magnification (b) Western blot 
analysis of phosphorylated AKT (60kDa) in Hs68 fibroblasts expressing the control vector (PURO), 
RUNX1P2, RE or RE9a 6 days after puromycin selection. 293T cells were used as a positive control 
for AKT phosphorylation and Jurkat cells were used as a negative control. Results shown are 
representative of three biological replicates. 
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4.2.2 RUNX1-ETO9a Fails to Induce Reactive Oxygen Species  
 
While replicative stress and DNA damage were not features of RE-induced SLGA, 
induction of ROS was previously reported in RE-expressing Hs68 fibroblasts [59]. 
To determine whether RE9a senescence escape is associated with a failure to 
accumulate intracellular ROS, a FACs-based detection of fluorescence emitted 
by a peroxide-sensitive fluorophore, DCF-DA, was used to measure intracellular 
ROS 6 days after selection. In support of previous observations, RE but not 
RUNX1P2 induced significant levels of intracellular ROS relative to the PURO 
control [59]. RE9a, in contrast, failed to accumulate intracellular ROS supporting 
previous evidence that ROS correlates with and is causally involved in RE-
induced SLGA (Figure 4.2 a). To address this question, cultures were treated at 
the initiation of selection with 250µM sodium pyruvate and again at 2-3 days 
intervals to suppress intracellular ROS. Successful scavenging was confirmed 6 
days post selection by DCF-DA detection. Although scavenging was observed in 
all cultures, RE-expressing cells showed the most significant decrease in mean 
fluorescence with intracellular ROS levels restored to background levels (Figure 
4.2 b). The reduction in ROS in RE-expressing cultures was accompanied by an 
increase in proliferation which was not observed in RE9a or PURO control cells in 
response to sodium pyruvate treatment. Indeed, PURO control cells appeared to 
be negatively affected by sodium pyruvate treatment, with cultures exhibiting 
slower growth rates throughout the time course (Figure 4.2 c). The increased 
proliferation of RE-expressing cells was accompanied by a shift to more 
fibroblastoid cell morphology and a reduced SA-β-Gal staining pattern. RE9a 
cultures, in contrast, retained a fibroblastoid non-senescent morphology in the 
presence and absence of sodium pyruvate (Figure 4.3 d). Together these data 
demonstrate that ROS accumulation is critical for RE-induced SLGA and likely to 
be dependent on the NHR3 and NHR4 ETO repressor domains that are absent 
from RE9a. 
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Figure 4.2 RUNX1-ETO9a fails to induce ROS in Hs68s 
Hs68 cells were transduced with a lentivirus encoding RE, RE9a or a control lentivirus (PURO) and 
intracellular ROS levels measured using a flow cytometer to detect DCF-DA fluorescence 6 days 
after puromycin selection. The data shown are respresentative of 3 independent biological 
replicates. (a(i)) Representative flow cytometric histograms showing DCF-DA fluorescence 
against cell count in cells transduced with the PURO control vector overlaid with histograms 
generated bycells expressing RUNX1P2, RE or RE9a. (a(ii)) Bar chart showing fold change ± SD in 
mean fluorescence intensity compared with PURO control. Significance was determined using a 
one-way ANOVA comparing all pairs of columns. (b) Bar chart showing fold change in DCF-DA 
mean fluorescence measured 6 days post-transduction in cells transduced as above and treated 
with 250µM sodium pyruvate from the point of transduction compared with  untreated cells. Data 
was collected using a flow cytometer and analysed as in (a (ii).  (c) Growth curves from cells 
transduced and treated with or without 250 µM sodium pyruvate as a scavenger of intracellular 
ROS as in (b). Plots show the mean of three independent cell counts ±SD. (d) Images of cells 
stained for SA-β-Gal activity at pH6.0 in cells treated with or without sodium pyruvate on day 6 
post-selection. Images were captured using 20x magnification. 
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4.2.3 RUNX1-ETO9a Fails to Induce p38MAPK Activation 
 
P38MAPK was previously identified as an essential driver of RE-induced SLGA [59, 
225] and has been identified as a downstream effector of ROS signalling. To 
examine whether the failure of RE9a to induce ROS is supported by an inability 
to activate p38MAPK, the phosphorylation status of p38MAPK was examined by 
western blotting. As shown in Figure 4.3 a, phosphorylated p38MAPK was 
completely undetectable in Hs68 fibroblasts expressing RE9a on day 0 after 
puromycin selection (Figure 4.3 a). Moreover, RE9a-expressing cells were also 
refractory to growth stimulation by a p38MAPK inhibitor (SB203580) which 
reversed SLGA (Figure 4.3 b) and senescence morphology (Figure 4.3 c) of RE-
expressing cells. In contrast, phosphorylated p38MAPK was readily detectable in 
the presence of RE but not in vector control cultures or those expressing 
RUNX1P2 (Figure 4.3 a) which also failed to accumulate ROS, consistent with 
previous reports [59]. To examine the relationship between ROS and p38MAPK, a 
ROS scavenger, sodium pyruvate, was included in the growth media at the point 
of selection and p38MAPK phosphorylation re-examined in response to RE. As 
shown in Figure 4.3 d, p38MAPK phosphorylation was suppressed by sodium 
pyruvate in the presence of RE, confirming dependence on ROS for p38MAPK 
activation (Figure 4.3d). p16INK4A expression was also examined since it has been 
reported to be downstream of ROS-p38MAPK signalling. However, in this case 
induction was diminished but not abolished in the presence of sodium pyruvate, 
suggesting that RE can activate p16INK4A expression through alternative signalling 
pathways or that this is a more sensitive marker of incomplete ROS removal 
(Figure 4.4 e). Together these data suggest that ROS-p38MAPK signalling is 
required for RE-induced SLGA and that failure of RE9a to induce senescence may 
in part reflect its inability to accumulate ROS and activate p38MAPK. 
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Figure 4.3 RUNX1-ETO9a fails to induce p38-P activation of Hs68s 
Hs68 cells were transduced with a lentivirus vector encoding RE, RE9a or the PURO empty 
vector. (a) Western blot analysis of phospho-p38MAPK (9211 Cell Signalling Technology) 
expression in cells harvested on day 1 post-selection. Total p38MAPK was used as a control (9212 
Cell Signalling Technology) to show that all cell types examined displayed similar p38MAPK 
expression levels. (b) Growth curves showing proliferation of transduced cells over 9 days in the 
presence or absence of 8µM SB203580. Plots show the mean of three independent cell counts 
±SD. (c) SA-β-Gal staining of day 6 Hs68 cells transduced and treated as in (b).Images were 
captured using 20x magnification. (d) Western blot analysis of phospho-p38MAPK and total 
p38MAPK expression (9211 and 9212, Cell Signalling Technology) immediately after puromycin 
selection in Hs68 cells transduced with RE and cultured in the presence or absence of 250µM 
sodium pyruvate. (e) Western blot analysis of p16INK4A (sc-468, Santa Cruz Biotechnology Ltd) 
expression measured 6 days post-selection in Hs68 cells transduced and treated with sodium 
pyruvate as in D. 
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4.3 Discussion 
 
This study establishes the failure to engage the ROS-p38MAPK stress response 
pathway as a key feature of the RE9a expression phenotype. This study shows 
that, in contrast to RE, neither ROS accumulation nor p38MAPK activation is 
induced by RE9a. Furthermore, inclusion of sodium pyruvate in the growth media 
to scavenge ROS or direct inhibition of p38MAPK activity is sufficient to 
attenuate RE-induced SLGA but has only a slight repressive effect on the growth 
of RE9a-expressing cells, confirming the importance of these signalling factors 
for RE-induced SLGA and their evasion by RE9a. 
Excessive ROS was initially reported to be associated with HRASV12-induced 
senescence where it induced DNA damage in the form of replicative and 
oxidative stress [241]. Knock-down of key DDR components such as ATM, Chk2 
and p53 resulted in abrogation of RAS-induced senescence, confirming the 
importance of this pathway in OIS [169]. Indeed, DNA damage has also been 
described in response to the RE fusion protein. Sustained proliferation of human 
CD34+ cells was attributed to expression of RE-mediated DNA damage and 
repression of DNA repair genes and RE-induced SLGA was characterised by a 
weak DDR in primary human fibroblasts and haematopoietic progenitor cells 
[228]. In contrast to these reports, no DNA damage was observed in this study in 
the presence of RE. Indeed, in line with a previous report in Hs68 fibroblasts 
[59], RE induced a rapid and profound growth arrest that was associated with 
little or no DNA damage. The disparity between these studies may simply reflect 
the use of different cell types and viral transduction systems or the fact that 
CD34+ cells were selected for survival after long term culture rather than after 
the initial stress of RE transduction. Evidence of premature senescence in the 
absence of proliferative and genotoxic stress is becoming more prevalent with 
reports that leukaemic fusion oncoproteins such as BCR-ABL and CBFβ-MYH11 
induce senescence in the absence of DNA damage [225]. Together they 
corroborate the findings from this study and support the existence of DDR-
independent pathways to RE-induced SLGA. 
The PI3K/AKT signalling pathway represents a DDR independent senescence 
signalling pathway that can be activated through oxidative stress [226]. Strong 
accumulation of ROS was observed in response to ectopic RE but activation of 
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AKT was modest compared to RUNX1P2 suggesting that PI3K/AKT signalling may 
be more important for RUNX1P2-induced SLGA than for SLGA induced by RE. An 
alternative pathway downstream of ROS also implicated in premature 
senescence involves the redox-dependent phosphorylation of p38MAPK by ASK1 
[194]. Activation of p38MAPK has been widely associated with premature 
senescence [189] where it has been identified as an upstream activator of 
p16INK4A [188, 242]. The potential significance of this pathway for RE-induced 
SLGA is evidenced by data from this and another study showing induction of 
p16INK4A in response to RE and reversal of the senescence phenotype when RE 
expressing cultures were grown in the presence of a p38MAPK inhibitor SB203580 
[59]. Furthermore, it was demonstrated that RE-expressing cells grown in the 
presence of sodium pyruvate, a scavenger of ROS, continued to proliferate and 
failed to phosphorylate p38MAPK further implicating ROS-p38MAPK signalling in 
RE-induced SLGA and the absolute requirement for p38MAPK activity.  
Involvement of ROS-p38MAPK signalling in premature senescence is not without 
precedent. It has previously been reported that oncogenic HRASV12 induces 
premature senescence that is associated with persistent ROS-p38MAPK-p16INK4A 
signalling [188, 242]. Moreover, leukaemogenic fusions including BCR-ABL and 
CBFβ-MYH11 induce p38MAPK and cellular senescence in the absence of DNA 
damage which supports the existence of DNA-damage independent pathways to 
cellular senescence. Although intracellular ROS was not assayed in the presence 
of these fusions, it has also been reported that ROS accumulation can occur in 
the absence of DNA damage [186].  
The data presented in this study demonstrated a transient activation of p38MAPK 
activity in the presence of RE. Indeed, reversal of the RE-induced growth arrest 
was restricted to cells exposed to ROS scavengers immediately after viral 
transduction suggesting that p38MAPK signalling is required for induction of RE 
senescence but may be dispensable for maintenance of the response. Transient 
induction of p38MAPK is commonly observed in response to cellular stress [243] 
but persistent activation has been identified as an inducer of cellular senescence 
in human fibroblast cells [185]. In this respect it is notable that expression of RE 
from a retroviral vector in Hs68 fibroblasts was associated with a more sustained 
activation of p38MAPK and significantly higher levels of ROS [59]. Furthermore 
somewhat intermediate levels of ROS were observed in response to RE9a that 
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appeared insufficient to induce SLGA, suggesting that a threshold level of ROS is 
required for p38MAPK activation and senescence induction in vitro. Although 
activation of p38MAPK was transient in response to RE it was undoubtedly 
required for SLGA as evidenced by the phenotypic reversal with sodium pyruvate 
and SB203580. The signalling pathways downstream of p38MAPK associated with 
premature senescence include activation of p16INK4A and p53 [244]. p53 was 
previously described as a critical mediator of RE-induced SLGA [59] but was only 
modestly induced in this study. In contrast a significant induction of p16INK4A was 
observed in response to RE which was conspicuously absent in the presence of 
RE9a. Moreover, RE9a failed to induce p38MAPK or premature senescence, 
supporting a causal link between p38MAPK, p16INK4A and senescence. However, 
the incomplete suppression of p16INK4A induction by RE in the presence of sodium 
pyruvate shows that low level induction is insufficient to drive the senescence 
response. Whether this reflects incomplete scavenging or ROS-independent 
p16INK4A activation pathways has not been determined. 
From the evidence presented here it may be predicted that opposition of ROS-
p38MAPK signalling represents a mechanism by which RE9a evades premature 
senescence. Furthermore persistent proliferation may contribute to the 
increased leukaemogenicity of the RE9a fusion oncoprotein in vivo. 
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5   Mutation of NHR3 and NHR4 is Necessary 
for Complete Abrogation of RE-Induced 
SLGA 
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5.1  Introduction  
 
Previous studies have shown that the RE fusion oncoprotein behaves as a 
constitutive transcriptional repressor of RUNX1 gene targets due to the presence 
of Nervy Homology Regions (NHR) in the ETO protein [70]. The four NHR domains 
are effective recruiters of co-repressor complexes including NCoR, mSin3A, SON 
and SMRT which interact with histone deacetylases (HDACs) to repress gene 
transcription [70]. NHR1 and NHR2 are also important for RE/ETO 
oligomerisation and are essential for RE9a oncogenic activity [89, 92, 245].  
This study demonstrates that the C-terminal portion of ETO encoding the NHR3 
and NHR4 domains is critical for RE-induced SGLA Since premature senescence is 
an important failsafe mechanism that restricts transformation in vitro and in 
vivo [246] and RE9a, unlike RE, evades senescence and is capable of inducing 
leukaemogenesis in murine models [80], it was important to determine whether 
loss of NHR3 or NHR4 was responsible. Previous studies have demonstrated that 
deletion or disruption of RE NHR4 results in an enhanced leukaemogenic 
phenotype in murine models [95, 97].  However other studies indicate that 
mutations affecting NHR4 rarely occur in human leukaemias [247] arguing 
against the significance of this single domain for leukaemia development. 
Similarly disruption of the NHR3 domain was shown to have minimal impact on 
the leukaemogenic potential of RE [93, 95] suggesting that the loss of both 
domains in the RE9a spliced variant is required – a finding also supported by the 
identification of the RE9a spliced variant in over 70% of t(8;21) patient samples 
[80]. To determine whether loss of both the NHR3 and NHR4 domains was 
similarly required for senescence evasion by RE9a, a series of RE deletion and 
point mutants specifically targeting the NHR3 and NHR4 domains (Figure 5.1 and 
kindly gifted by Prof. Dong Er Zhang) were subcloned into pLenti PURO and 
introduced into Hs68 cells to monitor for hallmarks of premature senescence. 
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Figure 5.1 RE, RE9a and the NHR mutants 
Schematic representation of RE, RE9a, DNHR3 (Deleted NHR3), DNHR4 (Deleted NHR4) or mNHR3 
(6 amino-acid alaninisation in NHR3 (TERAKM-AAAAAA)). 
 
5.1.1 Aims and Objectives 
 
 Determine the effect of loss or disruption of NHR3 or NHR4 for RE induced 
growth arrest of Hs68 primary fibroblasts. 
 
 Explore the consequences of disruption of the NHR3 and NHR4 domains 
for RE–induced premature senescence staining and morphology in Hs68 
fibroblasts.   
 Determine whether ROS/p38MAPK signalling is retained or compromised 
in Hs68 fibroblasts expressing RE NHR mutants. 
 
 Explore the relationship between p16INK4a expression and RE induced 
senescence  in the presence and absence of NHR3 and NHR4.    
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5.2 Results  
5.2.1 NHR3 is Critical for a RUNX1-ETO-Induced Growth Arrest.  
 
Expression levels of RE, RE9a, DNHR3, DNHR4 and mNHR3 were assayed in Hs68 
cells by western blotting. The mutants were expressed at high and 
approximately equivalent levels compared to RE (Figure 5.2 a). As reported 
previously, RE expression in Hs68 cells was accompanied by a profound growth 
arrest whereas proliferation of RE9a transduced cells was essentially 
indistinguishable from that of the controls. The growth of Hs68 cells was 
similarly unaffected by expression of DNHR3 and mNHR3 although an initial 
growth delay was observed in the presence of mNHR3 from which the cells 
recovered after 9 days in culture. In contrast, ectopic expression of DNHR4 
restricted the growth of Hs68 cells over the time course of the experiment. Slow 
growth was maintained compared to RE-expressing cells but the restriction was 
severe with approximately three fold lower cell numbers at the end of the 
experiment compared to the control and NHR3 mutants (Figure 5.2 b). The 
reduced growth was accompanied by the appearance of senescent cells and 
positive staining for SA-β-Gal activity (Figure 5.2 c; red arrowhead). In contrast 
to RE, fibroblastoid like cells were also observed in the DNHR4 cultures (Figure 
5.2 c; blue arrowhead) but these were much fewer in number than in the 
control cells or cultures expressing DNHR3 or mNHR3. Together these data 
suggest that NHR3 is absolutely required for induction of a senescence like 
growth arrest by RE but that NHR4 may contribute additional functions to drive 
the complete response. 
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Figure 5.2 The NHR3 domain is essential for the senescence-inducing activity of RE 
Hs68 cells were transduced with lentiviral vectors expressing RE, RE9a, DNHR3, DNHR4 or 
mNHR3. The empty pLenti vector (PURO) was included as a control. (a) Western blot analysis of 
ectopic RE, RE9a, DNHR3, DNHR4 and mNHR3 expression levels in transduced Hs68 fibroblasts 
using an anti-RUNX antibody (D207-3, MBL Ltd) immediately after puromycin selection. (b) 
Representative growth curves measuring proliferation of transduced cells over 9 days. Plots show 
the mean of three independent replicates ±SD. (c) SA-β-Gal staining (pH6.0) of Hs68 cells 
expressing PURO, RE, RE9a, DNHR3, DNHR4 or mNHR3 at day 6 post-selection. The red arrow 
indicates a cell displaying senescent morphology and characteristic SA-β-Gal perinuclear staining 
while the blue indicates a spindle-shaped fibroblastoid cell. Images were captured using 20x 
magnification. 
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5.2.2 Disruption of Either NHR3 or NHR4 is Insufficient to Completely 
Oppose Induction of ROS and p38MAPK Activation.  
 
We have previously demonstrated that accumulation of intracellular ROS is 
essential for RE-induced SLGA and is conspicuously absent from RE9a-expressing 
cells which also fail to senesce. To determine whether the NHR3 domain is 
sufficient for ROS accumulation by RE or if the NHR4 domain is also required, 
intracellular ROS was assayed by FACS-based detection of DCF-DA fluorescence 
in Hs68 cells expressing DNHR3, DNHR4 and mNHR3 6 days after puromycin 
selection and the levels compared to those achieved by cells expressing RE or 
RE9a. As shown in Figure 5.3a, ROS accumulation was elevated by all three 
mutants to levels approximately equivalent to RE expressing cultures and 
exceeding those achieved in the presence of RE9a or the control vector. To 
determine whether downstream signalling pathways were activated 
differentially by ROS in the presence of the NHR mutants, day 0 protein lysates 
were prepared and analysed for phospho-p38MAPK expression which depends on 
ROS accumulation (Figure 4.4a). As reported previously RE expression resulted 
in p38MAPK phosphorylation whereas the protein remained unphosphorylated in 
the presence of RE9a. Modest but equivalent levels of phospho-p38MAPK were 
recorded in Hs68 cells expressing DNHR3 and DNHR4 despite their differential 
senescence responses suggesting that p38MAPK activity contributes to, but is not 
sufficient for, RE-induced SLGA in the absence of NHR3 or NHR4 and that 
deletion of both NHR domains is required to avoid p38MAPK activation. In 
support of this interpretation, cells expressing mNHR3 which differs from RE by 
only 6 amino acids displayed the highest levels of phosphorylated p38MAPK yet 
failed to senesce (Figure 5.3b). Comparing the levels of ROS accumulation with 
phosphorylated p38MAPK for the NHR mutants yielded no immediate correlation 
suggesting that ROS was not rate-limiting under these conditions and that loss of 
a single functional NHR domain is insufficient to completely restore the effects 
of the C terminal deletion in RE9a. To determine the functional consequences of 
p38MAPK activation for cell growth in the presence of the NHR mutants the 
experiment was repeated in the presence and absence of a p38MAPK inhibitor, 
SB203580, and growth monitored for 12 days. As shown in Figure 5.3c the 
inhibitor had an early positive effect on the growth of all the mutants 
particularly DNHR3 that was not observed in control cultures. The early 
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proliferative response was sustained in cultures expressing DNHR3 and 
accompanied by the appearance of very fibroblastoid looking cells (Figure 
5.3d). More modest shifts to a fibroblastoid morphology were also observed in 
cells expressing mNHR3 and even DNHR4 (Figure 5.3d; blue arrowhead) despite 
the persistence of senescent cells within the DNHR4 cultures (Figure 5.3d; red 
arrowhead). Since SB203580 was added at the point of puromycin selection 
before senescence was visually apparent these data suggest that p38MAPK 
activity is not absolutely required for senescence induction by RE but does 
continue to be restrictive for cellular growth. Additional functions residing in the 
NHR3 domain and to a lesser extent the NHR4 domain must be required for a 
complete response.  
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Figure 5.3 Disruption of the NHR domains of RE affect ROS production and activation of p38-
P 
Hs68 human fibroblasts were infected with a lentivirus encoding RE, RE9a, DNHR3, DNHR4, 
mNHR3 or a control lentivirus (PURO), and ROS measured with DCF-DA 6 days after puromycin 
selection. (a) Bar chart showing fold change ± SD in mean fluorescence intensity compared with 
PURO control. (b) Western blot analysis of phospho-p38MAPK and total p38MAPK expression (9211 
and 9212, Cell Signalling Technology) on day 1 post-selection in transduced Hs68 fibroblasts. (c) 
Growth curves showing viable cell numbers in Hs68 cell populations expressing either a control 
vector (PURO), DNHR3, DNHR4 or mNHR3 and grown over 12 days in the presence or absence of 
8µM SB203580. Plots show the mean of three independent replicates ±SD. (d) SA-β-Gal staining of 
Hs68 cells expressing PURO, RE, RE9a, DNHR3, DNHR4 or mNHR3 in the presence or absence of 
8µM SB203580 on day 6 post-selection. Red arrowhead indicates a senescent cell and the blue 
arrow indicates a spindle-shaped fibroblast cell. Images were captured using 20x magnification. 
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5.2.3 p16INK4a Signalling is not Required for DNHR4-Induced SLGA 
 
Activation of p16INK4a transcription is a major feature of human cellular 
senescence both in vitro and in vivo [126, 143, 234]. Multiple signalling 
pathways including p38MAPK have been associated with p16INK4a activation and 
its downstream growth arrest and cellular senescence phenotypes [242]. This 
study previously showed that p16INK4a was induced by RE but not RE9a in Hs68 
fibroblasts and correlated with induction of premature senescence (Figure 3.1a-
c). To determine whether p16INK4a was induced by the NHR mutants western blot 
analysis was performed on samples 6 days after puromycin selection when visible 
signs of senescence were apparent. RE was included as a positive control for 
p16INK4a induction and as before gave a readily detected band which was not 
observed in the presence of RE9a. None of the NHR single mutants induced 
detectable p16INK4a despite activation of the p38MAPK signalling pathway 
suggesting that this pathway alone was not responsible for p16INK4A induction. 
Most significantly p16INK4a was not induced in cells expressing DNHR4 despite the 
appearance of senescent cells in these cultures (Figure 5.4a). To address the 
absolute requirement for p16INK4a RE, RE9a and DNHR4 were introduced into 
p16INK4a-null primary diploid human foreskin fibroblasts (Leiden cells) and the 
cultures examined for cell growth. As shown in Figure 5.4 b, Leiden cells 
expressing RE failed to senesce and grew more rapidly than the control cultures 
suggesting that p16INK4A is absolutely required for RE senescence and opposes the 
growth promoting activities of RE. It must be presumed that these additional 
growth promoting functions are absent in RE9a since the growth of these cells 
was comparable to control cultures. In contrast Leiden cells expressing DNHR4 
remained growth-arrested for the duration of the experiment suggesting that 
growth restriction by RE in the absence of an intact NHR4 domain is independent 
of p16INK4a signalling (Figure 5.4b). Together these data confirm the existence of 
additional senescence inducing pathways encoded by the NHR3 domain that are 
revealed in the absence of NHR4 and may contribute to the strength of the RE-
induced senescence response.   
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Figure 5.4 DNHR4-induced senescence is refractory to p16INK4a expression. 
(a) Western blot analysis of p16INK4a expression (sc-468, Santa Cruz Biotechnology) in transduced 
Hs68 fibroblasts infected with a lentivirus encoding RE, RE9a, DNHR3, DNHR4, mNHR3 or control 
lentivirus (PURO). Actin () was used as a loading control. (b) Growth curve showing viable cell 
numbers in p16INK4A-null Leiden cell populations expressing the control vector (PURO), RE, RE9a 
or DNHR4 over a 15 day period. Plots show the mean of three independent replicates ±SD.  
 
5.3 Discussion 
 
The data presented here provide evidence that loss of either the NHR3 or NHR4 
domain is insufficient to completely oppose RE-induced SLGA and that deletion 
of both domains is required. Disruption or mutation of NHR3 was permissive for 
growth and prevented the appearance of senescent cells whereas deletion of 
NHR4 was accompanied by a weak senescent phenotype characterised by the 
persistence of fibroblastoid cells within the culture and delayed rather than 
completely arrested growth. In contrast to RE9a, cell growth and a fibroblast-
like morphology was partially restored or intensified in the presence of a 
p38MAPK inhibitor, suggesting that p38MAPK signalling and growth suppression is 
at least partially retained by functional deletion of NHR3 or NHR4. Together 
these results suggest a dominant role for NHR3 in RE-induced SLGA that is 
potentiated by additional functions of NHR4.   
How the NHR3 and NHR4 domains engage senescence signalling pathways is less 
apparent since mutants of either domain retained the ability to accumulate ROS 
and activate p38MAPK which are essential for RE-induced SLGA. p16INK4A was not 
induced, however, supporting the existence of p38MAPK-independent pathways 
of p16INK4A induction. More surprising was the growth arrest of p16INK4A-null 
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fibroblasts transduced with DNHR4 despite the persistent sensitivity of all the 
mutants to p38MAPK inhibition. The data are consistent with alternative p16INK4A-
independent p38MAPK signalling pathways that are presumably unmasked by loss 
of the NHR4 domain and to a lesser extent the NHR3 domain, and which 
contribute growth inhibitory functions to RE. Ablation of these activities is only 
achieved by complete loss of NHR3 and NHR4 as is observed in the RE9a splice 
variant.  
It is notable that RE9a failed to induce accelerated growth in either Hs68 
fibroblasts or p16INK4A null Leiden cells. SLGA was lost in the former cell type but 
growth was maintained at comparable rates to the controls in both cultures 
suggesting that NHR3 and NHR4 function to mediate RE growth inhibition and 
additional domains are required to provide growth-promoting activities revealed 
in the absence of p16INK4A. Although NHR3 was more significant for RE-induced 
SLGA in vitro, NHR4 was identified as the more critical domain in vivo with 
complete restoration of the RE9a leukemic phenotype in mouse models when 
NHR4 was deleted [95, 97]. It was subsequently shown that NHR4 abrogates 
leukaemogenesis through interactions with accessory proteins including NCoR 
and SON [95, 97]. It is notable that another naturally occurring splice variant of 
RE, RE11a, has been identified in t(8;21) leukaemia which retains NHR1-3 but 
has lost NHR4 [94]. It will be of considerable interest to determine whether this 
variant is leukaemogenic in vivo. The NHR3 domain was more critical for RE-
induced SLGA in Hs68 cells but has been less well characterised in vivo. It shares 
structural homology with AKAPs and interacts with PKA(IIα) but this interaction 
was demonstrated to have little significance for the anti-leukaemogenic activity 
of RE [93].  
The possibility that both the NHR3 and NHR4 domains are required to induce a 
robust senescence response is supported by reports that both domains have 
binding sites for NCoR/SMRT and SON, major co-repressor complexes implicated 
in RE-mediated gene regulation and cell growth [95, 97]. If effective co-
repressor binding requires both domains this may explain the loss of RE-induced 
SLGA in single-domain mutants. Alternatively, the individual deletion mutants 
may be sufficient to maintain weak interactions with repressor complexes to 
promote a partial induction of ROS/p38MAPK signalling that is insufficient for a 
complete senescence response and/or p16INK4A induction. Interestingly, mNHR3 
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exhibited maximal p38MAPK activation but failed to induce p16INK4a, providing 
further indirect evidence of p38MAPK independent pathways of p16INK4a 
activation that require intact NHR3 and NHR4 sequences. To this end it would be 
informative to immunoprecipitate RE and the NHR mutants and compare their 
interacting proteins by mass spectrometry. The presence of NCoR/SMRT and SON 
might not be unexpected but additional components may distinguish between 
the independent phenotypes exhibited by each mutant and define how each 
contributes to the RE senescence phenotype.  
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6  RE and its Mutants Induce Differing 
Secretory Profiles in Hs68 Cells 
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6.1  Introduction  
 
This study has identified NHR3 as an essential domain for RE-induced SLGA and 
NHR4 as an accessory domain that is required for the complete senescence 
response. In contrast to RE9a which lacks NHR3 and NHR4, all of the NHR 
mutants displayed ROS accumulation and p38MAPK phosphorylation, which have 
been associated with activation of NFB, a master regulator of the SASP [248].  
The SASP develops after the appearance of senescent cells and comprises a 
plethora of inflammatory cytokines and growth factors that can maintain the 
senescent phenotype of cells or signal clearance of senescent cells by the 
immune system [249]. However, a persistent SASP can also induce chronic low 
level inflammation which can have detrimental effects on cells and promote 
oncogenesis [205]. The SASP is often associated with a persistent DDR [250] and 
has been reported to be independent of p16INK4A activation [251]. As this study 
and others have demonstrated that RE-induced senescence in Hs68 cells is 
dependent on p16INK4A activity and occurs in the absence of significant DNA 
damage [59, 225], it might be hypothesized that RE-induced senescence is 
independent of a SASP. Alternatively it has also been demonstrated that RE-
induced senescence is dependent on ROS and p38MAPK signalling in Hs68 cells 
which have been associated with SASP induction particularly in the absence of 
DNA damage [185, 186]. 
To determine whether a SASP is a feature of RE-induced SLGA and if so whether 
it could be used to discriminate between the senescence-inducing functions of 
NHR3 and NHR4, secretion of IL-6, a prominent SASP marker, was initially 
examined. The study was then extended to a human cytokine antibody array 
representing a large panel of secretory markers associated with the SASP [185].  
6.1.1 Aims and Objectives 
 
 Determine whether induction of the SASP is a feature of RE-induced 
senescence. 
 Examine how the SASP profile induced by RE compares with those 
induced by RE9a and the NHR mutants. 
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6.2  Results  
6.2.1 RUNX1-ETO and RUNX1-ETO9a Induce Differing Secretory Profiles in 
Hs68 Cells.  
 
IL-6 is a major component of SASP and can be induced through p38MAPK 
activation of IL-1-β [252] and by NFĸB-mediated transcriptional upregulation 
[253]. To determine whether IL-6 is differentially regulated by RE and RE9a, 
conditioned medium was collected from cells 6 days post-selection when visible 
signs of senescence were apparent and assayed for secreted levels of IL-6 using 
the Human IL-6 Quantikine ELISA kit. Conditioned medium was diluted to 
account for differences in cell numbers between populations and the IL-6 
concentration normalised to the quantity secreted in pLentiPURO-transduced 
cells which fail to senesce in vitro. RUNX1P2 failed to induce IL-6 secretion 
above background levels (Figure 6.1a). In contrast, RE expressing cells secreted 
high levels of IL-6 consistent with their p38MAPK activation, ROS accumulation 
and senescence induction. RE9a gave an intermediate level of IL-6 secretion 
suggesting that NHR3 and NHR4 are necessary but not sufficient for maximal 
induction of IL-6 by RE. 
IL-6 is just one of many factors associated with SASP and cancer [145], but these 
results encouraged us to examine the SASP profile of RE-expressing cells more 
closely. To do so a human cytokine array was obtained which detects secretion 
of 120 cytokines, 100 of which are represented here, and the results compared 
with those of RE9a and RUNX1P2 which had displayed lower levels of IL-6 
secretion by ELISA. Transduced Hs68 cells were selected for puromycin 
resistance for 5 days and then transferred into complete growth medium. After 4 
days, the serum concentration was reduced to 0.2% to minimise the potential 
cytokine contribution from FCS and the cells were cultured for a further 2 days. 
The conditioned medium was then harvested and filtered and while cell counts 
were performed. Samples of conditioned media from independent transductions 
were diluted to normalise for cell number and applied to the cytokine array chip 
for final data analysis. OD values were adjusted to exclude background 
fluorescence and the data normalised to the PURO control. In the heat-maps 
generated, yellow indicates upregulation, blue indicates downregulation and 
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grey is used to represent the basal levels of secretion (equivalent to PURO). 
Heat map gene order was sorted on the values obtained from the RE array.  
Conditioned medium from RE expressing cells produced a robust SASP as the 
majority of secretory markers were increased relative to the PURO control 
(Figure 6.1b). Of these factors, only six were also upregulated by RUNX1P2 
(MCP1, Eotaxin, CK beta 8-1, MCP4, GM-CSF and uPAR). Indeed the majority of 
factors, including IL-6, were unchanged or downregulated by RUNX1P2 which 
validates the ELISA data and strongly suggests that senescence secretion is either 
a very limited component of RUNX1P2-induced SLGA or is actually repressed by 
RUNX1P2. RE9a presented an intermediate profile, failing to induce secretion of 
many of RE-induced factors and inducing others to a lesser degree. Exceptions 
include SDF1, BTC, NT3 and IL12 p70 which were secreted at comparable or 
elevated levels relative to RE. These factors were also strongly repressed by 
RUNX1P2, suggesting that NHR1 and NHR2 were required for their secretion. 
Where secretion was not induced by RE9a, distinct patterns emerged. Markers 
such as IGFBP6, IL-8, Angiogenin and RANTES were repressed to equivalent levels 
in cells expressing RE9a or RUNX1P2 suggesting that in the absence of NHR3 and 
NHR4 the effects of RUNX1P2 sequences within RE9a predominate. For one 
secretory marker, MCP4, expression levels were selectively repressed by RE9a 
supporting a role for NHR1 and NHR2. A third group was induced by RE9a but not 
as effectively as by RE.  These include MCP1, GRO and IL-6.  A final group was 
represented by TNF-R11, BLC and AXL and appeared to be somewhat refractory 
to RE9a expression despite significant repression by RUNX1P2 and induction by 
RE. The remainding factors were repressed by RUNX1P2, RE and RE9a and were 
presumably regulated by the RUNX1P2 core sequences common to all 3 proteins. 
Together these data show that RE9a partially antagonises but does not 
completely invert the SASP driven by RE. The lack of detectable ROS 
accumulation and p38MAPK signal activation in RE9a expressing cells and the 
association of these pathways with SASP strongly suggests that they contribute 
to the SASP induced by RE. The qualitative and quantitative differences in 
secretory markers generated by RE9a expressing cells are associated with 
interplay between NHR1, NHR2 and RUNX1 domains resulting in a weakened 
secretory profile that may account for the ability of RE9a to escape senescence 
in vitro. 
110 
 
 
Figure 6.1. RUNX1-ETO induced senescence is accompanied by a robust SASP in Hs68 cells 
Hs68 cells were transduced with lentiviral vectors expressing RUNX1P2, RE or RE9a. The empty 
vector (PURO) was included as a control. (a) Supernatant collected from cells 6 days post-
selection was subjected to ELISA for IL-6. Bar chart shows fold change in IL-6 concentration ±SD 
compared with PURO control. (b) Supernatant collected from cells 6 days post selection was 
subjected to a human cytokine array. Heat-map generated from data (See Page 100) obtained 
using a human cytokine array to measure SASP induction by transduced Hs68 cells. Yellow 
indicates upregulation relative to the PURO control while blue indicates downregulation. 
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6.2.2 Mutation of the NHR3 or NHR4 Domains of RE is Insufficient to 
Reproduce the RE9a Secretory Phenotype.  
 
To determine whether the SASP profile of RE was dependent on the NHR3 or the 
NHR4 domain, the NHR mutants were first examined for their ability to induce 
IL-6 secretion using the Human IL-6 Quantikine ELISA kit. Conditioned media 
collected from Hs68 cells expressing DNHR3, DNHR4 and mNHR3 revealed levels 
of IL-6 secretion that were equivalent to RE9a suggesting that both domains are 
required to fully restore IL-6 secretion by RE (Figure 6.2 a). Since ROS 
accumulation and p38MAPK activation were present in cells expressing the NHR 
mutants the data also suggests that these pathways are not sufficient for 
complete induction of the RE SASP profile. 
To investigate whether this pattern was typical over a broader range of SASP 
markers, the secretory profiles of DNHR3, DNHR4, mNHR3 were compared to RE 
and RE9a using the human cytokine array described previously. As before, 
conditioned media were diluted to account for cell number and the OD values 
normalised to the PURO control cells which fail to senesce. As shown in the heat 
maps generated in Figure 6.2 b, the NHR mutants failed to fully restore the 
SASP generated by RE, with each inducing a unique secretory profile that 
diverged less extensively from the RE SASP than RE9a.  
A subset of factors including IGFBP6, BDNF and MCP4 were induced to equivalent 
levels by RE or functional deletion of NHR3 or NHR4, suggesting that retention of 
either domain is sufficient to induce secretion. Other factors were increased 
only by mutants retaining NHR4 (PDGF-BB, bFGF) or NHR3 (Angiogenin, MIF) 
indicating a more specific requirement for one domain or the other. A minority 
were refractory to either mutant remaining strongly downregulated in the 
presence of the double (RE9a) or the single (NHR3, NHR4) deletion mutants. 
These include RANTES, osteoprotegerin and TIMP1 and may depend on the NHR1 
and/or NHR2 domains for their downregulation in the absence of an intact 
RUNX1 C-terminal domain.  
To further compare the SASP profiles, the absolute number of upregulated 
secretory factors shared with RE was expressed as a percentage for RE9a and 
each of the NHR mutants. RUNX1P2 was also included as it appears to repress 
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the secretion of numerous SASP components. The list of RE upregulated targets 
was determined relative to the PURO empty vector control which was arbitrarily 
given a value of 1.0. As shown in Figure 6.3a, RUNX1P2 showed the least 
similarity, displaying upregulation of only 13% of the secretory factors induced 
by RE; RE9a expressing cells induced an intermediate profile with 53% similarity 
to RE whereas mNHR3, DNHR4 and DNHR3 were 77%, 77% and 90% respectively. 
To examine the relative expression levels of each secreted factor compared to 
the pLentiPURO control, box-whisker plots were drawn for RE, RE9a and the NHR 
mutants. As shown in Figure 6.3b RUNX1P2 and RE displayed significantly 
changed secretory profiles compared to pLentiPURO with RE inducing (p=2.8E-5) 
and RUNX1P2 repressing (p=2.8E-33) the phenotype. RE9a displayed an 
intermediate phenotype that was induced relative to the pLentiPURO control 
(p=2.5E-8) but significantly less than RE (p= 3.3E-11). The NHR mutants 
displayed SASP profiles that were much more equivalent to RE. DNHR3 was not 
significantly different (p=0.15) whereas mNHR3 and DNHR4 showed relatively 
weak significance levels when a direct RE comparison was made (mNHR3 
p=0.024; DNHR4 p=0.001). Together these data suggest that loss of NHR3 and 
NHR4 is required to completely restrain the secretory phenotype of RE and that 
the presence of either domain is sufficient to substantially restore senescence 
secretion by RE.  
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Figure 6.2 Loss of DNHR3 or DNHR4 is insufficient to recapitulate RE9a secretory profile in 
Hs68 cells 
Hs68 cells were transduced with lentiviral vectors expressing RE, RE9a, DNHR3, DNHR4 or 
mNHR3. The empty vector (PURO) was included as a control. Supernatant was collected from 
cells 6 days post-selection. (a) IL-6 concentration in supernatants was determined by ELISA. Bar 
chart shows fold change in IL-6 concentration ±SD compared with the PURO control. (b) 
Supernatant collected from cells 6 days post selection was subjected to a human cytokine array. 
Heat-map generated from data (See Page 104) obtained using a human cytokine array to measure 
SASP induction by transduced Hs68 cells. Yellow indicates upregulation relative to the PURO 
control while blue indicates downregulation. 
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Figure 6.3 Percentage similarity between RE, RE9a and the NHR mutants 
The total factors upregulated by RE were denoted as a 100% SASP and compared with 
upregulated factors from RUNX1P2, RE9a and the NHR mutants. (a) Graphic showing the 
percentage of similarity of upregulated SASP profiles of Hs68 cells expressing RE9a (53%), DNHR3 
(90%), DNHR4 (77%), mNHR3 (77%) and RUNX1P2 (13%) relative to RE (100%). (b) Relative 
secretion by cells expressing RE, RUNX1P2, RE9a, DNHR3, DNHR4 or mNHR3 expressed as box-
whisker plots. 
 
 
6.3  Discussion 
 
This study demonstrates that RE-induce SLGA is accompanied by increased IL-6 
secretion and an extensive SASP in Hs68 cells. In contrast, Hs68 cells expressing 
RUNX1P2 displayed a marked downregulation of the majority of examined SASP 
markers, possibly indicating that RUNX1P2 actively represses senescence 
secretion. RE9a-expressing Hs68 cells displayed an intermediate profile that 
included a vestigial SASP but appeared largely repressive when compared to RE. 
Further study of the SASP using the NHR3 and NHR4 mutants demonstrated that 
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each domain contributes to the SASP phenotype but that none of the mutants 
fully recapitulate the robust RE SASP or the attenuated RE9a secretory profile. 
Interestingly, mNHR3 and DNHR4 more closely resemble the RE9a profile than 
DNHR3. It is possible that the exchange of the TERAKM motif for hydrophobic 
alanines has more profoundeffects on protein structure than simple deletion of 
NHR3. 
Ectopic expression of RUNX1 in Hs68 cells has been documented to establish a 
potent senescence-like growth arrest in Hs68 cells [59]. The findings from this 
study show that RUNX1P2-induced SLGA involves at most a minimal SASP 
response. This observation may be related to the absence of ROS and p38MAPK 
activation observed in response to RUNX1P2 which have been associated with the 
activation of NF and induction of the SASP [185, 186, 218, 248, 254]. 
Furthermore, it has been demonstrated that NFB-related genes are upregulated 
in human RUNX1 fusion protein-related leukaemias including t(8;21)-positive AML 
and that this effect can be recapitulated by knocking down RUNX1, suggesting 
that RUNX1 may abrogate NFB signalling in vivo [255]. It is notable that 
RUNX1P2 induced senescence that was dependent on p16INK4A in Hs68 cells. 
p16INK4A has been reported to induce senescence in the absence of a SASP and 
may even restrain the SASP in some contexts [251]. Interestingly, expression of 
p16INK4A was reported to partially inhibit the SASP during replicative senescence 
in human fibroblasts [251]. This phenomenon was not observed for RE which 
both induced a p16INK4A-dependent SLGA and a robust SASP in Hs68 cells. Indeed, 
the NHR mutants retained a virtually intact SASP despite failing to induce 
p16INK4A suggesting that the RE-associated SASP was somewhat refractory to 
p16INK4A expression. In contrast, ROS accumulation and p38MAPK were features of 
RE and NHR mutant expression in Hs68 cells and are capable of activating NF, 
a master regulator of the SASP [248]. Since the ROS-p38MAPK signalling pathway 
was not induced by RE9a and the SASP was severely compromised by this mutant 
it may be predicted that this pathway represents a significant inducer of the 
secretory phenotype associated with RE expression in human fibroblasts. 
Consistent with this interpretation is the observation that NF activity was 
induced in RE-transduced murine haematopoietic cells where it played a critical 
role in cellular transformation [255]. In this case activation of NFkB was 
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attributed to the loss of C-terminal domains in RUNX1 which are also absent 
from the RE constructs described in my study.   
The qualitative differences between the secretory phenotype induced by RE and 
those induced by each of the NHR mutants suggest that particular NHR domains 
may modify NFkB signalling in some way or even activate alternative signalling 
pathways. In this respect it is notable that RE9a induced a vestigial SASP that 
was independent of ROS and p38MAPK activation. Reintroduction of the NHR3 or 
the NHR4 domain did not completely rescue the secretory profile of RE 
suggesting that both domains are required for maximal senescence secretion. 
Cooperation between NHR3 and NHR4 has been noted in the recruitment of 
corepressor complexes such as SON and NCoR/SMRT to ETO [11] and may be 
important for a maximal SASP induction by RE. In this respect it is of interest 
that NCoR/SMRT complexes have also been reported to directly repress 
transcription of a variety of inflammatory cytokines [256] so their improper 
recruitment in the context of RE may have consequences for senescence 
secretion.  
The relevance of these findings for t(8;21) leukaemias is illustrated by t(8;21) 
Kasumi 1 cells that exhibit a dependence on increased levels of NFB signalling 
for their cellular proliferation [255]. A SASP is often described as having 
“antagonistic pleiotropy”. As an acute response it may be beneficial protecting 
against oncogenic transformation and mobilising the immune system to remove 
senescent cells, but over the longer term its’ effects may prove deleterious 
inducing cellular and tissue damage through chronic inflammation [2]. The 
opposing effects of a SASP are mediated by individual SASP factors that exert 
antagonistic effects in different contexts. For example, IL-6, a key SASP 
component has been identified in a positive feedback signalling pathway with 
ROS, p38MAPK and NFand may consolidate SLGA [257] but IL-6 has also been 
identified as an important pro-oncogenic factor in numerous cancers and other 
age-related pathologies [258, 259]. It is of note that IL-6 was identified as a 
strongly upregulated factor in response to RE in Hs68 cells but was not induced 
by RUNX1P2. Ectopic expression of RE in primary fibroblasts was immediately 
repressive for cellular proliferation and therefore represents an acute response. 
In this case it was associated with a robust and extensive secretory phenotype 
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that may serve to enhance the SGLA. For the NHR mutants, however the 
secretory profile was associated with proliferative phenotypes of varying degrees 
providing clear evidence that the SASP is not necessarily indicative of SLGA but 
can also be associated with proliferating cells. It is possible that in the context 
of established t(8;21) leukaemic cells which not only frequently co-express RE 
and RE9a but also other cooperating mutations, the RE-induced SASP may 
promote stress and proliferation of pre-malignant and malignant cells which may 
contribute to their leukaemogenic phenotype in vivo. 
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7  TEL-RUNX1 Expression Promotes Evasion 
of Premature Senescence in Hs68 Cells 
121 
 
7.1  Introduction  
 
The TR fusion protein generated by the t(12;21) chromosomal translocation is 
associated with approximately 25% of childhood B-cell ALL [260]. TR alone fails 
to induce leukaemia in murine models [101] but promotes leukaemogenesis in 
collaboration with inactivation of p16INK4a or by insertional mutagenesis by a 
sleeping beauty transposon [103, 104] suggesting that additional mutations are 
required for TR-mediated transformation in vivo. 
The TR oncoprotein represents an in-frame fusion between the N-terminus of the 
TEL transcriptional repressor and the C-terminus of the P1 variant of RUNX1 
[261]. The helix-loop-helix (HLH) domain is the only functional domain of TEL 
that is retained by the fusion protein. The HLH domain is required for protein-
protein interactions and has been associated with TEL transcriptional repression 
and nuclear localisation [112, 262]. Deletion of the HLH domain renders TR 
unable to drive primary B-cell expansion in vitro indicating a pro-proliferative 
function consistent with a role in B-cell transformation [263]. This group 
previously reported that TR fails to induce premature senescence in primary 
human fibroblasts and suggested that this may be important for the 
leukaemogenicity of the fusion protein [59]. To address whether the P1 variant 
of RUNX1 or the HLH domain was responsible for escape, RUNX1P1 and a series 
of TR HLH mutants were introduced into primary human fibroblasts and their 
ability to induce senescence was examined.   
Aims and Objectives 
 Compare the proliferative and senescence phenotypes of cells expressing 
RUNX1P1 and RUNX1P2 to determine whether evasion of senescence by TR 
could partially be attributed to the presence of the RUNX1P1 isoform in 
the TR fusion protein. 
 Examine mutants affecting the TR HLH domain to determine whether this 
region of the fusion transcript is important for TR-mediated senescence 
evasion. 
 If the HLH domain is required, determine the mechanism by which it 
directs senescence evasion.  
122 
 
7.2 Results  
7.2.1 Resistance to senescence is not conferred by the P1 isoform of 
RUNX1  
RUNX1P2 induces premature senescence in primary human fibroblasts [59]. To 
determine whether the P1 variant of RUNX1 displays a similar phenotype, 
RUNX1P1 was introduced into Hs68 cells on a pLentiPURO vector with RUNX1P2 
and pLentiPURO as positive and negative controls respectively. Cultures were 
then examined for parameters of premature senescence. 
Western blot analysis of selected cells revealed slightly higher levels of RUNX1P2 
that RUNX1P1 but both proteins were expressed at significantly higher levels 
than endogenous RUNX1 in the PURO control cultures (Figure 7.1 a). Ectopic 
expression of RUNX1P1 was associated with a profound growth arrest that was 
essentially indistinguishable from that observed with RUNX1P2 (Figure 7.1 b). 
Moreover, the cells assumed a flattened and enlarged morphology and displayed 
positive SA-β-Gal staining (Figure 7.1 c) consistent with the onset of premature 
senescence. 
Previous studies in primary Hs68 fibroblasts demonstrated association between 
RUNX1P2-induced SLGA and upregulation of p16INK4a [59]. This study 
demonstrates phosphorylation of AKT in response to ectopic expression of 
RUNX1P2 in the same cell background (Chapter 4, Figure 6.1b). To determine 
whether RUNX1P1 shares this phenotype, expression levels of p16INK4a and 
phosphorylated AKT were assayed in RUNX1P1 transduced Hs68 cells 6 days post-
selection when visible signs of senescence were apparent. Although both 
RUNX1P1 and RUNX1P2 induced expression of p16INK4a and phosphorylated AKT, 
RUNX1P1 appeared to induce p16INK4a expression more strongly than RUNX1P2 
while RUNX1P2 cells displayed greater activation of AKT (Figure 7.1 d). 
Together these data suggest that the P1 and P2 isoforms of RUNX1 exhibit bias 
towards specific signalling pathways resulting in quantitative differences in 
pathway activation.  
To further discriminate between the P1 and P2 isoforms of RUNX1, their 
secretory profiles were examined using a human cytokine array (RayBiotech). 
Conditioned medium was harvested 6 days after puromycin selection when 
visible signs of senescence were apparent. In the heat-maps generated, yellow 
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indicates upregulation, blue indicates downregulation and grey is used to 
represent the basal levels of secretion (equivalent to PURO). The heat maps 
were sorted according to magnitude changes induced by RE which was included 
as a positive control for SASP. A comparison of the heat maps revealed 
considerable differences between RUNX1P1 and RUNX1P2, with increased levels 
of secretory markers largely observed in the media harvested from RUNX1P1 
expressing cells and only one factor specifically induced by RUNX1P2 (MCP1). Of 
the upregulated targets, 2 were shared between RUNX1P1 and RUNX1P2 (CK beta 
8-1 and Eotaxin) and the remainder were downregulated by RUNX1P2 suggesting 
that RUNX1P1 is capable of inducing a much more substantial SASP compared to 
RUNX1P2 (Figure 7.1 e). To quantify the phenotype, the absolute numbers of 
upregulated secretory factors in each heat map were compared to RE which was 
used as a positive control for secretion. This study shows that RUNX1P1 induced 
73% of the factors upregulated by RE compared to only 13% by RUNX1P2 (Figure 
7.1 f). 
Together these data demonstrate that RUNX1P1 is capable of inducing 
premature senescence in primary human fibroblasts. The pathways involved are 
subtly different to RUNX1P2 and include induction of a substantial secretory 
profile. From this evidence, it could be predicted that the P1 isoform of RUNX1 
is not responsible for the escape from senescence observed when TR is 
introduced into primary human fibroblasts. 
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Figure 7.1 RUNX1P1 and RUNX1P2 induce premature senescence in Hs68 cells 
Hs68 cells were transduced with lentivirus vectors expressing RUNX1P1 and RUNX1P2. The empty 
vector was included as a negative control and will be referred to as PURO. Cells were selected in 
puromycin. (a) Western Blot analysis of RUNX1P1 and RUNX1P2 expression in transduced Hs68 
cells using anti-RUNX (D207-3, MBL Ltd). (b) Growth curves of cells expressing PURO, RUNX1P1 or 
RUNX1P2. Growth was recorded in triplicate over a 9 day period. (c) Transduced cells stained for 
SA-β-Gal on day 6 post selection. Images were captured using 20x magnification. (d) Western 
blot analysis of phosphorylated AKT (#9271, Cell Signaling Technology) and p16INK4a (sc-468, Santa 
Cruz Biotechnology) in transduced Hs68 cells harvested 6 days post-selection. (e) Supernatants 
harvested from transduced cells on day 6 post-selection were subjected to human cytokine array 
analysis. Data was normalised to the PURO empty vector control. Heat-map plot generated from 
data obtained using a human cytokine array to measure the SASP of Hs68 cells expressing 
RUNX1P1 and RUNX1P2. Yellow indicates upregulation while blue indicates downregulation of 
secreted factors. RE is included here as a positive control for SASP. (f) Graphic showing the 
percentage of similarity of SASP profiles of Hs68 cells expressing RUNX1P2 (13%) or RUNX1P1 
(73%) relative to RE (100%). 
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7.2.2 Escape from senescence is mediated by the HLH domain of TEL  
 
To determine whether the inability of TR to induce senescence is a function of 
the HLH domain, a HLH deletion mutant (Figure 7.2 a) (kindly gifted by 
Professor O. Williams) was subcloned into the pBabe PURO retroviral vector and 
the cells examined for markers of premature senescence.  
As previously reported, Hs68 cells expressing TR continued to divide at a 
comparable rate to PURO control cultures. In contrast, Hs68 cells expressing 
TRHLH displayed a rapid and dramatic growth arrest (Figure 7.2 b) and visible 
signs of premature senescence (Figure 7.2 c) strongly supporting a requirement 
for the HLH domain for TR-induced evasion of premature senescence. However, 
data from protein expression analyses revealed markedly reduced levels of TR 
compared to RUNX1P1 or TRHLH and the possibility that TR transduced cells are 
refractory to premature senescence simply due to insufficient TR protein 
expression (Figure 7.2 d). A similar pattern was observed when expression was 
driven by a lentiviral vector in human fibroblasts but not when TR was expressed 
from the same retroviral vectors in murine NIH3T3 cells where the level of 
ectopic TR was comparable to RUNX1P1 (Figure 7.2 e). Together these data 
exclude a technical problem with the expression vector and rather suggest that 
TR might be subject to sequestration in a specific cellular compartment in 
human cells that is less amenable to extraction by conventional techniques. 
To address this question, parallel cell pellets of Hs68 cells expressing TR were 
extracted under increasing denaturing conditions and the lysates examined for 
expression of TR. As shown in Figure 7.2 f, expression of TR was dramatically 
increased in the presence of 1% SDS. Extraction in lower concentrations of SDS 
(0.1%) or non-ionic weaker denaturing detergents including Triton (0.4%) and 
NP40 (0.5%) was less successful suggesting that full length TR was localised to an 
inaccessible cellular compartment in human cells in a manner dependent on the 
HLH domain. In support of this hypothesis, subcellular fractionation of the 
endogenous fusion protein in the t(12;21) positive REH cell line revealed that in 
contrast to nuclear RUNX1, TR was localised to the membraneous compartment 
(Figure 7.2 g) represented by structures such as the Golgi and the endoplasmic 
reticulum (ER) and known to require higher levels of detergent for successful 
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solubilisation [264]. Calnexin was used to delineate the ER-associated membrane 
fraction as it is a chaperone localised to the ER [265]. Together these data 
suggest that subcellular localisation of TR is regulated by the HLH domain and 
may contribute to the failure of TR to induce premature senescence in human 
fibroblasts.  
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Figure 7.2 The HLH domain of TEL is essential for TR-mediated escape from senescence 
Hs68 cells were transduced to express RUNX1P1, TR, and TRHLH mutant. (a) Schematic of the 
TR fusion protein and TRHLH. (b) Growth curves of transduced cells taken over a 9 day period. 
(c) SA-β-Gal staining performed day 6 post-selection. Images were captured using 20x 
magnification. (d) Western blot showing RUNX1P1 (53 kDa), TR (98 kDa) and TRHLH (80 kDa) 
expression in Hs68 cells transduced as described above measured using an anti-RUNX antibody 
(D207-3, MBL Ltd). REH cell lysate was included as a positive control for RUNX1 and TR 
expression. (e) Western blot analysis comparing RUNX1P1 and TR expression levels Hs68 cells 
transduced using lentivirus vectors and murine 3T3 cells transduced using retroviral (pBabe) 
vectors using an anti-RUNX primary antibody (D207-3, MBL, Ltd). (f) Western blot analysis of TR 
and RUNX1 levels (D207-3, MBL Ltd) after protein extraction in TR-transduced Hs68 cells using 
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different denaturing detergents. Cells transduced to express TR were lysed using WCL buffer 
(0.4% Triton), NLT buffer (0.5% NP40), RIPA (0.1% SDS) or RIPA (1% SDS). (g) Western blot analysis 
of cytoplasmic, nuclear and membraneous fractions of REH cells probed with anti-RUNX antibody 
(D207-3, MBL Ltd) and anti-calnexin (ab22595, Abcam) to differentiate the membraneous 
fraction from the cytoplasmic/nuclear fractions. 
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7.2.3 Lysine 99 of the HLH domain is sufficient to allow TR-induced escape 
from senescence  
 
Lysine 99 (K99) within the HLH domain of TEL has previously been identified as a 
critical residue for the subcellular localisation of TR. Indeed mutation of K99 to 
an arginine (R) residue was sufficient to disrupt the nuclear export of TEL [114]. 
To determine whether this residue is also sufficient to restore a senescence 
phenotype in TR expressing cells, a TR K99R mutant was generated by site-
directed mutagenesis (with thanks to Dr Anna Kilbey) and sub-cloned into a 
pLentiPURO lentiviral vector for transduction into Hs68 cells. Transduced cells 
were harvested after puromycin selection and western blotting performed on 
extracts prepared under standard conditions (0.4% Triton) for expression of 
RUNX1P1, TR and TR K99R. As predicted, the apparent expression level of TR 
was low compared to that of RUNX1P1. In contrast, the TR K99R expression level 
was high and approximately equivalent to RUNX1P1 (Figure 7.3 a). Moreover, 
Hs68 fibroblasts expressing TR K99R underwent a profound growth arrest (Figure 
7.3 b) that was accompanied by a flattened and enlarged morphology and 
positive staining for SA-β-Gal activity that was comparable to that observed for 
RUNX1P1 (Figure 7.3 c) . To determine whether this mutation induced a distinct 
mode of senescence or simply activated RUNX1 specific senescence pathways 
transduced Hs68 cells were examined 6 days after selection for p16INK4A 
expression, which is upregulated during RUNX1-induced SLGA (Figure 7.1 d), and 
ROS, which is not (Chapter 4, Figure 6.2 a). As shown in Figure 7.3 d, K99R 
induced increased p16INK4A expression relative to the wildtype fusion protein but 
not as acutely as RUNX1P1. In contrast ROS production was significantly 
upregulated by expression of K99R in comparison to the PURO vector control 
cells (Figure 7.3 e). RUNX1P1, like RUNX1P2, failed to upregulate ROS 
production confirming that this pathway is also not required for RUNX1P1-
induced SLGA. p16INK4a and ROS accumulation were refractory to TR expression 
consistent with the inability of TR to induce senescence. Together these data 
indicate that mutation of lysine 99 to arginine within the HLH domain of the full 
length TR fusion protein is sufficient to restore premature senescence in human 
fibroblasts and suggest that the pathways involved are quantitatively and 
qualitatively distinguishable from those utilised by RUNX1P1.  
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To determine whether mutation of K99 alters the subcellular distribution of TR, 
Hs68 cells were stably transduced with TR and K99R and the proteins visualised 
by indirect immunofluorescence on a Zeiss LSM 710 confocal microscope. As 
shown in Figure 7.3 f, TR was localised to distinct punctate perinuclear 
structures whereas TR K99R was predominantly detected in a diffuse pattern in 
the nucleus co-localising with DAPI. From these data it can be concluded that 
the K99 residue within the HLH domain regulates the subcellular distribution of 
TR to the cytoplasm. In this localisation TR supports a proliferative phenotype 
that may be critical for its pre-leukaemic activity. 
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Figure 7.3 Lysine 99 of the HLH domain is essential for TR-mediated escape from senescence 
 
Hs68 cells were transduced to express RUNX1P1, TR, TRHLH and TR K99R. The PURO empty 
vector was included as a positive control. (a) Western Blot analysis of expression of RUNX1P1(53 
kDa), TR (98 kDa), TRHLH (80kDa) and TR K99R (98 kDa) detected with anti-RUNX antibody 
(D207-3). (b) Growth curve analysis of Hs68 cells expressing RUNX1P1, TR and TR K99R measured 
proliferation over a 9 day period. (c) Images taken after staining cells for SA-β-Gal on day 6 post-
selection. Images were captured using 20x magnification. (d) Western blot analysis of p16INK4a 
expression levels (sc-468, Santa Cruz Biotechnology) in transduced Hs68 cells. (e) Intracellular 
ROS levels were measured by FACs-based detection of DCF-DA fluorescence. DCF-DA 
fluorescence was quantified and normalised to PURO. Significance was determined using 
students t-test and error bars refer to standard deviation. (f) HA-tagged TR and TR K99R 
detected by indirect immunofluorescence using an anti-HA antibody and a FITC-conjugated 
secondary. The nuclei of the cells were stained using DAPI. 
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7.2.4 Is Lysine 99 of TEL-RUNX1 subject to SUMOylation?  
 
Previous studies suggest that K99 SUMOylation within TEL or the TR fusion 
protein regulates the subcellular compartmentalisation of both proteins [113, 
114]. SUMOylation is a post-translational modification whereby small ubiquitin-
like modifier (SUMO) proteins become covalently attached and detached from 
target proteins in a cyclic manner [266]. Consensus SUMOylation sites can be 
identified using predictor tools such as SUMOplot™ and consist of a Ψ-K-x-D/E 
motif where Ψ is a hydrophobic amino acid, K is the Lysine residue to which 
SUMO becomes conjugated, x is any amino acid and D/E is an acidic amino acid 
[267]. Interrogation of the sequence around K99 using SUMOplot™ failed to 
identify K99 as a consensus SUMOylation motif due to the presence of a 
hydrophilic amino acid (Threonine) rather that a hydrophobic one preceding K99. 
As previously reported, a second site, K11, was confirmed by SUMOplot™ as 
being within a consensus SUMOylation motif [115] (Figure 7.4 a).  
To establish whether TR K99 is a non-consensus SUMOylation site, pLentiNEO 
lentiviruses expressing TR and TR K99R were introduced into HepaRG cells stably 
expressing His-tagged SUMO proteins (SUMO-1, SUMO-2 and SUMO-3) under 
puromycin selection (Kindly gifted by Dr Elizabeth Sloan). Neomycin-resistant 
cells were harvested after 5-7 days and SUMOylated proteins pulled down by 
Nickel-Affinity Purification and analysed by western blot (Figure 7.4 b). 
Interrogation of the blots with an anti-RUNT antibody specifically detected TR 
and TR K99R in cells expressing SUMO1-3 but not in the HIS-only control cells 
suggesting that both proteins were subject to SUMOylation by SUMO1, 2 and 3. In 
addition, a ladder of higher molecular weight RUNX reactive bands was detected 
in His-SUMO1 HepaRG cells expressing either TR or TR K99R which may be 
consistent with multiple SUMOylations. Reprobing of the blots with an anti-His 
antibody revealed that free His-SUMO1 was less prevalent than either SUMO2 or 
SUMO3 but as yet it is not possible to say whether this reflects a greater 
proportion of SUMO1 existing in the conjugated state or simply lower absolute 
expression levels of His-SUMO1 in HepaRG cells. As observed in human Hs68 
cells, TR was detected at lower levels that TR K99R but both proteins essentially 
displayed the same pattern of affinity purified bands supporting the conclusion 
that K99 does not regulate TR subcellular localisation as part of a consensus 
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SUMOylation site and that TR may be SUMOylated on alternative lysine residues 
such as K11 which is present in both proteins. 
 
Figure 7.4 Lysine 99 of the HLH domain is not a SUMOylation site 
HepaRG cells expressing His-tagged SUMO proteins were transduced with lentivirus vectors 
encoding TR or TR K99R. (a) Comparison of the consensus SUMOylation sequence, ψKxD/E (ψ= 
hydrophobic amino acid, K= Lysine, x= any amino acid, D/E= acidic amino acid) to proposed 
SUMOylation sites at K99 and K11 of TEL/TEL-RUNX1 as determined by SUMOplot. (b) Western 
Blot analysis of Nickel affinity purified samples taken from HepaRG cells expressing His-tagged 
SUMO1, SUMO2 or SUMO3. Purified SUMO and interacting TR or TR K99R were detected using an 
antibody against SUMO. 
 
7.2.5 A t(12;21) Leukaemic Cell-Line is Refractory to TR K99R-Induced 
SLGA 
 
To determine whether the effects of TR K99R on senescence are restricted to 
primary cells or can be extended to more physiologically relevant cell 
backgrounds TR K99R was introduced into REH cells which represent an end 
stage t(12;21) positive leukaemic line. Using a lentiviral vector delivery system, 
high levels of ectopic TR K99R were detected compared to the endogenous TR 
protein in REH cells (Figure 7.5 a). In contrast to primary human fibroblasts 
expression of TR K99R failed to induce SLGA in REH cells and consistently 
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promoted their growth relative to the empty vector (PURO) control cultures 
(Figure 7.5 b) REH cells lack expression of the p16INK4A tumour suppressor and 
also display high levels of endogenous RUNX1 [268]. To determine whether the 
growth inhibitory properties of RUNX1 are silenced by loss of p16INK4A RUNX1P2 
was introduced into p16INK4A-null primary human diploid fibroblasts (Leiden cells) 
and examined their growth. As shown in Figure 7.5 c, RUNX1 promoted growth 
in this cell background suggesting that loss of p16INK4A reveals pro-oncogenic 
functions of RUNX1 that render end stage leukaemic cells refractory to 
premature senescence. 
 
 
Figure 7.5 A t(12;21) leukaemic cell-line is refractory to TR K99R-induced senescence 
REH cells were transduced with a lentivirus vector encoding TR K99R or the PURO empty vector 
control. (a) Growth curves showing proliferation of PURO and TR K99R-expressing REH cells over 
a 4-day period. (b) Western blot analysis of TR, TR K99R and RUNX1 expression in transduced and 
non-transduced REH cells using an anti-RUNX antibody (D207-3, MBL Ltd). Leiden fibroblasts 
(p16INK4A-null) were transduced with a lentivirus vector encoding RUNX1P2 or the PURO empty 
vector control. (c) Growth curves showing proliferation of PURO and RUNX1-expressing Leiden 
cells measured over a 15-day period. 
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7.3 Discussion 
In line with a previous report, this study has shown that despite retention of an 
almost intact RUNX1 sequence, TR fails to induce senescence in Hs68 cells [59]. 
The possibility that RUNX1P1 sequences are responsible can now be excluded 
and Lysine 99 within the TEL HLH domain was identified as a critical residue 
responsible for the subcellular localisation of TR and escape from premature 
senescence. 
I have shown that RUNX1P1 SLGA is visually indistinguishable from RUNX1P2 but 
unique with respect to senescence secretion which is robust and largely 
restricted to RUNX1P1. It has previously been reported that RUNX1 attenuates 
NFB activation through a direct interaction with the IB Kinase (IKK) complex 
[255]. While this may account for the weak SASP associated with RUNX1P2, our 
data suggest that RUNX1P1 is capable of inducing a SASP, possibly as a less 
effective attenuator of NFB activity or through alternative signalling pathways. 
It is notable that sequences outwith the RHD and C-terminus of RUNX1 were also 
required to attenuate NFB activity in murine haematopoietic cells [255]. 
Furthermore, a failure of RUNX1P1 to accumulate intracellular ROS was observed 
in human fibroblasts. Elevated ROS is reported to activate p38MAPK, a major 
inducer of NFB and the secretory phenotype, supporting the existence of an 
alternative pathway. Finally, RUNX1P1 and RUNX1P2 induced SLGA through 
subtly different signalling pathways, confirming that these isoforms do not 
behave identically in human fibroblasts. 
A SASP can be beneficial or deleterious depending on cellular context [205]. As 
an acute response to oncogene expression, the SASP can reinforce SLGA in 
senescent lesions and the surrounding cells via autocrine and paracrine 
mechanisms thereby contributing to tumour suppression. However, persistent 
SASP signalling can promote malignant phenotypes through chronic inflammation 
[145, 186, 205, 206, 209]. It is therefore interesting that RUNX1P1 and not 
RUNX1P2 was identified as a collaborating oncogene in a CD2-Myc retroviral 
insertional model of murine lymphoma [58]. Moreover, RUNX1P1 is the 
predominant isoform expressed in childhood B-cell ALL (M. Stewart, Unpublished 
data) where RUNX1 is frequently amplified [269-273], all suggesting that 
RUNX1P1 may be the more oncogenic isoforms of RUNX1 in lymphoid leukaemia 
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[274]. The t(12;21) chromosomal translocation encodes almost the entire P1 
isoform of RUNX1 fused to the TEL HLH domain [105]. From the data presented 
here, it seems unlikely that P1 sequences are responsible for TR-induced evasion 
of SLGA but they may none-the-less contribute to the oncogenicity of the fusion 
protein in the context of leukaemia development. 
The HLH domain is the only functional domain of TEL retained by the TR fusion 
and is required for the preleukaemic activity of TR in haematopoietic stem cell 
models of B-cell ALL [112]. Early B cells derived from these models display 
enhanced colony formation in vitro and an advantage over normal 
haematopoietic progenitors when reconstituted in vivo [102, 263, 275]. 
Furthermore, it has been reported that TR positive murine pre-B cells display 
reduced sensitivity to growth inhibitory signalling by TGF-β which was 
hypothesized to result in preferential pre-leukaemic cell expansion [229]. These 
observations have now been extended to primary human fibroblasts, showing 
that TR expression is consistent with a proliferative phenotype that essentially 
evades SLGA and is entirely dependent on Lysine 99 within the HLH domain. The 
biological significance of this result is realised by the fact that the TR fusion 
alone is insufficient to drive leukaemia in murine haematopoietic models 
supporting a requirement for secondary cooperating mutations [101, 103, 263]. 
Consistent with this interpretation is the high incidence of t(12;21) chromosomal 
translocations in newborns that far exceeds the occurrence of childhood B-ALL 
[276], and retrospective analyses of Guthrie Spots showing that the TR 
preleukaemic clone arises in utero and persists for several years before 
developing into ALL [277]. My data shows that TR evades SLGA and sustains the 
proliferation of human fibroblasts through a mechanism of cytoplasmic 
sequestration regulated by Lysine 99. Lysine 99 was previously reported as a site 
of SUMOylation in TEL and TR that regulates nuclear export [114]. It was not 
possible to confirm Lysine 99 as a perfect SUMO consensus sequence or indeed a 
specific site of SUMOylation in TR, but mutation of Lysine 99 to an arginine 
residue was sufficient to redistribute TR to the nucleus and induce SGLA. TR 
K99R has not been described as a naturally occurring mutant but localisation of 
TR to the membraneous compartment in the REH B-ALL cell line strongly 
suggests that cytoplasmic sequestration is not simply a feature of overexpression 
in fibroblasts and may be relevant in a leukaemic context. Moreover this study 
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shows that TR resisted extraction in human fibroblasts which is consistent with 
membrane localisation. Nuclear import of TR K99R was confirmed by 
immunofluorescence. It has been proposed that nuclear TR functions as a 
negative repressor of RUNX1 activity [109]. As a nuclear transcription factor, the 
TEL HLH domain interacts with a number of co-repressor complexes including 
KAP1, NCoR/SMRT, mSin3A and HDACs [278-280]. It is believed that TEL 
recruitment of co-repressors to RUNX1 responsive gene promoters via the RUNX1 
RHD results in constitutive transcriptional repression of RUNX1 targets [110]. 
While this is an attractive model it has also been reported that TR expression 
derepressed a number of RUNX1 dependent promoters in murine fibroblasts [75] 
and that TR can sequester co-factors in the cytoplasm including RUNX1 co-
activators such as p300 [262]. Together these reports suggest that TR is more 
than just a constitutive repressor of RUNX1 function and support findings from 
this study, showing that TR K99R-induced SLGA was distinct from RUNX1P1 in 
human fibroblasts. Although the cultures were visually indistinguishable they 
were biochemically distinct, particularly with respect to the dramatic 
accumulation of intracellular ROS associated with TR K99R, suggesting that TR 
K99R is capable of directing a unique senescence phenotype from RUNX1P1. 
Contrary to the effects of TR K99R in human fibroblasts this mutant was unable 
to induce premature senescence in REH cells suggesting that these end stage 
leukaemic cells have become refractory to senescence failsafe mechanisms. 
Consistent with this argument is the amplification and/or overexpression of 
RUNX1 commonly associated with childhood B-cell ALL and B-cell ALL cell lines 
that is apparently compatible with cellular proliferation [274, 281]. Since 
RUNX1 and TR K99R are sufficient to induce SLGA in primary human fibroblasts it 
may be predicted that end stage leukaemia cells have acquired secondary 
mutations that mask this activity. In this respect it is notable that RUNX1P1 [59] 
and RUNX1P2 promoted the growth of p16INK4A null Leiden cells supporting the 
existence of RUNX1 oncogenic functions revealed only in the absence of p16INK4A. 
Moreover REH cells harbour deletions affecting the CDKN2A gene which encodes  
p16INK4A and p14ARF [282]. Finally TR, unlike RUNX1P1 or TR K99R failed to induce 
p16INK4A or SLGA in human fibroblasts providing a strong causative link between 
p16INK4A and RUNX1-induced SLGA in vitro. From the evidence presented here it 
may be predicted that suppression of RUNX1-induced growth arrest by the TEL 
140 
 
fusion moiety is critical for leukaemia initiation but is dispensable for end-stage 
leukaemias that have become refractory to this failsafe mechanism.   
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8 General Discussion 
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8.1  What is the Biological Significance of SLGA?  
 
As discussed in chapter 1, OIS was initially described in murine and human 
fibroblasts in response to H-RasV12 and attributed to a DDR triggered by hyper-
replication [130, 169, 170]. It has since been described by us and others in 
response to a wide range of oncogenes but does not necessarily involve DNA 
damage [59, 225, 226]. Rather, the common factor appears to be the induction 
of major tumour suppressor pathways including p53 and p16INK4A to induce SLGA. 
p53 activation was a feature of Runx-induced senescence in primary MEFS and 
associated with a rapid and profound SLGA in the absence of DNA damage [224]. 
This study has demonstrated a similar phenotype in response to RUNX1ETO, 
albeit through the engagement of distinct tumour suppressor pathways, lending 
credence to the hypothesis that immediate inhibition of cell cycle transit is 
achievable in the absence of hyper-replication and DNA damage.  
Potential inducers of cell cycle arrest independently of serum restriction include 
the CDK inhibitors p21CIP1 and p16INK4A. These effectors are activated in response 
to multiple senescence-inducing agents including oncogenes such as RUNX1 and 
RUNX1ETO [59, 225]. It is notable that CDK inhibitors also induce reversible 
quiescence following growth factor withdrawal suggesting that the defining 
feature of premature senescence is not the cell cycle inhibition per se but the 
persistence of growth promoting pathway activity that continues even after a 
stable proliferative arrest [283]. In this respect oncogenes not only induce CDK 
inhibitors and SLGA but also regulate growth promoting signals that facilitate 
cellular transformation when barriers to cell cycle progression such as p53 and 
p16INK4a are removed. The biological significance of premature senescence is 
indicated by the observation of SLGA in premalignant lesions of multiple human 
tumours in vivo [132-134]. Indeed it has been proposed that senescence acts as a 
failsafe mechanism to restrict cancer development [131, 284, 285]. In this 
regard it is notable that RUNX1 and RE induce leukaemia in vivo but are 
associated with a rapid and profound SLGA in vitro [59, 225]. The findings that 
SLGA potential is masked in TR by fusion to TEL and attenuated by the 
leukaemogenic isoform of RE, RE9a, argues strongly in favour of SLGA as a 
cancer failsafe response rather than an artefact of in vitro culture conditions or 
ectopic expression of proteins at non-physiological levels. Together the data 
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suggest that oncogenic stress represents a potent inducer of SLGA that can 
restrict leukaemia development in vivo when cell cycle inhibition is maintained.  
8.2  The Inflammatory Secretome and SLGA  
 
Senescence represents a metabolically active, stable growth arrest associated 
with an inflammatory secretome or SASP enriched for pro-inflammatory 
cytokines and chemokines, growth factors, cell surface molecules and survival 
factors [205]. Since the SASP is wide ranging in multiple cell types and a feature 
of replicative and premature senescence different inducers of SLGA were 
compared for senescence secretion and revealed marked differences between 
RUNX1 isoforms and between RUNX1 and its fusion derivatives. Specifically, 
RUNX1P2 actively repressed secretion whereas RUNX1P1 induced a robust 
secretory phenotype that was exceeded only by RE. The minimal SASP response 
evoked by RUNX1P2 raises the question as to whether this SASP has any 
biological function. Indeed does a SASP-deficient SLGA simply represent normal 
physiological growth arrest? This seems unlikely since RUNX1 expression was 
associated with the typical cellular hypertrophy and SA-β-Gal activity 
characteristic of senescent cells. Moreover p16INK4A activation was induced by 
RUNX1 in the presence of continuous growth stimulation, providing a profile of 
“active” cell cycle arrest that is commonly used to distinguish between 
senescent and quiescent cells [283].  
When considering whether SASP repression by RUNX1P2 has biological function it 
is relevant to consider the tumour-promoting activities of senescence-associated 
secretion. In general, a pro-inflammatory tissue environment is pro-tumourigenic 
[286]. The SASP encompasses a plethora of growth factors and other effectors 
that can modify the microenvironment to facilitate metastasis and promotes 
secretion or shedding of cytokine receptors to allow neighbouring pre-malignant 
and malignant cells to evade immune surveillance. Any repression of the 
secretory phenotype might therefore be regarded as tumour suppressive so it is 
notable that the p53 tumour suppressor, in addition to suppressing cancer by 
inhibiting cell growth also does so through restraint of the secretory phenotype, 
earning it the title of “super suppressor” [127]. This study has shown that 
RUNX1P2-induced SLGA is dependent on p16INK4A which fails to influence the 
SASP and indeed is not required for its development [251]. Others have reported 
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that RUNX1 functions as a cytoplasmic attenuator of NFB signalling, which is a 
major regulator of the secretory phenotype [255]. From the evidence presented 
here it may be predicted that RUNX1 controls senescence secretion through 
downregulation of NFB signalling which, in collaboration with p16INK4A-induced 
growth arrest, sustains RUNX1-induced SLGA. The biological significance of this 
model for tumour development is evident in the myeloid system where RUNX1 is 
generally considered to act as a tumour suppressor and to repress myeloid 
tumour development through attenuation of NFB signalling [255]. For lymphoid 
malignancies the consequences of RUNX1 expression are quite different. 
Evidence from this group supports an oncogenic function for RUNX1 in this 
lineage with Runx1P1 and c-Myc cooperating in the development of murine 
lymphoma [287] and over-expression and/or amplification of RUNX1P1 reported 
in a subgroup of ALL. Moreover RUNX1P1 is the isoform expressed from the 
t(12;21) translocation [288] further emphasizing the significance of RUNX1P1 
oncogenic functions in the lymphoid lineage. Results from this study 
demonstrate a robust secretory phenotype in human fibroblasts in response to 
ectopic RUNX1P1 consistent with oncogenic activity. The dramatic difference 
between RUNX1P1 and RUNX1P2 expression for senescence secretion in this cell 
background supports further investigation of NFB signalling pathways. It will be 
of interest to determine how the activity of NFB affects senescence secretion 
and whether it relates to the oncogenic and tumour suppressor functions of 
RUNX1 in the lymphoid and myeloid lineages respectively.  
The most robust secretory phenotype observed in human fibroblasts was in 
response to ectopic expression of RE and was accompanied by a rapid and 
dramatic SLGA. RE9a, in contrast, failed to induce SLGA but was much less 
effective at restraining the SASP suggesting that these represent independent 
functions. In support of this hypothesis, p53 inhibition in cells where p16INK4A is 
only weakly expressed is sufficient to reverse the SLGA but not the SASP [127]. 
Moreover, relatively similar SASP profiles were noted in response to the NHR 
mutants despite their disparate effects on cell growth. Together these data 
suggest that senescence secretion is compatible with proliferative phenotypes, 
raising the possibility that a SASP has very different effects on proliferating and 
non-proliferating cell populations. The apparent paradox may be explained by 
the antagonistic functions of senescence secretion to both reinforce senescence 
145 
 
growth arrest and promote degenerative and hyperproliferative effects in 
neighbouring cells to promote tumour cell growth. The dual potential has 
parallels with the theory of antagonistic pleiotropy that was proposed to explain 
the evolutionary selection for gene functions that promote senescence [289]. 
Moreover, it may provide an explanation for why the acute repose to RE in 
primary human fibroblasts was an SLGA reinforced by a robust SASP, whereas in 
end stage AML and t(8;21) AML patient samples high levels of ROS and NFB 
activity have been directly associated with cellular proliferation [255, 290]. In 
this respect it is noteworthy that RE and RE9a are co-expressed in t(8;21) 
leukaemias and RE and RE9a have been shown to cooperate in the development 
of myeloid leukaemia in mouse models [80]. It was shown that RE9a sustained a 
proliferative population in human fibroblasts which may prove more susceptible 
to the transforming effects of senescence secretion than a non-proliferating 
population. It is not possible to conclude whether RE9a opposed cell cycle arrest 
directly or indirectly through partial restraint of the SASP, but cellular 
proliferation is essential for the acquisition of secondary mutations and is likely 
to provide a critical component of the cooperation between RE and RE9a in vivo. 
A similar conclusion may be drawn from studies involving the TR fusion 
oncoprotein. While sustained proliferation was demonstrated in TR-expressing 
human fibroblasts, others have reported a similar phenotype in pre-leukaemic B 
cells [291]. In the study mentioned, proliferation was accompanied by high 
levels of ROS and DNA damage both of which have been associated with 
senescence secretion and suggested to contribute to the acquisition of secondary 
mutations required for tumour development [291]. Together these results 
suggest that overcoming the senescence failsafe represents a genuine 
mechanism for leukaemia development. However they also provide evidence 
that elements of the senescent phenotype persist and modulate the response in 
vivo. In this respect it is notable that knockdown of endogenous RUNX1 
expression induced apoptosis in t(8;21) positive Kasumi 1 cells [292]. It would be 
of interest to determine whether RUNX1 opposition of senescence secretion acts 
to modulate the dramatic effects of RE on this pathway and thereby promote 
survival of the leukaemic cell.   
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8.3  How is RUNX1-Induced SLGA Overcome in Natural Tumourigenesis?  
 
I have demonstrated that RUNX1 and RE induce SLGA in vitro despite their strong 
association with leukaemia in vivo and that the senescence failsafe is evaded by 
RE9a and TR. Moreover RE9a is associated with a more leukaemogenic phenotype 
in animal models suggesting that cooperating mutations that evade SLGA 
promote tumourigenesis.  
8.3.1 RUNX1 Leukaemogenesis  
 
Animal models have facilitated the identification of cooperating genes required 
for Runx1 tumourigenicity and include loss of p53 and overexpression of Myc. A 
previous report from this laboratory demonstrated escape from Runx1-induced 
senescence and cellular transformation in p53-null primary MEFs suggesting that 
loss of p53 releases cells from Runx1-induced proliferative arrest [230]. A similar 
conclusion was drawn for the Runx/Myc collaboration in murine T cell lymphoma 
where Myc overexpression rescued a Runx2 induced differentiation block to 
promote T cell proliferation [287]. Growth arrest represents a critical 
component of senescence. It is accompanied by an active metabolism that is 
only revealed as tumour-promoting when cell cycle arrest is overcome [283]. In 
this respect it is notable that p53 loss induces inflammatory secretion in human 
fibroblasts and c-Myc modulation of protein synthesis is both critical for Myc 
oncogenicity and associated with senescence metabolism pathways such as 
mTOR and PI3K/AKT [127, 293, 294]. From this evidence it may be predicted 
that RUNX1 collaborators not only overcome cell cycle arrest but are also 
important for tumour cell growth, making them ideally suited to overcome 
Runx1-induced senescence and to promote cellular transformation. Further 
evidence to support this is provided by the cooperation between RUNX1 and loss 
of p53 or overexpression of MYC in human leukaemias. Gene expression profiling 
of precursor B-cell ALL revealed overexpression of RUNX1 and cMyc while in rare 
cases of RUNX1 amplification in therapy related myelodysplasia (AML or 
myelodysplastic syndrome (MDS)) inactivating mutations of p53 were consistently 
described [295, 296]. The role of RUNX1 in these cases is not well defined but 
animal models suggest that cell survival may be the key. Depletion of Runx1-
induced Fas ligand in a p53-null mouse model of thymic lymphoma and Runx2-
dependent inhibition of Myc-induced apoptosis was described in Runx2/Myc 
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thymic lymphomas [287, 297]. Moreover addiction to Runx1 was also observed in 
a floxed Runx1 model of primary EµMyc lymphomas with Runx1-expressing cell 
lines derived from the lymphomas displaying an increased resistance to DNA 
damaging agents compared to their Runx1-excised counterparts [298]. In this 
respect it is of note that senescence secretion includes a number of survival 
factors and was induced by the P1 isoform of RUNX1 which was also expressed in 
precursor B-ALL (Monica Stewart pers comm) and identified by retroviral 
insertion in a CD2Myc model of thymic lymphoma. Moreover tumour suppressors 
implicated in premature senescence such as PML and FOXO have been shown to 
play important survival roles in leukaemic stem cells [299, 300] and experiments 
to reintroduce a survival signal into Runx1-deleted leukaemic cells derived from 
a mouse model of MLL-ENL partially rescued the Runx1 growth phenotype all 
suggesting that features of the senescence failsafe can be exploited to promote 
survival of tumour cells when proliferative arrest is overcome [301]. 
8.3.2 TEL-RUNX1 Leukaemogenesis  
 
The t(12;21) translocation is present in approximately 25% of childhood B cell 
precursor ALL but fails to induce leukaemia in mouse models suggesting that 
secondary events are required [103]. It was shown that TEL masks RUNX1 activity 
in the TR fusion protein to evade SLGA in vitro thereby maintaining a 
proliferative phenotype that may be important for the acquisition of secondary 
mutations. Although p53 mutation is observed at relapse and is associated with 
poor outcome, loss of p53 function has not been observed in primary t(12;21) 
leukaemias suggesting that it is unlikely to be a major TR cooperating event 
[302]. An analysis of genetic abnormalities in newly diagnosed ALL revealed c-
Myc translocations in 5 out of 1346 cases. All were in cases of childhood B-cell 
ALL but it was unclear whether these overlapped with the t(12;21) translocation 
[303]. Cooperation between Myc and TR was supported by another study, 
however, that reported Myc overexpression in patient-derived cells addicted to 
the t(12;21) fusion oncoprotein and apoptotic cell death when Myc activity is 
inhibited in t(12;21) REH cells [304]. It would therefore be of interest to 
determine whether c-Myc transcription was specifically upregulated in response 
to TR in human fibroblasts and required to maintain cellular proliferation. One 
of the most frequent genetic events in childhood ALL is loss of heterozygocity 
(LOH) in chromosome arm 9p including the CDKN2A locus encoding p16INK4A and 
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p14ARF. For childhood precursor B-ALL the occurrence of 9p LOH is approximately 
21% whereas for the t(12;21) subgroup it is around 15% [305]. The importance of 
this gene locus for tumour suppression is evidenced by the increased incidence 
of t(12;21) leukaemias in retroviral transduction transplantation models where 
CDK2NA is deleted [103]. p14ARF was not detected in Hs68 fibroblasts but a 
requirement for 16INK4A was demonstrated in RUNX1-induced SLGA with loss of 
p16INK4A associated with accelerated growth in response to RUNX1P1 [59], 
RUNX1P2 or the TR K99R mutant. Together these data support the hypothesis 
that loss of the second allele or happloinsufficiency of CDKN2A is an important 
collaborating event in B-ALL. TR expression sustained proliferation of Hs68 
fibroblasts and, in contrast to RUNX1 and TR K99R had no apparent effect on 
p16INK4A expression levels. It seems unlikely that CDKN2A happloinsufficiency was 
responsible for TR-induced evasion of senescence in such a short time frame 
experiment. Instead, the lack of p16INK4A expression may either reflect a 
dominant negative suppressor activity of TR towards a RUNX1 gene target [306] 
or the cytoplasmic distribution of TR observed in Hs68 fibroblasts. In this respect 
it is noteworthy that REH end stage t(12;21) leukaemic cells maintain high levels 
of endogenous RUNX1 expression but are genetically null for CDKN2A suggesting 
that loss of p16INK4A may be more relevant to later progression stages where 
increased RUNX1 copy number is selected for and the requirement to evade 
RUNX1-induced senescence more significant. Moreover silencing of TR in 
t(12;21)-positive B-ALL cell lines abrogates PI3K/AKT/mTOR signalling to reduce 
cellular proliferation and survival suggesting that TR exploits this metabolic 
senescence-inducing pathway to expose tumour promoting functions when 
obstacles favouring proliferative arrest are removed [307]. From the evidence 
presented here it may be predicted that suppression of RUNX1-induced growth 
arrest by the TEL fusion moiety is critical for leukaemia initiation but 
dispensable for end-stage leukaemias that have become refractory to this 
failsafe mechanism.  
8.3.3 RUNX1-ETO Leukaemogenesis  
 
RE is atypical in that it is associated with a high proportion of M2 AML but, unlike 
TR and RE9a, induces an intense SLGA in human fibroblasts. The pathways 
involved are distinct from RUNX1 and include ROS-p38MAPK signalling and robust 
senescence secretion. The significance of RE-induced senescence is realised by 
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the inability of RE to induce leukaemia in mouse models [80] and suggests a 
requirement for secondary mutations to overcome the senescence failsafe. This 
hypothesis is supported by the leukaemogenicity of the RE9a isoform [80] that 
evades senescence in vitro, and has provided the impetus to identify the 
secondary cooperating events in t(8;21) leukaemias. From such studies it has 
been shown that while p53 mutation is not a general feature of t(8;21) 
leukaemias, trisomy 8 with amplification of c-Myc at 8q24 is represented in 
approximately 15-20% and 10-15% of MDS and AML respectively [308, 309]. 
Moreover the increase in c-MYC copy number appears to be important for 
disease progression suggesting that Myc may cooperate with RE in vivo. MYC has 
also been shown to overcome cell cycle inhibition by CBFβ-SMMHC which, like 
RE, is associated with a CBF leukaemia and induces SLGA in vitro suggesting that 
this collaboration may represent a more widespread feature of CBF 
transformation [225, 310]. It was shown that RE-induced SGLA was dependent on 
p16INK4A in primary human fibroblasts. Moreover, p16INK4A was not induced by 
RE9a, which also evaded SLGA, suggesting a critical role in the senescence 
failsafe in response to RE. Deletions or intragenic mutations of p16INK4A are 
infrequently observed in AML [308]. However, t(8;21) patients are reported to 
show high levels of hypermethylation of the p15 and adjacent p16 gene that at 
least for p15 show excellent concordance with disease progression [311]. 
Hypermethylation may suppress expression of these CDK inhibitors as well as the 
overlapping ARF gene that governs the activity of MDM2 and thence the activity 
of p53. In this respect it is notable that t(8;21) patient samples revealed 
markedly lower levels of p14ARF mRNA when compared with AMLs lacking this 
translocation [312].  
If secondary mutations play a role in escape from the senescence failsafe when 
and how do they occur in vivo? Retroviral transduction of RE into human CD34+ 
stem cells was associated with an early and robust growth arrest that persisted 
for 4-6 weeks before the emergence of a RE-expressing proliferative population 
exhibiting a down regulation of DNA repair enzymes [82]. It is notable that p53 
response pathways were also activated in this population. A similar pattern was 
observed in t(8;21) compared to other AML patient samples and hypothesised to 
contribute to their favourable response to chemotherapy in the clinic [313]. 
Since germline p53 mutations are rare in AML and p53 restrains the activities of 
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ROS and the SASP [127, 314], the data suggests that other secondary mutations 
are required to overcome the initial RE-induced growth arrest. We hypothesise 
that additional events, such as loss of p53, determine how quickly that 
proliferating population progresses to full-blown leukaemia. It is therefore 
notable that RE9a and RE cooperate to induce a more aggressive leukaemic 
phenotype in vivo [80] and it is possible that the toxic combination of cellular 
proliferation with ROS and senescence secretion is responsible. It should also be 
noted that RE9a was capable of inducing a vestigial SASP that was qualitatively 
distinct from RE and for this reason cannot be excluded as a contributing factor 
in the RE and RE9a cooperation. 
8.4  Conclusions  
 
Oncogene-induced-senescence is recognised as a physiological mechanism that 
limits the progression of premalignant lesions and is associated with a number of 
leukaemic fusion oncoproteins including RE, BCR-ABL and CBF-MYH11 [59, 225].  
For initiated cells to progress to a tumour the profound growth arrest that 
accompanies OIS must be overcome and secondary mutations acquired.  However 
it now seems likely that some survival signals characterising the senescence 
phenotype may actually persist in cancer development and promote survival 
within a different cellular context.  In this respect it is  notable that two tumour 
suppressors implicated in premature senescence, PML and FOXO, were also 
reported to have important survival roles in leukaemic stem cells [299, 300]. 
Furthermore, RUNX1 has been demonstrated as an essential survival factor in a 
murine model of MLL-ENL and yet is an inducer of premature senescence in 
primary fibroblasts [230, 301]. The survival of preleukaemic proliferating cells is 
now considered crucial for leukaemogenesis.  The TR translocation occurs in 
utero in early B cell progenitors establishing a pre-leukaemic clone that can 
persist for up to several years [52, 276, 277]. Similar observations have been 
made for RE and MLL-AF4 [315] suggesting that this may represent a more 
general phenomenon of leukaemogenesis.   
This study shows that the initial response to nuclear expression of TR (K99R) or 
RE in human primary fibroblasts is a profound SLGA. It is significant that the 
expansion of human CD34+ cells in response to RE infection was preceded by an 
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early and persistent growth restriction suggesting that acquisition of a 
proliferative phenotype is essential for emergence of the pre-leukaemic clone 
[82]. Both ROS and SASP were observed in response to expression of RE in 
primary human fibroblasts and both have been directly or indirectly implicated 
in AML. Elevated ROS promotes proliferation of AML cell lines and primary AML 
blasts  and was observed in over 60% of AML patient samples whereas PKD1 was 
identified as a poor prognosis factor in AML and has been linked to 
overexpression of NFkB, a master regulator of the SASP [186, 290, 316]. ROS was 
also a feature of TR-induced senescence when TR (K99R) was redistributed to 
the nucleus. Although ROS accumulation was not observed with wild-type TR, 
high ROS and a DNA damage response have been reported in TR expressing pre-
leukaemic pro-B cell lines and proposed to underlie the mechanism for 
acquisition of secondary mutations [291]. In this regard it is interesting that the 
proliferative capacity of t(8;21) positive leukaemias was opposed by ROS 
scavengers [290] and NF inhibitors [255], supporting a critical requirement for 
specific features of the senescent phenotype to preserve the proliferation of 
pre-leukaemic cells and favour leukaemia development.  
Chronic inflammatory stimulation may also provide an explanation for the more 
aggressive leukaemic phenotype observed when RE and RE9a were combined in a 
retroviral transduction transplantation mouse model [80]It is possible that RE 
provides additional paracrine stimuli in the form of ROS and chronic 
inflammatory factors to increase the likelihood of secondary mutations in the 
proliferating RE9a compartment thereby facilitating leukaemia progression. In 
this regard it is interesting that RE9a shares over 30% of the gene signature 
expressed by RE particularly favouring genes involved in cell survival and 
proliferation [317]. A similar mechanism may be exploited by TR since it also 
maintains rather than promotes the proliferation of in Hs68 fibroblasts.  In this 
case the factors responsible for driving secondary mutation are less clear but it 
is interesting that  TR expressing pro-B-cells are characterised by a positive 
signature for cellular stress and immune function genes with potential for 
inducing the opportunity for secondary mutations [318]. A requirement for 
secondary mutations was also observed in this study when TR K99R and RE were 
introduced into p16INK4A null cell backgrounds.  Loss of p16INK4A revealed novel 
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oncogenic functions in both fusion proteins that promoted the growth of REH and 
Leiden fibroblasts respectively. 
Persisting RUNX1 expression is a feature of many fusion leukaemias including TR 
and RE.  It is rarely mutated and cases of compensation by other RUNX family 
members have been reported where RUNX1 expression was experimentally 
reduced in vitro [301]. An essential proliferative role is evidenced by the 
requirement for proper RUNX1 function for the efficient growth of RE, MLL-AF9 
and MLL-AF4 leukaemic cells [301, 319].  Moreover t(12;21) leukaemias 
invariably express RUNX1 without mutation and recurrent copy number changes 
involving the 21q22 amplicon encoding RUNX1 are commonly observed [295, 320, 
321]. Our results may initially seem to contrast with these observations since 
both isoforms of RUNX1 were associated with a rapid and robust SLGA in primary 
human fibroblasts.  However as these cells were non-leukaemic and engineered 
to induce ectopic RUNX1 proteins it is conceivable that cellular background and 
expression levels are critical. In this regard it is notable that high levels of 
RUNX1 arrested growth in human CD34+ cells but maintained the proliferation of 
MLL-AF4 leukaemic cells [82, 319]. In contrast, more modest levels of RUNX1 
were necessary to support the growth of myeloid leukaemic lines expressing RE 
or MLL-AF9 [301]. Similarly, an intolerance of high ectopic RUNX1 protein 
expression was observed in murine thymic lymphoma cell lines but lower levels 
of the endogenous protein equip murine B-cell lymphoma cell lines with a 
greater proliferative capacity than their floxed Runx1 counterparts [298].  
The decision to promote or restrict growth by RUNX1 may operate at the 
transcriptional level.  Introduction of a series of naturally occurring RUNX1 
mutants into RE and MLL-AFN leukaemic cell lines revealed that the RUNT 
homology domain was critical for both accelerated and restricted growth 
suggesting that specific transcriptional programmes are directed through RUNX1 
recruitment of particular co-factors associated with growth suppression or 
growth activation [301]. In addition to an essential role for growth, RUNX1 may 
also be required for the survival of fusion leukaemias.  Runx1 has been 
associated with upregulation of the Bcl-2 survival factor in MLL fusion leukaemia 
and addiction to RUNX1 was demonstrated in t(8;21) and inv(16) myeloid 
leukaemic cell lines [292]. In this respect it is noteworthy that addiction to 
Runx1 was also a feature of a floxed Runx1 model of primary EMyc lymphomas 
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with in vitro lines displaying an increased resistance to DNA damaging agents 
compared to their excised counterparts [298]. Enhanced survival is an essential 
feature of the leukaemic initiating cell.  RUNX1 expression conveys a survival 
phenotype and crucially does so in the absence of ROS or SASP thereby reducing 
the opportunity for acquisition of secondary mutations. It is possible that the 
stability of RUNX1 compared to RE mediated growth arrest in human CD34+ cells 
is a consequence of this and a crucial component of RUNX1 addiction in fusion 
leukaemias [82].  
From the evidence presented it may be predicted that senescence represents an 
important failsafe that is relevant to leukaemia development in vivo. Signalling 
pathways invoked in leukaemogenesis commonly reverse proliferative growth 
arrest or enhance metabolic growth-promoting pathways associated with 
premature senescence. The pattern enforces the current dogma that senescence 
pathways have antagonistic functions in survival and tumour progression, both of 
which appear to be exploited in leukaemia. RUNX1 and its fusion oncoproteins 
do not disappoint in this respect with roles in growth and survival that present as 
SLGA or uncontrolled proliferation depending on cooperating mutations and the 
microenvironment. Treatment failure in acute leukaemia is believed to be 
caused by the persistence of leukaemia-initiating cells after conventional 
therapy and is a major prognostic factor for disease relapse. Genes that are 
essential for their growth and survival could present promising targets to 
selectively eradicate cancer cells while preserving normal stem cells. The 
finding that RUNX1 fusion oncoproteins promote ROS and SASP signalling is 
encouraging for ongoing efforts to specifically target SASP signalling in 
leukaemic cells. Moreover, the requirement for endogenous RUNX1 for the 
viability and growth of fusion-containing leukaemic cells supports the possibility 
of combination therapy between conventional therapeutics and RUNX1 inhibition 
for greater efficacy.      
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8.5  Future work 
 
RE and RE9a induce more rapid leukaemogenesis than RE9a alone [80] 
suggesting that RE9a functions to inhibit RE-dependent anti-cancer 
mechanisms such as cellular senescence. To address this it would be 
informative to co-express RE and RE9a in Hs68 cells which give a well-
defined senescence profile, and determine whether RE-induced 
senescence is opposed by RE9a. Such studies could also be extended to 
include co-expression of TR and RUNX1 which also show opposing effects 
on cellular senescence and are co-expressed in acute leukaemia.   
 
Fibroblasts do not represent a physiologically relevant target cell for 
RUNX1 or its fusion oncoproteins with respect to leukaemia. To determine 
whether the results achieved in this study are reproduced in more 
biologically relevant cell backgrounds it will be of interest to express 
RUNX1 and its fusion oncoproteins in CD34+ haematopoietic stem cells and 
examine them for signs of premature senescence.  For reasons described 
above these studies could be extended to include combinations of RE and 
RE9a or TR and RUNX1 to more closely mimic the pathologies they are 
associated with human leukaemia. 
 
The SASP has been identified as having both pro-senescence and pro-
oncogenic properties depending on the cellular context [205]. To address 
the particular functions of the SASP induced in response to RE, 
conditioned media could be collected and applied to parallel cultures 
expressing the RE9a construct or the vector only control. If the 
conditioned media was senescence promoting in these cell backgrounds it 
would be of interest to examine the effects of NFB inhibitors on RE-
induced senescence as this treatment would be expected to reverse the 
SASP. Alternatively, if the conditioned media accelerated the growth of 
RE9a expressing fibroblasts this might provide an explanation for the 
observed synergy between RE and RE9a in acute leukaemias [80] and a 
rationale for extending these studies into a more physiologically relevant 
target cell.  
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Pro-senescence therapies have been suggested as an approach to oppose 
cancer progression [322]. However as expression of RE and TR K99R in 
p16INK4A-null Leiden and REH cells resulted in accelerated proliferation, it 
is reasonable to suggest that established leukaemia cells will have 
acquired secondary mutations that render them refractory to pro-
senescence therapies that target the cell cycle.  An alternative approach 
may be to target the chronic inflammatory SASP that we have described in 
response to RE. NFBactivity and ROS are important for SASP 
development [186, 248] and have previously been identified as poor 
prognostic factors in AML [255, 290] supporting the importance of the 
SASP in RE mediated leukaemogenicity. To understand the SASP more fully 
and to identify potential drugable targets it will be important to define 
the phenotype in a more physiologically relevant target cell line such as 
CD34+ stem cells. The functional consequences of particular components 
could then be tested on RE9a expressing cells to determine their 
oncogenic potential and significance for leukaemia development.   
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